FUNGICIDAL HALOMETHYL KETONES, HYDRATES AND ENOL ETHERS AND THEIR MIXTURES

Abstract

Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof,

##STR00001##

wherein G, Z, L, J, A and T are as defined in the disclosure; and (b) at least one additional fungicidal compound.

Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an N-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent. Also disclosed are compounds of Formula 1 including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof.

Claims

1. A fungicidal composition comprising: (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof: ##STR00110## wherein T is selected from the group consisting of: ##STR00111## wherein the bond extending to the left is attached to A; R.sup.1 is CF.sub.3, CHF.sub.2 or CCl.sub.3; W is O, S or NR.sup.3; R.sup.3 is H, cyano, nitro, C(O)OH, benzyl, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, OR.sup.3a or NR.sup.3bR.sup.3c; R.sup.3a is H, benzyl, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 haloalkylcarbonyl; R.sup.3b is H, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 haloalkylcarbonyl; R.sup.3c is H or C.sub.1-C.sub.4 alkyl; or R.sup.3b and R.sup.3c are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; X is O, S or NR.sup.4a; Y is O, S or NR.sup.4b; R.sup.4a and R.sup.4b are each independently H, hydroxy or C.sub.1-C.sub.4 alkyl; R.sup.2a and R.sup.2b are each independently H, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.3-C.sub.15 trialkylsilyl or C.sub.3-C.sub.15 halotrialkylsilyl; or R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5- to 7-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 2 carbon atom ring members are independently selected from C(O) and C(S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy on carbon atom ring members; R.sup.2c is C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl or trifluoromethylsulfonyl, each optionally substituted with up 2 substituents independently selected from cyano, hydroxy, SCN and C.sub.1-C.sub.2 alkoxy; R.sup.2d is H, cyano, halogen or C.sub.1-C.sub.4 alkyl; when T is T-1 or T-2, then A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b, wherein A.sup.1 is connected to J, and CR.sup.5aR.sup.5b is connected to T; when T is T-3, then A is A.sup.1-A.sup.2, wherein A.sup.1 is connected to J, and A.sup.2 is connected to T; A.sup.1 is CR.sup.5aR.sup.5b, N(R.sup.6), O or S; A.sup.2 is a direct bond, CR.sup.5aR.sup.5b, N(R.sup.6), O or S; each R.sup.5a and R.sup.5b is independently H, cyano, hydroxy, halogen, C(O)OCH.sub.3 or C.sub.1-C.sub.4 alkyl; each R.sup.6 is independently H, C(O)H, cyano, C.sub.1-C.sub.4 alkyl or C.sub.2-C.sub.4 alkylcarbonyl; J is selected from the group consisting of: ##STR00112## ##STR00113## wherein the bond extending to the left is attached to L, and the bond extending to the right is attached to A; each R.sup.7 is independently F, Cl, I, Br, cyano, methyl, trifluoromethyl or methoxy; q is 0, 1, 2, 3 or 4; L is (CR.sup.8aR.sup.8b).sub.n; each R.sup.8a and R.sup.8b is independently H, halogen, cyano, hydroxy, nitro, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy or C.sub.1-C.sub.3 haloalkoxy; n is 0, 1, 2 or 3; G is phenyl is substituted with 1 to 3 substituents independently selected from R.sup.9 and optionally substituted with up to 3 substituents independently selected from R.sup.10; G is a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring is substituted with 1 to 3 substituents independently selected from R.sup.9 and optionally substituted with up to 3 substituents independently selected from R.sup.10; G is a 3- to 7-membered nonaromatic ring or an 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(O), C(S), S(O) and S(O).sub.2, each ring is substituted with 1 to 3 substituents independently selected from R.sup.9 and optionally substituted with up to 3 substituents independently selected from R.sup.10; each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f, C.sub.2-C.sub.6 alkyl(thiocarbonyl) or C.sub.2-C.sub.6 alkoxy(thiocarbonyl); each m is independently 1, 2 or 3; each R.sup.9a is independently C(O)NR.sup.12eR.sup.12g, OC(O)NR.sup.12cR.sup.12d or ONR.sup.12iR.sup.12j; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylthioalkoxy, C.sub.2-C.sub.8 alkylsulfinylalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.3-C.sub.9 alkenylcarbonylthio, C.sub.3-C.sub.9 alkynylcarbonylthio, C.sub.5-C.sub.9 cycloalkylcarbonylthio, C.sub.2-C.sub.8 alkoxycarbonylthio, C.sub.2-C.sub.8 alkylaminocarbonylthio, C.sub.3-C.sub.9 dialkylaminocarbonylthio, C.sub.5-C.sub.9 cycloalkylalkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.2-C.sub.8 alkylaminocarbonylamino, C.sub.3-C.sub.9 dialkylaminocarbonylamino, C.sub.5-C.sub.10 cycloalkylalkylcarbonylamino, C.sub.2-C.sub.8 alkenylthio, C.sub.2-C.sub.8 alkynylthio, C.sub.2-C.sub.8 alkylthioalkylthio, C.sub.4-C.sub.10 cycloalkylalkylthio, C.sub.2-C.sub.8 cyanoalkylthio, C.sub.2-C.sub.8 alkoxyalkylthio, C.sub.2-C.sub.8 alkylsulfinylalkylthio, C.sub.2-C.sub.8 alkylsufonylalkylthio, C.sub.3-C.sub.9 alkoxycarbonylalkylthio, C.sub.3-C.sub.9 alkylaminocarbonylalkylthio, C.sub.4-C.sub.10 dialkylaminocarbonylalkylthio, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.4-C.sub.10 cycloalkoxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, C.sub.3-C.sub.8 trialkylsilylalkoxy or C.sub.3-C.sub.15 halotrialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13; each R.sup.10 is independently cyano, halogen, hydroxy, nitro, SH, SF.sub.5, CH(O), C(O)OH, NR.sup.14aR.sup.14b, C(O)NR.sup.14aR.sup.14b, C(O)C(O)NR.sup.14aR.sup.14b, C(S)NR.sup.14aR.sup.14b, C(R.sup.15)NR.sup.16, NCR.sup.17NR.sup.18aR.sup.18b or UV-Q; or C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.3-C.sub.7 cycloalkenyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.3-C.sub.7 cycloalkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.1-C.sub.6 alkylsulfinyl, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylaminosulfinyl, C.sub.2-C.sub.6 dialkylaminosulfinyl, C.sub.1-C.sub.6 alkylsulfonyloxy, C.sub.1-C.sub.6 alkylsulfonylamino, C.sub.2-C.sub.6 alkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.6 alkoxycarbonyl, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.3-C.sub.6 alkynyloxycarbonyl, C.sub.4-C.sub.7 cycloalkoxycarbonyl, C.sub.3-C.sub.6 alkoxycarbonylcarbonyl, C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.4-C.sub.7 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy, C.sub.4-C.sub.7 cycloalkoxycarbonyloxy, C.sub.2-C.sub.6 alkylaminocarbonyloxy, C.sub.4-C.sub.7 cycloalkylaminocarbonyloxy, C.sub.2-C.sub.6 alkylcarbonylamino, C.sub.4-C.sub.7 cycloalkylcarbonylamino, C.sub.2-C.sub.6 alkoxycarbonylamino, C.sub.4-C.sub.7 cycloalkoxycarbonylamino, C.sub.2-C.sub.6 alkylaminocarbonylamino, C.sub.4-C.sub.7 cycloalkylaminocarbonylamino or C.sub.2-C.sub.6 dialkoxyphosphinyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19; each R.sup.11a and R.sup.11b is independently H, halogen, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.2-C.sub.4 haloalkoxycarbonyl, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.4 haloalkylcarbonyloxy; or R.sup.11a and R.sup.11b are taken together with the carbon atom to which they are attached to form a 3- to 6-membered carbocyclic or heterocyclic ring, each ring containing ring members selected from carbon atoms and optionally up to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(O), C(S), S(O) and S(O).sub.2, each ring optionally substituted with up to 3 substituents independently selected from halogen and C.sub.1-C.sub.3 alkyl; each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy, C.sub.3-C.sub.8 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.6 alkoxyalkoxy, C.sub.3-C.sub.8 trialkylsilyloxy and C.sub.3-C.sub.15 halotrialkylsilyloxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 haloalkyl; each R.sup.12b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.6-C.sub.14 cycloalkylcycloalkyl, C.sub.5-C.sub.10 alkylcycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.4-C.sub.10 cycloalkoxyalkyl, C.sub.3-C.sub.8 alkoxyalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfinylalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl, C.sub.2-C.sub.6 haloalkylaminoalkyl, C.sub.3-C.sub.8 dialkylaminoalkyl or C.sub.4-C.sub.10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.3-C.sub.15 trialkylsilyl or C.sub.3-C.sub.15 halotrialkylsilyl; each R.sup.12c is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.1-C.sub.4 alkylsulfonyl, C.sub.1-C.sub.4 haloalkylsulfonyl, C.sub.2-C.sub.4 alkylthioalkyl, C.sub.2-C.sub.4 alkylsulfinylalkyl, C.sub.2-C.sub.4 alkylsulfonylalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkoxycarbonylalkyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; each R.sup.12d is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.6-C.sub.14 cycloalkylcycloalkyl, C.sub.5-C.sub.10 alkylcycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.4-C.sub.10 cycloalkoxyalkyl, C.sub.3-C.sub.8 alkoxyalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfinylalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylcarbonyl, C.sub.2-C.sub.6 alkylaminoalkyl, C.sub.2-C.sub.6 haloalkylaminoalkyl, C.sub.3-C.sub.8 dialkylaminoalkyl or C.sub.4-C.sub.10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.3-C.sub.15 trialkylsilyl and C.sub.3-C.sub.15 halotrialkylsilyl; or R.sup.12c and R.sup.12d are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C.sub.1-C.sub.3 alkyl; each R.sup.12e is independently NH.sub.2, C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.5-C.sub.10 alkylcycloalkylalkyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.4-C.sub.10 cycloalkoxyalkyl, C.sub.3-C.sub.8 alkoxyalkoxyalkyl, C.sub.2-C.sub.6 alkylthio, C.sub.1-C.sub.6 haloalkylthio, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.1-C.sub.6 alkylsulfinyl, C.sub.2-C.sub.6 alkylsulfinylalkyl, C.sub.2-C.sub.6 alkylsulfonyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl, C.sub.2-C.sub.6 haloalkylaminoalkyl, C.sub.3-C.sub.8 dialkylaminoalkyl, C.sub.4-C.sub.10 cycloalkylaminoalkyl, C.sub.3-C.sub.8 alkylcarbonyl or C.sub.2-C.sub.8 haloalkylcarbonyl; each R.sup.12f is independently hydroxy or NR.sup.20aR.sup.20b; or C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy, C.sub.2-C.sub.5 alkoxycarbonyloxy, C.sub.2-C.sub.5 alkylaminocarbonyloxy or C.sub.3-C.sub.5 dialkylaminocarbonyloxy, each optionally substituted with up to 3 substituents independently selected from cyano, halogen, hydroxy and C(O)OH; each R.sup.12g is H, cyano, hydroxy, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl, C.sub.1-C.sub.5 alkoxy, C.sub.1-C.sub.5 haloalkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.1-C.sub.4 alkylsulfonyl or C.sub.1-C.sub.4 haloalkylsulfonyl; each R.sup.12i and R.sup.12j is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 haloalkylcarbonyl; or R.sup.12i and R.sup.12j are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(O), C(S), S(O) and S(O).sub.2, each ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R.sup.13 is independently C(O)OH, halogen, cyano, C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl or C.sub.3-C.sub.6 cycloalkyl; each R.sup.14a is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.1-C.sub.4 alkylsulfonyl, C.sub.1-C.sub.4 haloalkylsulfonyl, C.sub.2-C.sub.4 alkylthioalkyl, C.sub.2-C.sub.4 alkylsulfinylalkyl, C.sub.2-C.sub.4 alkylsulfonylalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkoxycarbonylalkyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; each R.sup.14b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.6-C.sub.14 cycloalkylcycloalkyl, C.sub.5-C.sub.10 alkylcycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.4-C.sub.10 cycloalkoxyalkyl, C.sub.3-C.sub.8 alkoxyalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfinylalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl, C.sub.2-C.sub.6 haloalkylaminoalkyl, C.sub.3-C.sub.8 dialkylaminoalkyl or C.sub.4-C.sub.10 cycloalkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.3-C.sub.15 trialkylsilyl and C.sub.3-C.sub.15 halotrialkylsilyl; or R.sup.14a and R.sup.14b are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 3 substituents independently selected from halogen and C.sub.1-C.sub.3 alkyl; each R.sup.15 is independently H, cyano, halogen, methyl, methoxy, methylthio or methoxycarbonyl; each R.sup.16 is independently hydroxy or NR.sup.20aR.sup.20b; or C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 alkynyloxy, C.sub.2-C.sub.4 alkylcarbonyloxy, C.sub.2-C.sub.5 alkoxycarbonyloxy, C.sub.2-C.sub.5 alkylaminocarbonyloxy or C.sub.3-C.sub.5 dialkylaminocarbonyloxy, each optionally substituted with up to 1 substituent selected from cyano, halogen, hydroxy and C(O)OH; each R.sup.17 is independently H, methyl, methoxy or methylthio; each R.sup.18a and R.sup.18b is independently H or C.sub.1-C.sub.4 alkyl; each R.sup.19 is independently amino, cyano, halogen, hydroxy, nitro, SH, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 halocycloalkyl, C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkoxyalkoxy, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsulfinyl, C.sub.1-C.sub.4 alkylsulfonyl, C.sub.1-C.sub.4 haloalkylsulfonyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.1-C.sub.6 alkylamino, C.sub.2-C.sub.6 dialkylamino, C.sub.2-C.sub.5 alkylaminocarbonyl, C.sub.3-C.sub.5 dialkylaminocarbonyl, C.sub.3-C.sub.5 alkylthioalkylcarbonyl, C.sub.3-C.sub.15 trialkylsily, C.sub.3-C.sub.15 halotrialkylsilyl, C(R.sup.21)NOR.sup.22 or C(R.sup.23)NR.sup.24; each U is independently a direct bond, C(O)O, C(O)N(R.sup.25) or C(S)N(R.sup.26), wherein the atom to the left is connected to G, and the atom to the right is connected to V; each V is independently a direct bond; or C.sub.1-C.sub.6 alkylene, C.sub.2-C.sub.6 alkenylene, C.sub.3-C.sub.6 alkynylene, C.sub.3-C.sub.6 cycloalkylene or C.sub.3-C.sub.6 cycloalkenylene, wherein up to 1 carbon atom is C(O), each optionally substituted with up to 3 substituents independently selected from halogen, cyano, nitro, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy; each Q is independently phenyl or phenoxy, each optionally substituted with up to 2 substituents independently selected from R.sup.27; or each Q is independently a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R.sup.27; or each Q is independently a 3- to 7-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(O), C(S), S(O) and S(O).sub.2, each ring optionally substituted with up to 2 substituents independently selected from R.sup.27; each R.sup.20a is independently H, C.sub.1-C.sub.4 alkyl or C.sub.2-C.sub.4 alkylcarbonyl; each R.sup.20b is independently H, cyano, C.sub.1-C.sub.5 alkyl, C.sub.2-C.sub.5 alkylcarbonyl, C.sub.2-C.sub.5 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkoxycarbonylalkyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; or R.sup.20a and R.sup.20b are taken together to form a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 methyl groups; each R.sup.21 and R.sup.23 is independently H, cyano, halogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.3-C.sub.6 cycloalkyl or C.sub.1-C.sub.3 alkoxy; or phenyl optionally substituted with up to 2 substituents independently selected from halogen and C.sub.1-C.sub.3 alkyl; each R.sup.22 is independently H, C.sub.1-C.sub.5 alkyl, C.sub.1-C.sub.5 haloalkyl, C.sub.2-C.sub.5 alkenyl, C.sub.2-C.sub.5 haloalkenyl, C.sub.2-C.sub.5 alkynyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 halocycloalkyl, C.sub.2-C.sub.5 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; or each R.sup.22 is phenyl optionally substituted with up to 2 substituents independently selected halogen and C.sub.1-C.sub.3 alkyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and C.sub.1-C.sub.3 alkyl; each R.sup.24 is independently H, cyano, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; each R.sup.25 and R.sup.26 is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.2-C.sub.4 alkoxycarbonyl or C.sub.2-C.sub.4 haloalkoxycarbonyl; each R.sup.27 is independently halogen, cyano, hydroxy, nitro, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; Z is a direct bond, O, S(O).sub.p, N(R.sup.28), C(O), C(O)N(R.sup.28), NR.sup.28C(O), N(R.sup.28)C(O)N(R.sup.28), N(R.sup.28)C(S)N(R.sup.28), OC(O)N(R.sup.28), N(R.sup.28)C(O)O, S(O).sub.2N(R.sup.28), N(R.sup.28)S(O).sub.2 or N(R.sup.28)S(O).sub.2N(R.sup.28), wherein the atom to the right is connected to L; each R.sup.28 is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.3 alkylcarbonyl or C.sub.2-C.sub.3 alkoxycarbonyl; and p is 0, 1 or 2; (b) at least one additional fungicidal compound; provided that: (a) when A.sup.1 is N(R.sup.6), O or S, then A.sup.2 is a direct bond or CR.sup.5aR.sup.5b; and (b) when A.sup.2 is N(R.sup.6), O or S; then A.sup.1 is CR.sup.5aR.sup.5b.

2. The composition of claim 1 wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein T is T-2 or T-3; R.sup.1 is CF.sub.3; X is O; Y is O; R.sup.2a and R.sup.2b are each independently H or C.sub.1-C.sub.2 alkyl; or R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(O) and C(S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members; R.sup.2c is methyl or ethyl; R.sup.2d is H or methyl; A.sup.1 is CR.sup.5aR.sup.5b or O; A.sup.2 is a direct bond, CR.sup.5aR.sup.5b or O; each R.sup.5a and R.sup.5b is independently H or methyl; J is J-1, J-6 or J-14; each R.sup.7 is independently F, Cl or methyl; q is 0, 1 or 2; each R.sup.8a and R.sup.8b is independently H, halogen or methyl; n is 0, 1 or 2; G is selected from the group consisting of: ##STR00114## ##STR00115## ##STR00116## ##STR00117## ##STR00118## wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3; and y is 0, 1, 2 or 3; each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); each m is independently 1 or 2; each R.sup.9a is independently OC(O)NR.sup.12 cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl or C.sub.3-C.sub.8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13; each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b or UV-Q; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19; each R.sup.11a and R.sup.11b is independently H, methyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl or C.sub.2-C.sub.3 haloalkoxycarbonyl; each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; each R.sup.12b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; each R.sup.12c is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; each R.sup.12d is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; or R.sup.12c and R.sup.12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R.sup.12e is independently C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.5 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkyl; each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsufonyl or C.sub.3-C.sub.6 cycloalkyl; each R.sup.14a is independently H, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; each R.sup.14b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl; or R.sup.14a and R.sup.14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; each R.sup.19 is independently cyano, halogen, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.2 alkoxy, C.sub.1-C.sub.2 haloalkoxy, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl or C.sub.2-C.sub.3 alkoxycarbonyl; each U is independently a direct bond, C(O)O or C(O)N(R.sup.25); each V is independently a direct bond; or C.sub.1-C.sub.3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy; each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27; each R.sup.25 is independently H, cyano, hydroxy or C.sub.1-C.sub.2 alkyl; each R.sup.27 is independently halogen, cyano, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl or C.sub.1-C.sub.4 alkoxy; and Z is a direct bond, 0, NH, C(O), C(O)NH, NHC(O), NHC(O)NH, OC(O)NH, NHC(O)O, S(O).sub.2NH, NHS(O).sub.2 or NHS(O).sub.2NH.

3. The composition of claim 2 wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein R.sup.2a and R.sup.2b are each independently H or methyl; or R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member; A.sup.1 is O; A.sup.2 is a direct bond, CH.sub.2 or O; J is J-1; q is 0; each R.sup.8a and R.sup.8b is independently H or methyl; n is 0 or 1; G is G-1, G-3, G-12, G-13 or G-20; x is 1 or 2; y is 0 or 1; each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R.sup.13; R.sup.10 is halogen, C(O)NR.sup.14aR.sup.14b; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19; each R.sup.11a and R.sup.11b is independently H, methyl or C.sub.2-C.sub.3 alkoxycarbonyl; each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; each R.sup.12b is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl; each R.sup.12c is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; each R.sup.12d is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl; each R.sup.12e is independently C.sub.2-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl; R.sup.14a is H or C.sub.1-C.sub.2 alkyl; R.sup.14b is H, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or cyclopropylmethyl; each R.sup.19 is independently halogen; and Z is a direct bond, O, NH or C(O).

4. The composition of claim 3 wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein R.sup.2a and R.sup.2b are each H; or R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; R.sup.2c is ethyl; R.sup.2d is H; A.sup.2 is a direct bond; each R.sup.8a and R.sup.8b is H; n is 1; G is G-12 or G-20; x is 1; y is 0; R.sup.9 is CH.sub.2R.sup.9a, CH.sub.2CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.13; R.sup.12a is C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy or phenyl-CH.sub.2O; R.sup.12b is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl; R.sup.12c is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; R.sup.12d is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl; R.sup.12e is C.sub.2-C.sub.3 alkyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen; each R.sup.13 is independently halogen, cyano, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl; and Z is a direct bond.

5. The composition of claim 4 wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein T is T-3; R.sup.9 is CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13; R.sup.12a is C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.4-C.sub.5 cycloalkylalkoxy or phenyl-CH.sub.2O; R.sup.12b is H, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl; R.sup.12c is H or C.sub.1-C.sub.3 alkoxy; R.sup.12d is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl; and each R.sup.13 is independently Br, Cl, F, cyano, methoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.2 alkylthio or cyclopropyl.

6. The composition of claim 5 wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein G is G-12 connected at the 1-position to Z and the 3-position is connected to R.sup.9; or G is G-12 connected at the 1-position to Z and the 5-position is connected to R.sup.9; or G is G-20 connected at the 2-position to Z; or G is G-20 connected at the 4-position to Z; R.sup.9 is CH.sub.2R.sup.9a; R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy each optionally substituted with up to 1 substituent selected from R.sup.13; R.sup.12c is methoxy; R.sup.12d is H, methyl or cyclopropylmethyl; and R.sup.13 is Br, Cl, F, cyano, methoxy, CH.sub.3OC(O), CH.sub.3S or cyclopropyl.

7. The composition of claim 1 wherein component (a) comprises a compound selected from the group consisting of O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate (Compound 7); (Z)-(1-(4-((2-ethoxy-3,3,3-trifluoroprop-1-en-1-yl)oxy)benzyl)-1H-pyrazol-4-yl)methyl methoxy(methyl)carbamate (Compound 18); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate (Compound 21); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl acetate (Compound 22); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methoxyacetate (Compound 23); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-methylbutanoate (Compound 27); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpentanoate (Compound 30); 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(phenylmethoxy)-1H-pyrazole-4-carboxamide (Compound 31); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3,3,3-trifluoropropanoate (Compound 35); 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-1H-pyrazole-4-carboxamide (Compound 45); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpropanoate (Compound 46); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2,2-dimethylpropanoate (Compound 47); 1-[[1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl]2-methyl ethanedioate (Compound 48); [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-(methylthio)propanoate (Compound 50); 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl methyl carbonate (Compound 52). 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 105); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 108); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 109); 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-ethyl-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 119); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-N-methyl-6-pyridinecarboxamide (Compound 120); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 121); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-N-methyl-6-pyridinecarboxamide (Compound 123); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-6-pyridinecarboxamide (Compound 124); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 125); 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-6-pyridinecarboxamide (Compound 127); 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-2-pyridinecarboxamide (Compound 131); 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-2-pyridinecarboxamide (Compound 132); and 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-2-pyridinecarboxamide (Compound 133).

8. The composition of claim 1 wherein component (b) includes at least one fungicidal compound selected from the group consisting of: (b1) methyl benzimidazole carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide (PA) fungicides; (b5) amine/morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine (AP) fungicides; (b10) N-phenyl carbamate fungicides; (b11) quinone outside inhibitor (QoI) fungicides; (b12) phenylpyrrole (PP) fungicides; (b13) azanaphthalene fungicides; (b14) cell peroxidation inhibitor fungicides; (b15) melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; (b16a) melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides; (b16b) melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides; (b17) keto reductase inhibitor (KRI) fungicides; (b18) squalene-epoxidase inhibitor fungicides; (b19) polyoxin fungicides; (b20) phenylurea fungicides; (b21) quinone inside inhibitor (QiI) fungicides; (b22) benzamide and thiazole carboxamide fungicides; (b23) enopyranuronic acid antibiotic fungicides; (b24) hexopyranosyl antibiotic fungicides; (b25) glucopyranosyl antibiotic: protein synthesis fungicides; (b26) glucopyranosyl antibiotic fungicides; (b27) cyanoacetamideoxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupling fungicides; (b30) organo tin fungicides; (b31) carboxylic acid fungicides; (b32) heteroaromatic fungicides; (b33) phosphonate fungicides; (b34) phthalamic acid fungicides; (b35) benzotriazine fungicides; (b36) benzene-sulfonamide fungicides; (b37) pyridazinone fungicides; (b38) thiophene-carboxamide fungicides; (b39) complex I NADH oxido-reductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) quinone outside inhibitor, stigmatellin binding (QoSI) fungicides; (b46) plant extract fungicides; (b47) cyanoacrylate fungicides; (b48) polyene fungicides; (b49) oxysterol binding protein inhibitor (OSBPI) fungicides; (b50) aryl-phenyl-ketone fungicides; (b51) host plant defense induction fungicides; (b52) multi-site activity fungicides; (b53) biologicals with multiple modes of action; (b54) fungicides other than fungicides of component (a) and components (b1) through (b53); and salts of compounds of (b1) through (b54).

9. The composition of claim 8 wherein component (b) comprises at least one fungicidal compound from each of two different groups selected from (b1) through (b54).

10. The composition of claim 1 wherein component (b) includes at least one compound selected from acibenzolar-S-methyl, aldimorph, ametoctradin, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl, benalaxyl-M, benodanil, benomyl, benthiavalicarb, benthiavalicarb-isopropyl, benzovindiflupyr, bethoxazin, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, carboxin, carpropamid, captafol, captan, carbendazim, chloroneb, chlorothalonil, chlozolinate, clotrimazole, copper hydroxide, copper salts, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap, dithianon, dodemorph, dodine, edifenphos, enestroburin, epoxiconazole, ethaboxam, ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, fluindapyr, flumetover, flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametpyr, hexaconazole, hymexazol, guazatine, imazalil, imibenconazole, iminoctadine, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandipropamid, maneb, mepronil, meptyldinocap, metalaxyl, metalaxyl-M, metconazole, methasulfocarb, metiram, metominostrobin, mepanipyrim, metarylpicoxamid, metrafenone, myclobutanil, naftifine, neo-asozin (ferric methanearsonate), nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, penconazole, pencycuron, penflufen, penthiopyrad, pefurazoate, phosphorous acid and salts thereof, phthalide, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamocarb, propamocarb-hydrochloride, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinomethionate, quinoxyfen, quintozene, sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquin, tecloftalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolylfluanid, tolnifanide, triadimefon, triadimenol, triazoxide, tricyclazole, tridemorph, triflumizole, tricyclazole, trifloxystrobin, triforine, trimorphamide, triticonazole, uniconazole, validamycin, valifenalate, vinclozolin, zineb, ziram, zoxamide, N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5]pyrimidine (DPX-BAS600F), N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide, 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]-methyl]propyl]carbamate, N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide, -(methoxyimino)-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]benzeneacetamide, N-[4-[4-chloro-3-(trifluoro-methyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, 2-[[[[3-(2,6-dichlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl]--(methoxyimino)-N-methylbenzeneacetamide and 1-[(2-propenylthio)carbonyl]-2-(1-methylethyl)-4-(2-methylphenyl)-5-amino-1H-pyrazol-3-one, 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine.

11. The composition of claim 10 wherein component (b) includes at least one compound selected from azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindapyr, flutriafol, fluxapyroxad, mancozeb, metarylpicoxamid, metominostrobin, picoxystrobin, prothioconazole, pydiflumetofen, pyraclostrobin, tebuconazole and trifloxystrobin.

12. A composition comprising: (a) at least one compound selected from the compounds of Formula 1 as defined in claim 1, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

13. A composition comprising the composition of claim 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

14. A method for protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying a fungicidally effective amount of the composition of claim 1 to the plant or plant seed.

15. A method for protecting a plant from a rust disease comprising applying to the plant a fungicidally effective amount of the composition of claim 1 wherein component (b) includes at least one fungicidal compound selected from (b11) quinone outside inhibitor fungicides. (b3) demethylation inhibitor fungicides, (b5) amine/morpholine fungicides, (b7) succinate dehydrogenase inhibitor fungicides, (b11) quinone outside inhibitor (QoI) fungicides, (b13) methyl benzimidazole carbamate fungicides and (b52) multi-site activity fungicides.

Description

DETAILS OF THE INVENTION

[0087] As used herein, the terms comprises, comprising, includes, including, has, having, contains, containing, characterized by or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.

[0088] The transitional phrase consisting of excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase consisting of appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

[0089] The transitional phrase consisting essentially of is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention.

[0090] The term consisting essentially of occupies a middle ground between comprising and consisting of.

[0091] Where applicants have defined an invention or a portion thereof with an open-ended term such as comprising, it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms consisting essentially of or consisting of.

[0092] Further, unless expressly stated to the contrary, or refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

[0093] Also, the indefinite articles a and an preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore a or an should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

[0094] The term agronomic refers to the production of field crops such as for food and fiber and includes the growth of maize or corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye and rice), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (e.g., berries and cherries) and other specialty crops (e.g., canola, sunflower and olives).

[0095] The term nonagronomic refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.

[0096] The term crop vigor refers to rate of growth or biomass accumulation of a crop plant. An increase in vigor refers to an increase in growth or biomass accumulation in a crop plant relative to an untreated control crop plant. The term crop yield refers to the return on crop material, in terms of both quantity and quality, obtained after harvesting a crop plant. An increase in crop yield refers to an increase in crop yield relative to an untreated control crop plant.

[0097] The term biologically effective amount refers to the amount of a biologically active compound (e.g., a compound of Formula 1 or a mixture with at least one other fungicidal compound) sufficient to produce the desired biological effect when applied to (i.e. contacted with) a fungus to be controlled or its environment, or to a plant, the seed from which the plant is grown, or the locus of the plant (e.g., growth medium) to protect the plant from injury by the fungal disease or for other desired effect (e.g., increasing plant vigor).

[0098] As referred to in the present disclosure and claims, plant includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds.

[0099] As referred to herein, the term seedling, used either alone or in a combination of words means a young plant developing from the embryo of a seed.

[0100] As referred to herein, the term broadleaf used either alone or in words such as broadleaf crop means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons.

[0101] As referred to in this disclosure, the terms fungal pathogen and fungal plant pathogen include pathogens in the Ascomycota, Basidiomycota and Zygomycota phyla, and the fungal-like Oomycota class that are the causal agents of a broad spectrum of plant diseases of economic importance, affecting ornamental, turf, vegetable, field, cereal and fruit crops. In the context of this disclosure, protecting a plant from disease or control of a plant disease includes preventative action (interruption of the fungal cycle of infection, colonization, symptom development and spore production) and/or curative action (inhibition of colonization of plant host tissues).

[0102] As used herein, the term mode of action (MOA) is as define by the Fungicide Resistance Action Committee (FRAC), and is used to distinguish fungicides according to their biochemical mode of action in the biosynthetic pathways of plant pathogens, and their resistance risk. FRAC-defined modes of actions include (A) nucleic acids metabolism, (B) cytoskeleton and motor protein, (C) respiration, (D) amino acids and protein synthesis, (E) signal transduction, (F) lipid synthesis or transport and membrane integrity or function, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis, (I) melanin synthesis in cell wall, (P) host plant defense induction, (U) unknown mode of action, (M) chemicals with multi-site activity and (BM) biologicals with multiple modes of action. Each mode of action (i.e. letters A through BM) contain one or more subgroups (e.g., A includes subgroups A1, A2, A3 and A4) based either on individual validated target sites of action, or in cases where the precise target site is unknown, based on cross resistance profiles within a group or in relation to other groups. Each of these subgroups (e.g., A1, A2, A3 and A4) is assigned a FRAC code which is a number and/or letter. For example, the FRAC code for subgroup A1 is 4. Additional information on target sites and FRAC codes can be obtained from publicly available databases maintained, for example, by FRAC.

[0103] As used herein, the term cross resistance refers to the phenomenon that occurs when a pathogen develops resistance to one fungicide and simultaneously becomes resistant to one or more other fungicides. These other fungicides are typically, but not always, in the same chemical class or have the same target site of action, or can be detoxified by the same mechanism.

[0104] In the above recitations, the term alkyl, used either alone or in compound words such as alkylthio or haloalkyl includes straight-chain and branched alkyl, such as, methyl, ethyl, n-propyl, i-propyl, and the different butyl, pentyl and hexyl isomers. Alkenyl includes straight-chain and branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. Alkenyl also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. Alkynyl includes straight-chain and branched alkynes such as ethynyl, 1-propynyl, 2-propynyl, and the different butynyl, pentynyl and hexynyl isomers. Alkynyl can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. Alkylene denotes a straight-chain or branched alkanediyl. Examples of alkylene include CH.sub.2, CH.sub.2CH.sub.2, CH(CH.sub.3), CH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH(CH.sub.3), and the different butylene isomers. Alkenylene denotes a straight-chain or branched alkenediyl containing one olefinic bond. Examples of alkenylene include CHCH, CH.sub.2CHCH, CHC(CH.sub.3) and the different butenylene isomers. Alkynylene denotes a straight-chain or branched alkynediyl containing one triple bond. Examples of alkynylene include CH.sub.2CC, CCCH.sub.2, and the different butynylene, pentynylene or hexynylene isomers. The term cycloalkylene denotes a cycloalkanediyl ring. Examples of cycloalkylene include cyclobutanediyl, cyclopentanediyl and cyclohexanediyl. The term cycloalkenylene denotes a cycloalkenediyl ring containing one olefinic bond. Examples of cycloalkenylene include cyclopropenediyl and cyclopentenediyl.

[0105] Alkoxy includes, for example, methoxy, ethoxy, n-propyloxy, i-propyloxy, and the different butoxy, pentoxy and hexyloxy isomers. Alkenyloxy includes straight-chain and branched alkenyl attached to and linked through an oxygen atom. Examples of alkenyloxy include H.sub.2CCHCH.sub.2O and CH.sub.3CHCHCH.sub.2O. Alkynyloxy includes straight-chain and branched alkynyl attached to and linked through an oxygen atom. Examples of alkynyloxy include HCCCH.sub.2O and CH.sub.3CCCH.sub.2O.

[0106] The term alkylthio includes straight-chain and branched alkylthio moieties such as methylthio, ethylthio, and the different propylthio and butylthio isomers. Alkylsulfinyl includes both enantiomers of an alkylsulfinyl group. Examples of alkylsulfinyl include CH.sub.3S(O), CH.sub.3CH.sub.2S(O), CH.sub.3CH.sub.2CH.sub.2S(O), (CH.sub.3).sub.2CHS(O), and the different butylsulfinyl isomers. Examples of alkylsulfonyl include CH.sub.3S(O).sub.2, CH.sub.3CH.sub.2S(O).sub.2, CH.sub.3CH.sub.2CH.sub.2S(O).sub.2, (CH.sub.3).sub.2CHS(O).sub.2, and the different butylsulfonyl isomers.

[0107] The term alkenylthio includes straight-chain and branched alkenyl attached to and linked through a sulfur atom. Examples ofalkenylthio include H.sub.2CCHCH.sub.2S and CH.sub.3CHCHCH.sub.2S. Alkenylsulfinyl includes both enantiomers of an alkenylsulfinyl group. Examples of alkenylsulfinyl include H.sub.2CCHCH.sub.2S(O), CH.sub.3CHCHCH.sub.2S(O), (CH.sub.3).sub.2CCHCH.sub.2S(O). Examples of alkenylsulfonyl include CH.sub.3CHCHS(O).sub.2, (CH.sub.3).sub.2CCHCH.sub.2S(O).sub.2.

[0108] The tern alkynylthio includes straight-chain and branched alkynyl attached to and linked through a sulfur atom. Examples of alkynylthio include HCCCH.sub.2S and CH.sub.3CCCH.sub.2S. Alkynylsulfinyl includes both enantiomers of an alkynylsulfinyl group. Examples of alkynylsulfinyl include HCCCH.sub.2S(O) and CH.sub.3CCCH.sub.2S(O). Examples of alkynylsulfonyl include CH.sub.3CCS(O).sub.2 and CH.sub.3CCCH.sub.2S(O).sub.2.

[0109] The term alkoxyalkylthio includes straight-chain and branched alkoxyalkyl moieties attached to and linked through a sulfur such as CH.sub.3OCH.sub.2CS and CH.sub.3CH.sub.2CH.sub.2OCH.sub.2CH.sub.2S.

[0110] Alkylthioalkyl denotes alkylthio substitution on alkyl. Examples of alkylthioalkyl include CH.sub.3SCH.sub.2, CH.sub.3SCH.sub.2CH.sub.2, CH.sub.3CH.sub.2SCH.sub.2, CH.sub.3CH.sub.2CH.sub.2SCH.sub.2 and CH.sub.3CH.sub.2SCH.sub.2CH.sub.2; alkylsulfinylalkyl and alkylsulfonylalkyl include the corresponding sulfoxides and sulfones, respectively. Alkylthioalkylthio denotes alkylthio substitution on an alkylthio group. Examples of alkylthioalkylthio include CH.sub.3SCH.sub.2S, CH.sub.3SCH.sub.2CH.sub.2S, CH.sub.3CH.sub.2SCH.sub.2S, CH.sub.3CH.sub.2CH.sub.2SCH.sub.2S and CH.sub.3CH.sub.2SCH.sub.2CH.sub.2S.

[0111] The term alkylsufonylalkylthio denotes alkylsufonyl substitution on alkylthio group. Examples of alkylsufonylalkylthio include CH.sub.3S(O).sub.2CH.sub.2S, CH.sub.3S(O).sub.2CH.sub.2CH.sub.2S and CH.sub.3CH.sub.2S(O).sub.2CH.sub.2CH.sub.2S.

[0112] The term alkylthioalkoxy denotes alkylthio substitution on an alkoxy group. Examples of alkylthioalkoxy include CH.sub.3SCH.sub.2O, CH.sub.3SCH.sub.2CH.sub.2O, CH.sub.3CH.sub.2SCH.sub.2O, CH.sub.3CH.sub.2CH.sub.2SCH.sub.2O and CH.sub.3CH.sub.2SCH.sub.2CH.sub.2O. Alkylsulfinylalkoxy and alkylsulfonylalkoxy include the corresponding sulfoxides and sulfones, respectively. Examples of alkylsulfinylalkoxy include CH.sub.3CH.sub.2(CH.sub.3)S(O)CH.sub.2O and CH.sub.3S(O)CH.sub.2O. Examples of alkylsulfonylalkoxy include CH.sub.3CH.sub.2CH.sub.2S(O).sub.2CH.sub.2CH.sub.2O and (CH.sub.3).sub.2CHS(O).sub.2CH.sub.2O.

[0113] The term alkylthioalkylcarbonyl denotes a straight-chain or branched alkylthioalkyl group bonded to a C(O) moiety. Examples of alkylthioalkylcarbonyl include CH.sub.3SCH.sub.2C(O), CH.sub.3SCH.sub.2CH.sub.2C(O), CH.sub.3CH.sub.2SCH.sub.2C(O) and CH.sub.3CH.sub.2SCH.sub.2CH.sub.2C(O).

[0114] (Alkylthio)carbonyl denotes a straight-chain or branched alkylthio group bonded to a C(O) moiety. Examples of (alkylthio)carbonyl include CH.sub.3SC(O), CH.sub.3CH.sub.2CH.sub.2SC(O) and (CH.sub.3).sub.2CHSC(O). The terms (alkenylthio)carbonyl and (alkynylthio)carbonyl are likewise defined. Examples of (alkenylthio)carbonyl include H.sub.2CCHCH.sub.2SC(O) and CH.sub.3CH.sub.2CHCHSC(O). Examples of (alkynylthio)carbonyl include HCCCH.sub.2SC(O) and CH.sub.3CCCH.sub.2SC(O).

[0115] Alkyl(thiocarbonyl) denotes a straight-chain or branched alkyl group bonded to a C(S) moiety. Examples of alkyl(thiocarbonyl) include CH.sub.3CH.sub.2C(S), CH.sub.3CH.sub.2CH.sub.2C(S) and (CH.sub.3).sub.2CHCH.sub.2C(S). The terms alkenyl(thiocarbonyl) and alkynyl(thiocarbonyl) are likewise defined. Examples of alkenyl(thiocarbonyl) include H.sub.2CCHCH.sub.2CH.sub.2C(S) and CH.sub.3CH.sub.2CHCHC(S). Examples of alkynyl(thiocarbonyl) include HCCCH.sub.2CH.sub.2C(S) and CH.sub.3CCCH.sub.2C(S). Alkoxy(thiocarbonyl) denotes a straight-chain or branched alkoxy group bonded to a C(S) moiety. Examples of alkoxy(thiocarbonyl) include CH.sub.3CH.sub.2OC(S), CH.sub.3CH.sub.2CH.sub.2OC(S) and (CH.sub.3).sub.2CHCH.sub.2OC(S).

[0116] Alkylamino(thiocarbonyl) denotes a straight-chain or branched alkylamino group bonded to a C(S) moiety. Examples of alkylamino(thiocarbonyl) include CH.sub.3NHC(S), CH.sub.3CH.sub.2CH.sub.2NHC(S) and (CH.sub.3).sub.2CHNHC(S). The terms alkenylamino(thiocarbonyl) and alkynylamino(thiocarbonyl) are likewise defined. Examples of alkenylamino(thiocarbonyl) include H.sub.2CCHCH.sub.2CH.sub.2NHC(S) and CH.sub.3CH.sub.2CHCHNHC(S). Examples of alkynylamino(thiocarbonyl) include HCCCH.sub.2CH.sub.2NHC(S) and CH.sub.3CCCH.sub.2NHC(S).

[0117] (Alkylthio)carbonylamino denotes a straight-chain or branched alkylthio group bonded to a C(O)NH moiety. Examples of (alkylthio)carbonylamino include CH.sub.3CH.sub.2SC(O)NH, CH.sub.3CH.sub.2CH.sub.2SC(O)NH and (CH.sub.3).sub.2CHSC(O)NH. The terms (alkenylthio)carbonylamino and (alkynylthio)carbonylamino are likewise defined. Examples of (alkenylthio)carbonylamino include H.sub.2CCHCH.sub.2SC(O)NH and CH.sub.3CHCHSC(O)NH. Examples of (alkynylthio)carbonylamino include HCCCH.sub.2CH.sub.2SC(O)NH and CH.sub.3CCCH.sub.2CH.sub.2SC(O)NH.

[0118] Alkylamino includes an NH radical substituted with a straight-chain or branched alkyl group. Examples of alkylamino include CH.sub.3CH.sub.2NH, CH.sub.3CH.sub.2CH.sub.2NH, and (CH.sub.3).sub.2CHCH.sub.2NH. Examples of dialkylamino include (CH.sub.3).sub.2N, (CH.sub.3CH.sub.2CH.sub.2).sub.2N and CH.sub.3CH.sub.2(CH.sub.3)N. Alkylaminoalkyl denotes alkylamino substitution on alkyl. Examples of alkylaminoalkyl include CH.sub.3NHCH.sub.2, CH.sub.3NHCH.sub.2CH.sub.2, CH.sub.3CH.sub.2NHCH.sub.2, CH.sub.3CH.sub.2CH.sub.2CH.sub.2NHCH.sub.2 and CH.sub.3CH.sub.2NHCH.sub.2CH.sub.2.

[0119] Alkylcarbonyl denotes a straight-chain or branched alkyl group bonded to a C(O) moiety. Examples of alkylcarbonyl include CH.sub.3C(O), CH.sub.3CH.sub.2CH.sub.2C(O) and (CH.sub.3).sub.2CHC(O). The terms alkenylcarbonyl and alkynylcarbonyl are likewise defined. Examples of alkenylcarbonyl include H.sub.2CCHCH.sub.2C(O) and CH.sub.3CH.sub.2CHCHC(O). Examples of alkynylcarbonyl include HCCCH.sub.2C(O) and CH.sub.3CCCH.sub.2C(O). Alkoxycarbonyl includes a C(O) moiety substituted with a straight-chain or branched alkoxy group. Examples of alkoxycarbonyl include CH.sub.3OC(O), CH.sub.3CH.sub.2OC(O), CH.sub.3CH.sub.2CH.sub.2OC(O) and (CH.sub.3).sub.2CHOC(O). The terms alkenyloxycarbonyl and alkynyloxycarbonyl are likewise defined. Examples of alkenyloxycarbonyl include H.sub.2CCHCH.sub.2OC(O) and CH.sub.3CH.sub.2CHCHOC(O). Examples of alkynyloxycarbonyl include HCCCH.sub.2OC(O) and CH.sub.3CCCH.sub.2OC(O).

[0120] The term alkoxycarbonylalkoxy denotes a straight-chain or branched alkoxycarbonyl substitution on an alkoxy group. Examples of alkoxycarbonylalkoxy include CH.sub.3CH.sub.2OC(O)CH.sub.2CH.sub.2O and CH.sub.3CH.sub.2(CH.sub.3)OC(O)CH.sub.2O. The term alkoxycarbonylcarbonyl denotes a straight-chain or branched alkoxy group bonded to a C(O)C(O) moiety. Examples of alkoxycarbonylcarbonyl include CH.sub.3CH.sub.2OC(O)C(O) and CH.sub.3CH(CH.sub.3)OC(O)C(O). The term alkoxycarbonylcarbonyloxy denotes a straight-chain or branched alkoxy group bonded to a C(O)C(O)O moiety. Examples of alkoxycarbonylcarbonyloxy include CH.sub.3OC(O)C(O)O and CH.sub.3CH.sub.2OC(O)C(O)O.

[0121] Alkylaminocarbonyl denotes a straight-chain or branched alkyl group bonded to a NHC(O) moiety. Examples of alkylaminocarbonyl include CH.sub.3NHC(O), CH.sub.3CH.sub.2NHC(O), CH.sub.3CH.sub.2CH.sub.2NHC(O) and (CH.sub.3).sub.2CHNHC(O). The terms alkenylaminocarbonyl and alkynylaminocarbonyl are likewise defined. Examples of alkenylaminocarbonyl include H.sub.2CCHCH.sub.2NHC(O) and (CH.sub.3).sub.2CCHCH.sub.2NHC(O). Examples of alkynylaminocarbonyl include CH.sub.3CCNHC(O) and CH.sub.3CCCH.sub.2NHC(O). Examples of dialkylaminocarbonyl include (CH.sub.3).sub.2N(O), (CH.sub.3CH.sub.2).sub.2NC(O), CH.sub.3CH.sub.2(CH.sub.3)NC(O), (CH.sub.3).sub.2CH(CH.sub.3)NC(O) and CH.sub.3CH.sub.2CH.sub.2(CH.sub.3)NC(O).

[0122] The term alkylcarbonylamino denotes a straight-chain or branched alkyl group bonded to a C(O)NH moiety. Examples of alkylcarbonylamino include CH.sub.3CH.sub.2C(O)NH and CH.sub.3CH.sub.2CH.sub.2C(O)NH. The terms alkenylcarbonylamino and alkynylcarbonylamino are likewise defined. Examples of alkenylcarbonylamino include H.sub.2CCHCH.sub.2C(O)NH and (CH.sub.3).sub.2CCHCH.sub.2C(O)NH. Examples of alkynylcarbonylamino include CH.sub.3CCCH(CH.sub.3)C(O)NH and HCCCH.sub.2CH.sub.2C(O)NH. The term alkoxycarbonylamino denotes alkoxy bonded to a C(O)NH moiety. Examples of alkoxycarbonylamino include CH.sub.3OC(O)NH and CH.sub.3CH.sub.2OC(O)NH.

[0123] The term alkylaminocarbonylamino denotes a straight-chain or branched alkyl group bonded to a NHC(O)NH moiety. Examples of alkylaminocarbonylamino include CH.sub.3CH.sub.2NHC(O)NH and (CH.sub.3CH.sub.2).sub.2CH.sub.2NHC(O)NH. The terms alkenylaminocarbonylamino and alkynylaminocarbonylamino are likewise defined. Examples of alkenylaminocarbonylamino include H.sub.2CCHCH.sub.2NHC(O)NH and (CH.sub.3).sub.2CCHCH.sub.2NHC(O)NH. Examples of alkynylaminocarbonylamino include CH.sub.3CCCH(CH.sub.3)NHC(O)NH and HCCCH.sub.2CH.sub.2NHC(O)NH.

[0124] Alkylsulfonylamino denotes an NH radical substituted with alkylsulfonyl. Examples of alkylsulfonylamino include CH.sub.3CH.sub.2S(O).sub.2NH and (CH.sub.3).sub.2CHS(O).sub.2NH. The terms alkenylsulfonylamino and alkynylsulfonylamino are likewise defined. Examples of alkenylsulfonylamino include H.sub.2CCHCH.sub.2CH.sub.2S(O).sub.2NH and (CH.sub.3).sub.2CCHCH.sub.2S(O).sub.2NH. Examples of alkynylsulfonylamino include CH.sub.3CCCH(CH.sub.3)S(O).sub.2NH and HCCCH.sub.2CH.sub.2S(O).sub.2NH. The term alkylsulfonyloxy denotes an alkylsulfonyl group bonded to an oxygen atom. Examples of alkylsulfonyloxy include CH.sub.3S(O).sub.2O, CH.sub.3CH.sub.2S(O).sub.2O, CH.sub.3CH.sub.2CH.sub.2S(O).sub.2O, (CH.sub.3).sub.2CHS(O).sub.2O, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers.

[0125] Alkylaminosulfonyl denotes a straight-chain or branched alkyl group bonded to a NHS(O).sub.2 moiety. Examples of alkylaminosulfonyl include CH.sub.3CH.sub.2NHS(O).sub.2 and (CH.sub.3).sub.2CHNHS(O).sub.2. The terms alkenylaminosulfonyl and alkynylaminosulfonyl are likewise defined. Examples ofalkenylaminosulfonyl include H.sub.2CCHCH.sub.2CH.sub.2NHS(O).sub.2 and (CH.sub.3).sub.2CCHCH.sub.2NHS(O).sub.2. Examples of alkynylaminosulfonyl include CH.sub.3CCCH(CH.sub.3)NHS(O).sub.2 and HCCCH.sub.2CH.sub.2NHS(O).sub.2.

[0126] Alkylaminosulfonylamino denotes a straight-chain or branched alkyl group bonded to a NHS(O).sub.2NH moiety. Examples ofalkylaminosulfonylamino include CH.sub.3CH.sub.2NHS(O).sub.2NH and (CH.sub.3).sub.2CHNHS(O).sub.2NH. The terms alkenylaminosulfonylamino and alkynylaminosulfonylamino are likewise defined. Examples of alkenylaminosulfonylamino include H.sub.2CCHCH.sub.2CH.sub.2NHS(O).sub.2NH and (CH.sub.3).sub.2CCHCH.sub.2NHS(O).sub.2NH. Examples of alkynylaminosulfonylamino include CH.sub.3CCCH(CH.sub.3)NHS(O).sub.2NH and HCCCH.sub.2CH.sub.2NHS(O).sub.2NH.

[0127] Alkoxyalkyl denotes alkoxy substitution on alkyl. Examples of alkoxyalkyl include CH.sub.3OCH.sub.2, CH.sub.3OCH.sub.2CH.sub.2, CH.sub.3CH.sub.2OCH.sub.2, CH.sub.3CH.sub.2CH.sub.2OCH.sub.2 and CH.sub.3CH.sub.2OCH.sub.2CH.sub.2. Alkoxyalkoxy denotes alkoxy substitution on another alkoxy moiety. Alkoxyalkoxyalkyl denotes alkoxyalkoxy substitution on alkyl. Examples of alkoxyalkoxyalkyl include CH.sub.3OCH.sub.2OCH.sub.2, CH.sub.3OCH.sub.2OCH.sub.2CH.sub.2 and CH.sub.3CH.sub.2OCH.sub.2OCH.sub.2.

[0128] The term alkylcarbonyloxy denotes a straight-chain or branched alkyl bonded to a C(O)O moiety. Examples of alkylcarbonyloxy include CH.sub.3CH.sub.2C(O)O and (CH.sub.3).sub.2CHC(O)O. The terms alkenylcarbonyloxy and alkynylcarbonyloxy are likewise defined. Examples of alkenylcarbonyloxy include H.sub.2CCHCH.sub.2CH.sub.2C(O)O and (CH.sub.3).sub.2CCHCH.sub.2C(O)O. Examples of alkynylcarbonyloxy include CH.sub.3CCCH(CH.sub.3)C(O)O and HCCCH.sub.2CH.sub.2C(O)O. The term alkoxycarbonyloxy denotes a straight-chain or branched alkoxy group bonded to a C(O)O moiety. Examples of alkoxycarbonyloxy include CH.sub.3CH.sub.2CH.sub.2OC(O)O and (CH.sub.3).sub.2CHOC(O)O. The term alkoxycarbonylalkyl denotes alkoxycarbonyl substitution on alkyl. Examples of alkoxycarbonylalkyl include CH.sub.3CH.sub.2OC(O)CH.sub.2, (CH.sub.3).sub.2CHOC(O)CH.sub.2 and CH.sub.3OC(O)CH.sub.2CH.sub.2. The term alkylaminocarbonyloxy denotes a straight-chain or branched alkylaminocarbonyl attached to and linked through an oxygen atom. Examples of alkylaminocarbonyloxy include (CH.sub.3).sub.2CHCH.sub.2NHC(O)O and CH.sub.3CH.sub.2NHC(O)O. The terms alkenylaminocarbonyloxy and alkynylaminocarbonyloxy are likewise defined.

[0129] The term alkylcarbonylthio denotes a straight-chain or branched alkyl group bonded to a C(O)S moiety. Examples of alkylcarbonylthio include CH.sub.3CH.sub.2C(O)S and CH.sub.3CH.sub.2CH.sub.2C(O)S. The term alkenylcarbonylthio denotes a straight-chain or branched alkenyl group bonded to a C(O)S moiety. Examples of alkenylcarbonylthio include CH.sub.3CHCHC(O)S and CH.sub.2CHCH.sub.2C(O)S. Alkynylcarbonylthio denotes a straight-chain or branched alkynyl group bonded to a C(O)S moiety. Examples of alkynylcarbonylthio include include CH.sub.3CCCH(CH.sub.3)C(O)S and HCCCH.sub.2CH.sub.2C(O)S.

[0130] The term alkoxycarbonylthio denotes a straight-chain or branched alkoxy group bonded to a C(O)S moiety. Examples of alkoxycarbonylthio include CH.sub.3CH.sub.2OC(O)S and CH.sub.3CH.sub.2CH.sub.2OC(O)S. The term alkylaminocarbonylthio denotes an alkyl group attached to and linked through a NHC(O)S moiety. Examples of alkylaminocarbonylthio include CH.sub.3CH.sub.2NHC(O)S and (CH.sub.3).sub.2CHCH.sub.2NHC(O)S. Examples of dialkylaminocarbonylthio include (CH.sub.3CH.sub.2).sub.2NC(O)S and CH.sub.3CH.sub.2N(CH.sub.3)C(O)S.

[0131] Cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term cycloalkylalkyl denotes cycloalkyl substitution on an alkyl moiety. Examples of cycloalkylalkyl include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to a straight-chain or branched alkyl group. The term alkylcycloalkyl denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, i-propylcyclobutyl, methylcyclopentyl and methylcyclohexyl. Alkylcycloalkylalkyl denotes alkylcycloalkyl substitution on alkyl. Examples of alkylcycloalkylalkyl include methylcyclohexylmethyl and ethylcycloproylmethyl. Cycloalkenyl includes groups such as cyclopentenyl and cyclohexenyl as well as groups with more than one double bond such as 1,3- or 1,4-cyclohexadienyl. The term cycloalkylcycloalkyl denotes cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members. Examples of cycloalkylcycloalkyl include cyclopropylcyclopropyl (such as 1,1-bicyclopropyl-1-yl, 1,1-bicyclopropyl-2-yl), cyclohexylcyclopentyl (such as 4-cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as 1,1-bicyclohexyl-1-yl), and the different cis- and trans-cycloalkylcycloalkyl isomers, (such as (1R,2S)-1,1-bicyclopropyl-2-yl and (1R,2R)-1,1-bicyclopropyl-2-yl).

[0132] The term cycloalkoxy denotes cycloalkyl attached to and linked through an oxygen atom including, for example, cyclopentyloxy and cyclohexyloxy. The term cycloalkoxyalkyl denotes cycloalkoxy substitution on an alkyl moiety. Examples of cycloalkoxyalkyl include cyclopropyloxymethyl, cyclopentyloxyethyl, and other cycloalkoxy groups bonded to a straight-chain or branched alkyl moiety.

[0133] The term cycloalkylaminoalkyl denotes cycloalkylamino substitution on an alkyl group. Examples of cycloalkylaminoalkyl include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to a straight-chain or branched alkyl group.

[0134] Cycloalkylcarbonyl denotes cycloalkyl bonded to a C(O) group including, for example, cyclopropylcarbonyl and cyclopentylcarbonyl. Cycloalkylcarbonyloxy denotes cycloalkylcarbonyl attached to and linked through an oxygen atom. Examples of cycloalkylcarbonyloxy include cyclohexylcarbonyloxy and cyclopentylcarbonyloxy. The term cycloalkoxycarbonyl means cycloalkoxy bonded to a C(O) group, for example, cyclopropyloxycarbonyl and cyclopentyloxycarbonyl. Cycloalkylaminocarbonylamino denotes cycloalkylamino bonded to a C(O)NH group, for example, cyclopentylaminocarbonyl-amino and cyclohexylaminocarbonylamino. Cycloalkylaminocarbonyloxy denotes cycloalkylamino bonded to a C(O)O group, for example, cyclopentylaminocarbonyloxy and cyclohexylaminocarbonyloxy.

[0135] The term halogen, either alone or in compound words such as haloalkyl, or when used in descriptions such as alkyl substituted with halogen includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as haloalkyl, or when used in descriptions such as alkyl substituted with halogen said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of haloalkyl or alkyl substituted with halogen include CF.sub.3, ClCH.sub.2, CF.sub.3CH.sub.2 and CF.sub.3CCl.sub.2. The terms haloalkenyl, haloalkynyl haloalkoxy, haloalkylsulfonyl, halocycloalkyl, and the like, are defined analogously to the term haloalkyl. Examples of haloalkenyl include Cl.sub.2CCHCH.sub.2 and CF.sub.3CH.sub.2CHCHCH.sub.2. Examples of haloalkynyl include HCCCHCl, CF.sub.3CC, CCl.sub.3CC and FCH.sub.2CCCH.sub.2. Examples of haloalkoxy include CF.sub.3O, CCl.sub.3CH.sub.2O, F.sub.2CHCH.sub.2CH.sub.2O and CF.sub.3CH.sub.2O. Examples of haloalkylsulfonyl include CF.sub.3S(O).sub.2, CCl.sub.3S(O).sub.2, CF.sub.3CH.sub.2S(O).sub.2 and CF.sub.3CF.sub.2S(O).sub.2. Examples of halocycloalkyl include 2-chlorocyclopropyl, 2-fluorocyclobutyl, 3-bromocyclopentyl and 4-chorocyclohexyl.

[0136] Cyanoalkyl denotes an alkyl group substituted with one cyano group. Examples of cyanoalkyl include NCCH.sub.2, NCCH.sub.2CH.sub.2 and CH.sub.3CH(CN)CH.sub.2. Cyanoalkoxy denotes an alkoxy group substituted with one cyano group. Examples of cyanoalkoxy include NCCH.sub.2O, NCCH.sub.2CH.sub.2O and CH.sub.3CH(CN)CH.sub.2O. Cyanoalkylthio denotes an alkylthio group substituted with one cyano group. Examples of cyanoalkylthio include NCCH.sub.2S, NCCH.sub.2CH.sub.2S and CH.sub.3CH(CN)CH.sub.2S. Hydroxyalkyl denotes an alkyl group substituted with one hydroxy group. Examples of hydroxyalkyl include HOCH.sub.2CH.sub.2, CH.sub.3CH.sub.2(OH)CH and HOCH.sub.2CH.sub.2CH.sub.2CH.sub.2.

[0137] Trialkylsilyl includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. The term halotrialkylsilyl is likewise defined. Examples of halotrialkylsilyl include trifluormethylsilyl and trichloromethylsilyl. Trialkylsilyloxy denotes a trialkylsilyl group attached to and linked through an oxygen atom, such as trimethylsilyloxy, triethylsilyloxy and tert-butyldimethylsilyloxy.

[0138] The total number of carbon atoms in a substituent group is indicated by the C.sub.i-C.sub.j prefix where i and j are numbers from 1 to 15. For example, C.sub.1-C.sub.4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C.sub.2 alkoxyalkyl designates CH.sub.3OCH.sub.2; C.sub.3 alkoxyalkyl designates, for example, CH.sub.3CH(OCH.sub.3), CH.sub.3OCH.sub.2CH.sub.2 or CH.sub.3CH.sub.2OCH.sub.2; and C.sub.4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH.sub.3CH.sub.2CH.sub.2OCH.sub.2 and CH.sub.3CH.sub.2OCH.sub.2CH.sub.2.

[0139] Generally when a molecular fragment (i.e. radical) is denoted by a series of atom symbols (e.g., C, H, N, O and S) the implicit point or points of attachment will be easily recognized by those skilled in the art. In some instances herein, particularly when alternative points of attachment are possible, the point or points of attachment may be explicitly indicated by a hyphen (-).

[0140] The term unsubstituted in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1. The term optionally substituted means that the number of substituents can be zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) ranges from 1 to 3. As used herein, the term optionally substituted is used interchangeably with the phrase substituted or unsubstituted or with the term (un)substituted.

[0141] The number of optional substituents may be restricted by an expressed limitation. For example, the phrase optionally substituted with up to 3 substituents independently selected from R.sup.10 means that 0, 1, 2 or 3 substituents can be present (if the number of potential connection points allows). When a range specified for the number of substituents (e.g., y being an integer from 0 to 3 in Exhibit A) exceeds the number of positions available for substituents on a ring (e.g., 1 position available for (R.sup.10).sub.y on G-1 in Exhibit A), the actual higher end of the range is recognized to be the number of available positions.

[0142] When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can vary (e.g., (R.sup.10).sub.y in Exhibit A wherein y is 1 to 3), then said substituents are independently selected from the group of defined substituents, unless otherwise indicated. When a variable group is shown to be optionally attached to a position, for example (R.sup.10).sub.y in Exhibit A wherein y may be 0, then hydrogen may be at the position even if not recited in the definition of the variable group.

[0143] The dotted line in rings depicted in the present description (e.g., the rings G-44, G-45, G-48 and G-49 shown in Exhibit A) represents that the bond indicated can be a single bond or double bond.

[0144] Naming of substituents in the present disclosure uses recognized terminology providing conciseness in precisely conveying to those skilled in the art the chemical structure. For sake of conciseness, locant descriptors may be omitted.

[0145] Unless otherwise indicated, a ring or ring system as a component of Formula 1 (e.g., G) is carbocyclic or heterocyclic. The term ring system denotes two or more connected rings. The term spirocyclic ring system denotes a ring system consisting of two rings connected at a single atom (so the rings have a single atom in common). The term bicyclic ring system denotes a ring system consisting of two rings sharing two or more common atoms. In a fused bicyclic ring system the common atoms are adjacent, and therefore the rings share two adjacent atoms and a bond connecting them.

[0146] The term ring member refers to an atom (e.g., C, O, N or S) or other moiety (e.g., C(O), C(S), S(O) and S(O).sub.2) forming the backbone of a ring or ring system. The term aromatic indicates that each of the ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and that (4n+2) electrons, where n is a positive integer, are associated with the ring to comply with Hckel's rule

[0147] The term carbocyclic ring denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Hckel's rule, then said ring is also called an aromatic ring. Saturated carbocyclic refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.

[0148] As used herein, the term partially unsaturated ring or partially unsaturated heterocycle refers to a ring which contains unsaturated ring atoms and one or more double bonds but is not aromatic.

[0149] The terms heterocyclic ring or heterocycle denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated heterocyclic ring satisfies Hckel's rule, then said ring is also called a heteroaromatic ring or aromatic heterocyclic ring. Saturated heterocyclic ring refers to a heterocyclic ring containing only single bonds between ring members.

[0150] Unless otherwise indicated, heterocyclic rings and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen atom by replacement of a hydrogen on said carbon or nitrogen atom.

[0151] Compounds of this invention can exist as one or more stereoisomers. Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis- and trans-isomers (also known as geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, 1994.

[0152] Compounds of this invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form. For example, when T is T-3, then Formula 1 compounds contain at least one double bond and the configuration of substituents about that double bond can be (Z) or (E) (cis or trans), or a mixture thereof. In the context of the present disclosure and claims, a wavy bond (e.g., as shown in the T-3 moiety in the Summary of the Invention) indicates a single bond which is linked to an adjacent double bond wherein the geometry about the adjacent double bond is either (Z)-configuration (syn-isomer or cis-isomer) or (E)-configuration (anti-isomer or trans-isomer), or a mixture thereof. That is, a wavy bond represents an unspecified (Z)- or (E)- (cis- or trans-) isomer, or mixture thereof. In addition, the compounds of the present invention can contain one or more chiral centers and therefore exist in enantiomeric and diastereomeric forms. Unless the structural formula or the language of this application specifically designate a particular cis- or trans-isomer, or a configuration of a chiral center, the scope of the present invention is intended to cover all such isomers per se, as well as mixtures of cis- and trans-isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well.

[0153] This invention also includes compounds of Formula 1 wherein one stereoisomer is enriched relative to the other stereoisomer(s). Of note are compounds of Formula 1 wherein T is T-3 and the substituents attached to the double bond in the T-3 moiety are in a predominately (Z)-configuration, or predominately an (E)-configuration. The ratio of the (Z)- to (E)-isomers in any compounds of Formula 1, whether produced stereoselectivity or non-stereoselectivity, may take on a broad range of values. For example, compounds of Formula 1 may comprise from about 10 to 90 percent by weight of the (Z)-isomer to about 90 to 10 percent by weight of the (E)-isomer. In other embodiments, Formula 1 compounds may contain from about 15 to 85 percent by weight of the (Z)-isomer and about 85 to 15 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 25 to 75 percent by weight of the (Z)-isomer and about 75 to 25 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 35 to 65 percent by weight of the (Z)-isomer and about 65 to 35 percent by weight of the (E)-isomer; in another embodiment, the mixture contains about 45 to 55 percent by weight of the (Z)-isomer and about 55 to 45 percent by weight of the (E)-isomer. These percentages by weight are based on the total weight of the composition, and it will be understood that the sum of the weight percent of the (Z)-isomer and the (E)-isomer is 100 weight percent. In other words, compounds of Formula 1 might contain 65 percent by weight of the (Z)-isomer and 35 percent by weight of the (E)-isomer, or vice versa.

[0154] In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1. When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess (ee), which is defined as (2x1).Math.100%, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers).

[0155] Preferably the compositions of this invention have at least a 50% enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

[0156] Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about an amide bond (e.g., C(O)N) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.

[0157] This invention comprises all stereoisomers, conformational isomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds.

[0158] One skilled in the art will appreciate that not all nitrogen containing heterocycles can form N-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form N-oxides. One skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18-20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol. 43, pp 149-161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, vol. 9, pp 285-291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

[0159] One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1, N-oxides, and agriculturally suitable salts, and solvates thereof.

[0160] Compounds selected from Formula 1, stereoisomers, tautomers, N-oxides, and salts thereof, typically exist in more than one form, and Formula 1 thus includes all crystalline and non-crystalline forms of the compounds that Formula 1 represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term polymorph refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1. Preparation and isolation of a particular polymorph of a compound represented by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., Polymorphism in the Pharmaceutical Industry, Wiley-VCH, Weinheim, 2006.

[0161] One skilled in the art recognizes that compounds of Formula 1 can exist as mixtures of ketonic and solvated forms (e.g., hemiketals, ketals and hydrates) and each are independently interconvertible and agriculturally active. For example, ketones of Formula 11 (i.e. compounds of Formula 1 wherein T is T-1) may exist in equilibrium with their corresponding hydrates of Formula 1.sup.2 (i.e. compounds of Formula 1 wherein T is T-2, and R.sup.2aX and R.sup.2bY are both OH). In cases where the ketone group is in close proximity to an electron-withdrawing group, such as when R.sup.1 is a trifluoromethyl group, the equilibrium typically favors the hydrate form.

##STR00006##

[0162] This invention comprises all ketonic and solvated forms of Formula 1 compounds, and mixtures thereof in all proportions. Unless otherwise indicated, reference to a compound by one tautomer description is to be considered to include all tautomers.

[0163] Additionally, some of the unsaturated rings and ring systems depicted in Exhibit A can have an arrangement of single and double bonds between ring members different from that depicted. Such differing arrangements of bonds for a particular arrangement of ring atoms correspond to different tautomers. For these unsaturated rings and ring systems, the particular tautomer depicted is to be considered representative of all the tautomers possible for the arrangement of ring atoms shown.

[0164] As described in the Summary of the Invention, an aspect of the present invention is directed to a composition comprising (a) at least one compound selected from Formula 1, N-oxides, and salts thereof, with (b) at least one additional fungicidal compound. More particularly, Component (b) is selected from the group consisting of [0165] (b1) methyl benzimidazole carbamate (MBC) fungicides; [0166] (b2) dicarboximide fungicides; [0167] (b3) demethylation inhibitor (DMI) fungicides; [0168] (b4) phenylamide (PA) fungicides; [0169] (b5) amine/morpholine fungicides; [0170] (b6) phospholipid biosynthesis inhibitor fungicides; [0171] (b7) succinate dehydrogenase inhibitor (SDHI) fungicides; [0172] (b8) hydroxy(2-amino-)pyrimidine fungicides; [0173] (b9) anilinopyrimidine (AP) fungicides; [0174] (b10) N-phenyl carbamate fungicides; [0175] (b11) quinone outside inhibitor (QoI) fungicides; [0176] (b12) phenylpyrrole (PP) fungicides; [0177] (b13) azanaphthalene fungicides; [0178] (b14) cell peroxidation inhibitor fungicides; [0179] (b15) melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; [0180] (b16a) melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides; [0181] (b16b) melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides; [0182] (b17) keto reductase inhibitor (KRI) fungicides; [0183] (b18) squalene-epoxidase inhibitor fungicides; [0184] (b19) polyoxin fungicides; [0185] (b20) phenylurea fungicides; [0186] (b21) quinone inside inhibitor (QiI) fungicides; [0187] (b22) benzamide and thiazole carboxamide fungicides; [0188] (b23) enopyranuronic acid antibiotic fungicides; [0189] (b24) hexopyranosyl antibiotic fungicides; [0190] (b25) glucopyranosyl antibiotic: protein synthesis fungicides; [0191] (b26) glucopyranosyl antibiotic fungicides; [0192] (b27) cyanoacetamideoxime fungicides; [0193] (b28) carbamate fungicides; [0194] (b29) oxidative phosphorylation uncoupling fungicides; [0195] (b30) organo tin fungicides; [0196] (b31) carboxylic acid fungicides; [0197] (b32) heteroaromatic fungicides; [0198] (b33) phosphonate fungicides; [0199] (b34) phthalamic acid fungicides; [0200] (b35) benzotriazine fungicides; [0201] (b36) benzene-sulfonamide fungicides; [0202] (b37) pyridazinone fungicides; [0203] (b38) thiophene-carboxamide fungicides; [0204] (b39) complex I NADH oxido-reductase inhibitor fungicides; [0205] (b40) carboxylic acid amide (CAA) fungicides; [0206] (b41) tetracycline antibiotic fungicides; [0207] (b42) thiocarbamate fungicides; [0208] (b43) benzamide fungicides; [0209] (b44) microbial fungicides; [0210] (b45) quinone outside inhibitor, stigmatellin binding (QoSI) fungicides; [0211] (b46) plant extract fungicides; [0212] (b47) cyanoacrylate fungicides; [0213] (b48) polyene fungicides; [0214] (b49) oxysterol binding protein inhibitor (OSBPI) fungicides; [0215] (b50) aryl-phenyl-ketone fungicides; [0216] (b51) host plant defense induction fungicides; [0217] (b52) multi-site activity fungicides; [0218] (b53) biologicals with multiple modes of action; [0219] (b54) fungicides other than fungicides of component (a) and components (b1) through (b53); and [0220] salts of compounds of (b1) through (b54).

[0221] Of note are embodiments wherein component (b) comprises at least one fungicidal compound from each of two different groups selected from (b1) through (b54).

[0222] Methyl benzimidazole carbamate (MBC) fungicides (b1) (FRAC code 1) inhibit mitosis by binding to -tubulin during microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Methyl benzimidazole carbamate fungicides include benzimidazole and thiophanate fungicides. The benzimidazoles include benomyl, carbendazim, fuberidazole and thiabendazole. The thiophanates include thiophanate and thiophanate-methyl.

[0223] Dicarboximide fungicides (b2) (FRAC code 2) inhibit a mitogen-activated protein (MAP)/histidine kinase in osmotic signal transduction. Examples include chlozolinate, dimethachlone, iprodione, procymidone and vinclozolin.

[0224] Demethylation inhibitor (DMI) fungicides (b3) (FRAC code 3) (Sterol Biosynthesis Inhibitors (SBI): Class I) inhibit C14-demethylase, which plays a role in sterol production. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. DMI fungicides are divided between several chemical classes: piperazines, pyridines, pyrimidines, imidazoles, triazoles and triazolinthiones. The piperazines include triforine. The pyridines include buthiobate, pyrifenox, pyrisoxazole and (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol. The pyrimidines include fenarimol, nuarimol and triarimol. The imidazoles include econazole, imazalil, oxpoconazole, pefurazoate, prochloraz and triflumizole. The triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, uniconazole-P, -(1-chlorocyclopropyl)--[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione and rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole. The triazolinthiones include prothioconazole. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective FungicidesProperties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258.

[0225] Phenylamide (PA) fungicides (b4) (FRAC code 4) are specific inhibitors of RNA polymerase in Oomycete fungi. Sensitive fungi exposed to these fungicides show a reduced capacity to incorporate uridine into rRNA. Growth and development in sensitive fungi is prevented by exposure to this class of fungicide. Phenylamide fungicides include acylalanine, oxazolidinone and butyrolactone fungicides. The acylalanines include benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl and metalaxyl-M (also known as mefenoxam). The oxazolidinones include oxadixyl. The butyrolactones include ofurace.

[0226] Amine/morpholine fungicides (b5) (FRAC code 5) (SBI: Class II) inhibit two target sites within the sterol biosynthetic pathway, .sup.8.fwdarw..sup.7 isomerase and .sup.14 reductase. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Amine/morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine and spiroketal-amine fungicides. The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin and piperalin. The spiroketal-amines include spiroxamine.

[0227] Phospholipid biosynthesis inhibitor fungicides (b6) (FRAC code 6) inhibit growth of fungi by affecting phospholipid biosynthesis. Phospholipid biosynthesis fungicides include phophorothiolate and dithiolane fungicides. The phosphorothiolates include edifenphos, iprobenfos and pyrazophos. The dithiolanes include isoprothiolane.

[0228] Succinate dehydrogenase inhibitor (SDHI) fungicides (b7) (FRAC code 7) inhibit complex II fungal respiration by disrupting a key enzyme in the Krebs Cycle (TCA cycle) named succinate dehydrogenase. Inhibiting respiration prevents the fungus from making ATP, and thus inhibits growth and reproduction. SDHI fungicides include phenylbenzamide, phenyloxoethylthiophene amide, pyridinylethylbenzamide, furan carboxamide, oxathiin carboxamide, thiazole carboxamide, pyrazole-4-carboxamide, N-cyclopropyl-N-benzyl-pyrazole carboxamide, N-methoxy-(phenyl-ethyl)-pyrazole carboxamide, pyridine carboxamide and pyrazine carboxamide fungicides. The phenylbenzamides include benodanil, flutolanil and mepronil. The phenyloxoethylthiophene amides include isofetamid. The pyridinylethylbenzamides include fluopyram. The furan carboxamides include fenfuram. The oxathiin carboxamides include carboxin and oxycarboxin. The thiazole carboxamides include thifluzamide. The pyrazole-4-carboxamides include benzovindiflupyr, bixafen, flubeneteram (provisional common name, Registry Number 1676101-39-5), fluindapyr, fluxapyroxad, furametpyr, inpyrfluxam, isopyrazam, penflufen, penthiopyrad, pyrapropoyne (provisional common name, Registry Number 1803108-03-3), sedaxane and N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide. The N-cyclopropyl-N-benzyl-pyrazole carboxamides include isoflucypram. The N-methoxy-(phenyl-ethyl)-pyrazole carboxamides include pydiflumetofen. The pyridine carboxamides include boscalid. The pyrazine carboxamides include pyraziflumid.

[0229] Hydroxy-(2-amino-)pyrimidine fungicides (b8) (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol and ethirimol.

[0230] Anilinopyrimidine (AP) fungicides (b9) (FRAC code 9) are proposed to inhibit biosynthesis of the amino acid methionine and to disrupt the secretion of hydrolytic enzymes that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil.

[0231] N-Phenyl carbamate fungicides (b10) (FRAC code 10) inhibit mitosis by binding to -tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Examples include diethofencarb.

[0232] Quinone outside inhibitor (QoI) fungicides (b11) (FRAC code 11) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Oxidation of ubiquinol is blocked at the quinone outside (Qo) site of the cytochrome bc.sub.1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone outside inhibitor fungicides include methoxyacrylate, methoxyacetamide, methoxycarbamate, oximinoacetate, oximinoacetamide and dihydrodioxazine fungicides (collectively also known as strobilurin fungicides), and oxazolidinedione, imidazolinone and benzylcarbamate fungicides. The methoxyacrylates include azoxystrobin, coumoxystrobin, enoxastrobin (also known as enestroburin), flufenoxystrobin, picoxystrobin and pyraoxystrobin. The methoxyacetamides include mandestrobin. The methoxy-carbamates include pyraclostrobin, pyrametostrobin and triclopyricarb. The oximinoacetates include kresoxim-methyl and trifloxystrobin. The oximinoacetamides include dimoxystrobin, fenaminstrobin, metominostrobin and orysastrobin. The dihydrodioxazines include fluoxastrobin. The oxazolidinediones include famoxadone. The imidazolinones include fenamidone. The benzylcarbamates include pyribencarb.

[0233] Phenylpyrrole (PP) fungicides (b12) (FRAC code 12) inhibit a MAP/histidine kinase associated with osmotic signal transduction in fungi. Fenpiclonil and fludioxonil are examples of this fungicide class.

[0234] Azanaphthalene fungicides (b13) (FRAC code 13) are proposed to inhibit signal transduction by a mechanism which is as yet unknown. They have been shown to interfere with germination and/or appressorium formation in fungi that cause powdery mildew diseases. Azanaphthalene fungicides include aryloxyquinolines and quinazolinones. The aryloxyquinolines include quinoxyfen. The quinazolinones include proquinazid.

[0235] Cell peroxidation inhibitor fungicides (b14) (FRAC code 14) are proposed to inhibit lipid peroxidation which affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes such as respiration and melanin biosynthesis. Cell peroxidation fungicides include aromatic hydrocarbon and 1,2,4-thiadiazole fungicides. The aromatic hydrocarboncarbon fungicides include biphenyl, chloroneb, dicloran, quintozene, tecnazene and tolclofos-methyl. The 1,2,4-thiadiazoles include etridiazole.

[0236] Melanin biosynthesis inhibitor-reductase (MBI-R) fungicides (b15) (FRAC code 16.1) inhibit the naphthal reduction step in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-reductase fungicides include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. The isobenzofuranones include fthalide. The pyrroloquinolinones include pyroquilon. The triazolobenzothiazoles include tricyclazole.

[0237] Melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides (b16a) (FRAC code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-dehydratase fungicides include cyclopropanecarboxamide, carboxamide and propionamide fungicides. The cyclopropanecarboxamides include carpropamid. The carboxamides include diclocymet. The propionamides include fenoxanil.

[0238] Melanin biosynthesis inhibitor-polyketide synthase (MBI-P) fungicides (b16b) (FRAC code 16.3) inhibit polyketide synthase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitor-polyketide synthase fungicides include trifluoroethylcarbamate fungicides. The trifluoroethylcarbamates include tolprocarb.

[0239] Keto reductase inhibitor (KRI) fungicides (b17) (FRAC code 17) inhibit 3-keto reductase during C4-demethylation in sterol production. Keto reductase inhibitor fungicides (also known as Sterol Biosynthesis Inhibitors (SBI): Class III) include hydroxyanilides and amino-pyrazolinones. Hydroxyanilides include fenhexamid. Amino-pyrazolinones include fenpyrazamine. Quinofumelin (provisional common name, Registry Number 861647-84-9) and ipflufenoquin (provisional common name, Registry Number 1314008-27-9) are also believed to be keto reductase inhibitor fungicides.

[0240] Squalene-epoxidase inhibitor fungicides (b18) (FRAC code 18) (SBJ: Class IV) inhibit squalene-epoxidase in the sterol biosynthesis pathway. Sterols such as ergosterol are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include thiocarbamate and allylamine fungicides. The thiocarbamates include pyributicarb. The allylamines include naftifine and terbinafine.

[0241] Polyoxin fungicides (b19) (FRAC code 19) inhibit chitin synthase. Examples include polyoxin.

[0242] Phenylurea fungicides (b20) (FRAC code 20) are proposed to affect cell division. Examples include pencycuron.

[0243] Quinone inside inhibitor (QiI) fungicides (b21) (FRAC code 21) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. Reduction of ubiquinone is blocked at the quinone inside (Qi) site of the cytochrome bc.sub.1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone inside inhibitor fungicides include cyanoimidazole, sulfamoyltriazole and picolinamide fungicides. The cyanoimidazoles include cyazofamid. The sulfamoyltriazoles include amisulbrom. The picolinamides include fenpicoxamid (Registry Number 517875-34-2) and metarylpicoxamid.

[0244] Benzamide and thiazole carboxamide fungicides (b22) (FRAC code 22) inhibit mitosis by binding to -tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. The benzamides include toluamides such as zoxamide. The thiazole carboxamides include ethylaminothiazole carboxamides such as ethaboxam.

[0245] Enopyranuronic acid antibiotic fungicides (b23) (FRAC code 23) inhibit growth of fungi by affecting protein biosynthesis. Examples include blasticidin-S.

[0246] Hexopyranosyl antibiotic fungicides (b24) (FRAC code 24) inhibit growth of fungi by affecting protein biosynthesis. Examples include kasugamycin.

[0247] Glucopyranosyl antibiotic: protein synthesis fungicides (b25) (FRAC code 25) inhibit growth of fungi by affecting protein biosynthesis. Examples include streptomycin.

[0248] Glucopyranosyl antibiotic fungicides (b26) (FRAC code U18, previously FRAC code 26 reclassified to U18) are proposed to inhibit trehalase and inositol biosynthesis. Examples include validamycin.

[0249] Cyanoacetamideoxime fungicides (b27) (FRAC code 27) include cymoxanil.

[0250] Carbamate fungicides (b28) (FRAC code 28) are considered multi-site inhibitors of fungal growth. They are proposed to interfere with the synthesis of fatty acids in cell membranes, which then disrupts cell membrane permeability. Iodocarb, propamacarb and prothiocarb are examples of this fungicide class.

[0251] Oxidative phosphorylation uncoupling fungicides (b29) (FRAC code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibiting respiration prevents normal fungal growth and development. This class includes dinitrophenyl crotonates such as binapacryl, meptyldinocap and dinocap, and 2,6-dinitroanilines such as fluazinam.

[0252] Organo tin fungicides (b30) (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide.

[0253] Carboxylic acid fungicides (b31) (FRAC code 31) inhibit growth of fungi by affecting deoxyribonucleic acid (DNA) topoisomerase type II (gyrase). Examples include oxolinic acid.

[0254] Heteroaromatic fungicides (b32) (FRAC code 32) are proposed to affect DNA/ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazoles and isothiazolones. The isoxazoles include hymexazole and the isothiazolones include octhilinone.

[0255] Phosphonate fungicides (b33) (FRAC code P07, previously FRAC code 33 reclassified to P07) include phosphorous acid and its various salts, including fosetyl-aluminum.

[0256] Phthalamic acid fungicides (b34) (FRAC code 34) include teclofthalam.

[0257] Benzotriazine fungicides (b35) (FRAC code 35) include triazoxide.

[0258] Benzene-sulfonamide fungicides (b36) (FRAC code 36) include flusulfamide.

[0259] Pyridazinone fungicides (b37) (FRAC code 37) include diclomezine.

[0260] Thiophene-carboxamide fungicides (b38) (FRAC code 38) are proposed to affect ATP production. Examples include silthiofam.

[0261] Complex I NADH oxidoreductase inhibitor fungicides (b39) (FRAC code 39) inhibit electron transport in mitochondria and include pyrimidinamines such as diflumetorim, pyrazole-5-carboxamides such as tolfenpyrad, and quinazoline such as fenazaquin.

[0262] Carboxylic acid amide (CAA) fungicides (b40) (FRAC code 40) inhibit cellulose synthase which prevents growth and leads to death of the target fungus. Carboxylic acid amide fungicides include cinnamic acid amide, valinamide carbamate and mandelic acid amide fungicides. The cinnamic acid amides include dimethomorph, flumorph and pyrimorph. The valinamide carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, tolprocarb and valifenalate (also known as valiphenal). The mandelic acid amides include mandipropamid, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide and N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide.

[0263] Tetracycline antibiotic fungicides (b41) (FRAC code 41) inhibit growth of fungi by affecting protein synthesis. Examples include oxytetracycline.

[0264] Thiocarbamate fungicides (b42) (FRAC code M12, previously FRAC code 42 reclassified to M12) include methasulfocarb.

[0265] Benzamide fungicides (b43) (FRAC code 43) inhibit growth of fungi by delocalization of spectrin-like proteins. Examples include pyridinylmethyl benzamides such as fluopicolide and fluopimomide.

[0266] Microbial fungicides (b44) (FRAC code BM02, previously FRAC code 44 reclassified to BM02) disrupt fungal pathogen cell membranes. Microbial fungicides include Bacillus species such as Bacillus amyloliquefaciens strains AP-136, AP-188, AP-218, AP-219, AP-295, QST713, FZB24, F727, MB1600, D747, TJ100 (also called strain 1 BE; known from EP2962568), and the fungicidal lipopeptides which they produce.

[0267] Quinone outside inhibitor, stigmatellin binding (QoSI) fungicides (b45) (FRAC code 45) inhibit complex III mitochondrial respiration in fungi by affecting ubiquinone reductase at the quinone outside (Qo) site, stigmatellin binding sub-site, of the cytochrome bc.sub.1 complex. Inhibiting mitochondrial respiration prevents normal fungal growth and development. QoSI fungicides include triazolopyrimidylamines such as ametoctradin.

[0268] Plant extract fungicides (b46) (FRAC code 46) cause cell membrane disruption. Plant extract fungicides include terpene hydrocarbons, terpene alcohols and terpen phenols such as the extract from Melaleuca alternifolia (tea tree) and plant oils (mixtures) such as eugenol, geraniol and thymol.

[0269] Cyanoacrylate fungicides (b47) (FRAC code 47) bind to the myosin motor domain and effect motor activity and actin assembly. Cyanoacrylates include fungicides such as phenamacril.

[0270] Polyene fungicides (b48) (FRAC code 48) cause disruption of the fungal cell membrane by binding to ergosterol, the main sterol in the membrane. Examples include natamycin (pimaricin).

[0271] Oxysterol binding protein inhibitor (OSBPI) Fungicides (b49) (FRAC code 49) bind to the oxysterol-binding protein in oomycetes causing inhibition of zoospore release, zoospore motility and sporangia germination. Oxysterol binding fungicides include piperdinylthiazoleisoxazolines such as oxathiapiprolin and fluoxapiprolin.

[0272] Aryl-phenyl-ketone fungicides (b50) (FRAC code 50, previously FRAC code U8 reclassified to 50) inhibit the growth of mycelium in fungi. Aryl-phenyl ketone fungicides include benzophenones such as metrafenone, and benzoylpyridines such as pyriofenone.

[0273] Host plant defense induction fungicides (b51) induce host plant defense mechanisms. Host plant defense induction fungicides include benzothiadiazole (FRAC code P01), benzisothiazole (FRAC code P02), thiadiazole carboxamide (FRAC code P03), polysaccharide (FRAC code P04), plant extract (FRAC code P05), microbial (FRAC code P06) and phosphonate fungicides (FRAC code P07, see (b33) above). The benzothiadiazoles include acibenzolar-S-methyl. The benzisothiazoles include probenazole. The thiadiazole carboxamides include tiadinil and isotianil. The polysaccharides include laminarin. The plant extracts include extract from Reynoutria sachalinensis (giant knotweed). The microbials include Bacillus mycoides isolate J and cell walls of Saccharomyces cerevisiae strain LAS117.

[0274] Multi-site activity fungicides (b52) inhibit fungal growth through multiple sites of action and have contact/preventive activity. Multi-site activity fungicides include copper fungicides (FRAC code M01), sulfur fungicides (FRAC code M02), dithiocarbamate fungicides (FRAC code M03), phthalimide fungicides (FRAC code M04), chloronitrile fungicides (FRAC code M05), sulfamide fungicides (FRAC code M06), multi-site contact guanidine fungicides (FRAC code M07), triazine fungicides (FRAC code M08), quinone fungicides (FRAC code M09), quinoxaline fungicides (FRAC code M10), maleimide fungicides (FRAC code M11) and thiocarbamate (FRAC code M12, see (b42) above) fungicides. Copper fungicides are inorganic compounds containing copper, typically in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate and copper hydroxide (e.g., including compositions such as Bordeaux mixture (tribasic copper sulfate). Sulfur fungicides are inorganic chemicals containing rings or chains of sulfur atoms; examples include elemental sulfur. Dithiocarbamate fungicides contain a dithiocarbamate molecular moiety; examples include ferbam, mancozeb, maneb, metiram, propineb, thiram, zinc thiazole, zineb and ziram. Phthalimide fungicides contain a phthalimide molecular moiety; examples include folpet, captan and captafol. Chloronitrile fungicides contain an aromatic ring substituted with chloro and cyano; examples include chlorothalonil. Sulfamide fungicides include dichlofluanid and tolyfluanid. Multi-site contact guanidine fungicides include, guazatine, iminoctadine albesilate and iminoctadine triacetate. Triazine fungicides include anilazine. Quinone fungicides include dithianon. Quinoxaline fungicides include quinomethionate (also known as chinomethionate). Maleimide fungicides include fluoroimide.

[0275] Biologicals with multiple modes of action (b53) include agents from biological origins showing multiple mechanisms of action without evidence of a dominating mode of action. This class of fungicides includes polypeptide (lectin), phenol, sesquiterpene, tritepenoid and coumarin fungicides (FRAC code BM01) such as extract from the cotyledons of lupine plantlets. This class also includes momicrobial fungicides (FRAC code BM02, see (b44) above).

[0276] Fungicides other than fungicides of component (a) and components (b1) through (b53); (b54); include certain fungicides whose mode of action may be unknown. These include: (b54.1) phenyl-acetamide fungicides (FRAC code U06), (b54.2) guanidine fungicides (FRAC code U12), (b54.3) thiazolidine fungicides (FRAC code U13), (b54.4) pyrimidinone-hydrazone fungicides (FRAC code U14), (b54.5) 4-quinolylacetate fungicides (FRAC code U16), (54.6) tetrazolyloxime fungicides (FRAC code U17) and glucopyranosyl antibiotic fungicides (FRAC code U18, see (b26) above). The phenyl-acetamides include cyflufenamid. The guanidines include dodine. The thiazolidines include flutianil. The pyrimidinonehydrazones include ferimzone. The 4-quinolylacetates include tebufloquin. The tetrazolyloximes include picarbutrazox.

[0277] The (b54) class also includes bethoxazin, dichlobentiazox (provisional common name, Registry Number 957144-77-3), dipymetitrone (provisional common name, Registry Number 16114-35-5), flometoquin, neo-asozin (ferric methanearsonate), pyrrolnitrin, tolnifanide (Registry Number 304911-98-6), N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate, N-[5-bromo-2-methyl-6-(1-methyl-2-propoxyethoxy)-3-pyridinyl]-N-ethyl-N-methyl-methanimidamide, N-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxyethoxy]-3-pyridinyl]-N-ethyl-N-methyl-methanimidamide, and N-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxyethoxy]-3-pyridinyl]-N-ethyl-N-methyl-methanimidamide.

[0278] Additional Fungicides other than fungicides of classes (1) through (54) whose mode of action may be unknown, or may not yet be classified include a fungicidal compound selected from components (b54.7) through (b54.13), as described below.

[0279] Component (54.7) relates to (1S)-2,2-bis(4-fluorophenyl)-1-methylethyl N-[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]-L-alaninate (provisional common name florylpicoxamid, Registry Number 1961312-55-9) which is believed to be a Quinone inside inhibitor (QiI) fungicide (FRAC code 21) inhibiting the Complex III mitochondrial respiration in fungi.

[0280] Component (54.8) relates to 1-[2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-3-methylphenyl]-1,4-dihydro-4-methyl-5H-tetrazol-5-one (provisional common name metyltetraprole, Registry Number 1472649-01-6), which is believed to be a quinone outside inhibitor (QoI) fungicide (FRAC code 45) inhibiting the Complex III mitochondrial respiration in fungi, and is effective against QoI resistant strains.

[0281] Component (54.9) relates to 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine (provisional common name pyridachlometyl, Registry Number 1358061-55-8), which is believed to be promoter tubulin polymerization, resulting antifungal activity against fungal species belonging to the phyla Ascomycota and Basidiomycota.

[0282] Component (54.10) relates to (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate (provisional common name aminopyrifen, Registry Number 1531626-08-0) which is believed to inhibit GWT-1 protein in glycosylphosphatidylinositol-anchor biosynthesis in Neurospora crassa.

Component (b54.11) Relates a Compound of Formula b54.11

##STR00007## [0283] wherein [0284] R.sup.b1 and R.sup.b3 are each independently halogen; and [0285] R.sup.b2 is H, halogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl or C.sub.3-C.sub.6 cycloalkyl.
Examples of compounds of Formula b54.11 include (b54.11a) methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, (b54.11b) methyl N-[[5-[1-(4-cyclopropyl-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, (b54.11c) methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]-methyl]carbamate, (b54.11d) methyl N-[[5-[1-(4-cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, (b54.11e) methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate and (b54.11f) methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate. Compounds of Formula b54.11, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publications WO 2008/124092, WO 2014/066120 and WO 2020/097012.

Component (b54.12) Relates a Compound of Formula b54.12

##STR00008##

wherein [0286] R.sup.b4 is

##STR00009## [0287] R.sup.b6 is C.sub.2-C.sub.4 alkoxycarbonyl or C.sub.2-C.sub.4 haloalkylaminocarbonyl; [0288] L is CH.sub.2 or CH.sub.2O, wherein the atom to the right is connected to the phenyl ring in Formula b54.12; and [0289] R.sup.b5 is

##STR00010##

Examples of compounds of Formula b54.12 include (b54.12a) N-(2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide and (b54.12b) ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl]-1H-pyrazole-4-carboxylate. Compounds of Formula b54.12, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publication WO 2020/056090.

Component (b54.13) Relates a Compound of Formula b54.13

##STR00011## [0290] wherein [0291] R.sup.b7, R.sup.b8 and R.sup.b9 are each independently H, halogen or cyano; and [0292] R.sup.b10 and R.sup.b11 are each independently H, halogen, C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 methoxy.
Examples of compounds of Formula b54.13 include (b54.13a) 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (b54.13b) 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (b54.13c) 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-benzonitrile and (b54.13d) N-(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine. Compounds of Formula b54.13, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publication WO 2020051402.

[0293] Component (54.14) relates to N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (common name flufenoxadiazam, Registry Number 1839120-27-2), which is believed to be a class II histone deacetylases (HDAC) inhibitor.

[0294] Embodiments of the present invention as described in the Summary of the Invention include those described below. In the following Embodiments, Formula 1 includes stereoisomers, N-oxides, and salts thereof, and reference to a compound of Formula 1 includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.

[0295] Embodiment 1. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, T is T-1.

[0296] Embodiment 2. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, T is T-2.

[0297] Embodiment 3. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, T is T-3.

[0298] Embodiment 4. The composition comprising components (a) and (b) described in the Summary of the Invention wherein in Formula 1, T is T-2 or T-3.

[0299] Embodiment 5. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 4 wherein in Formula 1, R.sup.1 is CF.sub.3.

[0300] Embodiment 6. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 5 wherein in Formula 1, W is O or S.

[0301] Embodiment 7. The composition of Embodiment 6 wherein W is O.

[0302] Embodiment 8. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 6 wherein in Formula 1, W is NR.sup.3.

[0303] Embodiment 9. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 8 wherein in Formula 1, R.sup.3 is H, cyano, C(O)OH, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl, OR.sup.3a or NR.sup.3bR.sup.3c.

[0304] Embodiment 10. The composition of Embodiment 8 wherein R.sup.3 is H, cyano, C.sub.1-C.sub.2 alkyl or OR.sup.3a.

[0305] Embodiment 11. The composition of Embodiment 10 wherein R.sup.3 is H, cyano or OR.sup.3a.

[0306] Embodiment 12. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 11 wherein in Formula 1, R.sup.3a is H, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.3 alkylcarbonyl or C.sub.2-C.sub.3 haloalkylcarbonyl.

[0307] Embodiment 13. The composition of Embodiment 12 wherein R.sup.3a is H.

[0308] Embodiment 14. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 13 wherein in Formula 1, when R.sup.3b is separate (i.e. not taken together with R.sup.3c to form a ring), then R.sup.3b is H, C.sub.1-C.sub.3 alkyl, C.sub.2-C.sub.3 alkylcarbonyl or C.sub.2-C.sub.3 haloalkylcarbonyl.

[0309] Embodiment 15. The composition of Embodiment 14 wherein R.sup.3b is H or methyl.

[0310] Embodiment 16. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 15 wherein in Formula 1, when R.sup.3c is separate (i.e. not taken together with R.sup.3b to form a ring), then R.sup.3c is H or C.sub.1-C.sub.2 alkyl.

[0311] Embodiment 17. The composition of Embodiment 16 wherein R.sup.3c is H or methyl.

[0312] Embodiment 18. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 17 wherein in Formula 1, X is O or NR.sup.4a.

[0313] Embodiment 19. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 17 wherein in Formula 1, X is O, S, NH or NOH.

[0314] Embodiment 20. The composition of Embodiment 19 wherein X is O or NOH.

[0315] Embodiment 21. The composition of Embodiment 20 wherein X is O.

[0316] Embodiment 22. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 21 wherein in Formula 1, Y is O or NR.sup.4b.

[0317] Embodiment 23. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 21 wherein in Formula 1, Y is O, S, NH or NOH.

[0318] Embodiment 24. The composition of Embodiment 23 wherein Y is O or NOH.

[0319] Embodiment 25. The composition of Embodiment 24 wherein Y is O.

[0320] Embodiment 26. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 25 wherein in Formula 1, wherein R.sup.4a and R.sup.4b are each independently H, hydroxy or C.sub.1-C.sub.2 alkyl.

[0321] Embodiment 27. The composition of Embodiment 26 wherein R.sup.4a and R.sup.4b are each independently H, hydroxy or methyl.

[0322] Embodiment 28. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 27 wherein in Formula 1, when R.sup.2a and R.sup.2b are separate (i.e. not taken together to form a ring), R.sup.2a and R.sup.2b are each independently H, C.sub.1-C.sub.3 alkyl, C.sub.2-C.sub.3 alkenyl, C.sub.3-C.sub.15 trialkylsilyl or C.sub.3-C.sub.15 halotrialkylsilyl.

[0323] Embodiment 29. The composition comprising components (a) and (b) described in the Summary of the Invention or Embodiment 28 wherein in Formula 1, R.sup.2a and R.sup.2b are each independently H, C.sub.1-C.sub.3 alkyl, C.sub.2-C.sub.3 alkenyl, trimethylsilyl or halotrimethylsilyl.

[0324] Embodiment 30. The composition of Embodiment 29 wherein R.sup.2a and R.sup.2b are each independently H, C.sub.1-C.sub.2 alkyl, trimethylsilyl or halotrimethylsilyl.

[0325] Embodiment 31. The composition of Embodiment 30 wherein R.sup.2a and R.sup.2b are each independently H or C.sub.1-C.sub.2 alkyl.

[0326] Embodiment 32. The composition of Embodiment 31 wherein R.sup.2a and R.sup.2b are each independently H or methyl.

[0327] Embodiment 33. The composition of Embodiment 32 wherein R.sup.2a and R.sup.2b are each H.

[0328] Embodiment 34. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 33 wherein in Formula 1, when R.sup.2a and R.sup.2b are taken together to form a ring (i.e. not separate), then R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(O) and C(S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members.

[0329] Embodiment 35. The composition of Embodiment 34 wherein R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is C(O), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members.

[0330] Embodiment 36. The composition of Embodiment 35 wherein R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl and methoxy on carbon atom ring members.

[0331] Embodiment 37. The composition of Embodiment 37 wherein R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member.

[0332] Embodiment 38. The composition of Embodiment 37 wherein R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms.

[0333] Embodiment 39. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 38 wherein in Formula 1, R.sup.2c is C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.3 haloalkenyl, C.sub.2-C.sub.3 alkynyl or C.sub.2-C.sub.3 haloalkynyl, each optionally substituted with up 1 substituent selected from cyano, hydroxy, SCN and C.sub.1-C.sub.2 alkoxy.

[0334] Embodiment 40. The composition of Embodiment 39 wherein R.sup.2c is C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.3 haloalkenyl, C.sub.2-C.sub.3 alkynyl or C.sub.2-C.sub.3 haloalkynyl, each optionally substituted with up 1 substituent selected from cyano and methoxy.

[0335] Embodiment 41. The composition of Embodiment 40 wherein R.sup.2c is C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.3 haloalkenyl or C.sub.2-C.sub.3 alkynyl.

[0336] Embodiment 42. The composition of Embodiment 41 wherein R.sup.2c is C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.3 alkenyl or C.sub.2-C.sub.3 alkynyl.

[0337] Embodiment 43. The composition of Embodiment 42 wherein R.sup.2c is methyl or ethyl.

[0338] Embodiment 44. The composition of Embodiment 43 wherein R.sup.2c is ethyl.

[0339] Embodiment 45. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 44 wherein in Formula 1, R.sup.2d is H, cyano, halogen or C.sub.1-C.sub.2 alkyl.

[0340] Embodiment 46. The composition of Embodiment 45 wherein R.sup.2d is H, cyano, Cl, F or methyl.

[0341] Embodiment 47. The composition of Embodiment 47 wherein R.sup.2d is H or methyl.

[0342] Embodiment 48. The composition of Embodiment 47 wherein R.sup.2d is H.

[0343] Embodiment 49. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 48 wherein in Formula 1, wherein A.sup.1 is CH.sub.2, NH, O or S

[0344] Embodiment 50. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 48 wherein in Formula 1, wherein A.sup.1 is CR.sup.5aR.sup.5b, O or S.

[0345] Embodiment 51. The composition of Embodiment 50 wherein A.sup.1 is CR.sup.5aR.sup.5b or O.

[0346] Embodiment 52. The composition of Embodiment 51 wherein A.sup.1 is CR.sup.5aR.sup.5b.

[0347] Embodiment 53. The composition of Embodiment 51 wherein A.sup.1 is O.

[0348] Embodiment 54. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 48 wherein in Formula 1, A.sup.1 is N(R.sup.6).

[0349] Embodiment 55. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 54 wherein in Formula 1, A.sup.2 is a direct bond, CR.sup.6eR.sup.6f, O or S.

[0350] Embodiment 56. The composition of Embodiment 55 wherein A.sup.2 is a direct bond, CR.sup.5aR.sup.5b, O or S.

[0351] Embodiment 57. The composition of Embodiment 56 wherein A.sup.2 is a direct bond, CR.sup.5aR.sup.5b or O

[0352] Embodiment 58. The composition of Embodiment 57 wherein A.sup.2 is a direct bond, CH.sub.2 or O.

[0353] Embodiment 59. The composition of Embodiment 58 wherein A.sup.2 is a direct bond or CH.sub.2.

[0354] Embodiment 60. The composition of Embodiment 58 wherein A.sup.2 is a direct bond or O.

[0355] Embodiment 61. The composition of Embodiment 60 wherein A.sup.2 is a direct bond.

[0356] Embodiment 62. The composition of Embodiment or any one of Embodiments 1 through 54 wherein A.sup.2 is N(R.sup.6).

[0357] Embodiment 63. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 63 wherein in Formula 1, when A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b, then A.sup.1-A.sup.2-CR.sup.5aR.sup.5b is selected from OCH.sub.2, OCH(Me), CH(OH)CH.sub.2, CH.sub.2CH.sub.2, SCH.sub.2, OCF.sub.2 and CH.sub.2OCH.sub.2.

[0358] Embodiment 64. The composition of Embodiment 63 wherein A.sup.1-A.sup.2-CR.sup.5aR.sup.5b is selected from OCH.sub.2, OCH(Me) and CH.sub.2CH.sub.2.

[0359] Embodiment 65. The composition of Embodiment 64 wherein A.sup.1-A.sup.2-CR.sup.5aR.sup.5b is selected from OCH.sub.2 and CH.sub.2CH.sub.2.

[0360] Embodiment 66. The composition of Embodiment 65 wherein A.sup.1-A.sup.2-CR.sup.5aR.sup.5b is OCH.sub.2.

[0361] Embodiment 67. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 66 wherein in Formula 1, when A is A.sup.1-A.sup.2, then A.sup.1-A.sup.2 is selected from O, CH.sub.2, OCH.sub.2 and CH.sub.2O.

[0362] Embodiment 68. The composition of Embodiment 67 wherein A.sup.1-A.sup.2 is selected from O, CH.sub.2 and CH.sub.2O.

[0363] Embodiment 69. The composition of Embodiment 68 wherein A.sup.1-A.sup.2 is selected from O and CH.sub.2.

[0364] Embodiment 70. The composition of Embodiment 69 wherein A.sup.1-A.sup.2 is O.

[0365] Embodiment 71. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 70 wherein in Formula 1, each R.sup.5a and R.sup.5b is independently H, cyano, hydroxy, Br, Cl, F or methyl.

[0366] Embodiment 72. The composition of Embodiment 71 wherein each R.sup.5a and R.sup.5b is independently H, cyano hydroxy or methyl.

[0367] Embodiment 73. The composition of Embodiment 72 wherein each R.sup.5a and R.sup.5b is independently H or methyl.

[0368] Embodiment 74. The composition of Embodiment 73 wherein each R.sup.5a and R.sup.5b is H.

[0369] Embodiment 75. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 74 wherein in Formula 1, each R.sup.6 is independently H, C.sub.1-C.sub.2 alkyl or C.sub.2-C.sub.3 alkylcarbonyl.

[0370] Embodiment 76. The composition of Embodiment 75 wherein each R.sup.6 is each independently H or C.sub.1-C.sub.2 alkyl.

[0371] Embodiment 77. The composition of Embodiment 76 wherein each R.sup.6 is each H.

[0372] Embodiment 78. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 77 wherein in Formula 1, J is J-1 through J-3, J-6 through J-10, J-14 or J-15.

[0373] Embodiment 79. The composition of Embodiment 78 wherein J is J-1 through J-3, J-6 through J-10 or J-14.

[0374] Embodiment 80. The composition of Embodiment 79 wherein J is J-1, J-2, J-3, J-6 or J-14.

[0375] Embodiment 81. The composition of Embodiment 80 wherein J is J-1, J-6 or J-14.

[0376] Embodiment 82. The composition of Embodiment 81 wherein J is J is J-1 or J-6.

[0377] Embodiment 83. The composition of Embodiment 82 wherein J is J-1.

[0378] Embodiment 84. The composition of Embodiment 82 wherein J is J-6.

[0379] Embodiment 85. The composition of Embodiment 81 wherein J is J-14.

[0380] Embodiment 86. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 85 wherein in Formula 1, each R.sup.7 is independently F, Cl or methyl.

[0381] Embodiment 87. The composition of Embodiment 86 wherein each R.sup.7 is independently F or Cl.

[0382] Embodiment 88. The composition of Embodiment 87 wherein each R.sup.7 is independently F or methyl.

[0383] Embodiment 89. The composition of Embodiment 88 wherein each R.sup.7 is F.

[0384] Embodiment 90. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 89 wherein in Formula 1, q is 0, 1 or 2.

[0385] Embodiment 91. The composition of Embodiment 90 wherein in Formula 1, q is 1 or 2.

[0386] Embodiment 92. The composition of Embodiment 91 wherein in Formula 1, q is 2.

[0387] Embodiment 93. The composition of Embodiment 90 wherein q is 0 or 1.

[0388] Embodiment 94. The composition of Embodiment 93 wherein q is 1.

[0389] Embodiment 95. The composition of Embodiment 93 wherein q is 0.

[0390] Embodiment 96. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 95 wherein in Formula 1, each R.sup.8a and R.sup.8b is independently H, halogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy or C.sub.1-C.sub.3 haloalkoxy.

[0391] Embodiment 97. The composition of Embodiment 96 wherein each R.sup.8a and R.sup.8b is independently H, halogen, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl.

[0392] Embodiment 98. The composition of Embodiment 97 wherein each R.sup.8a and R.sup.8b is independently H, halogen or methyl.

[0393] Embodiment 99. The composition of Embodiment 98 wherein each R.sup.8a and R.sup.8b is independently H or methyl.

[0394] Embodiment 100. The composition of Embodiment 99 wherein each R.sup.8a and R.sup.8b is H.

[0395] Embodiment 101. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 100 wherein in Formula 1, n is 0, 1 or 2.

[0396] Embodiment 102. The composition of Embodiment 101 wherein n is 1 or 2.

[0397] Embodiment 103. The composition of Embodiment 102 wherein n is 2.

[0398] Embodiment 104. The composition of Embodiment 101 wherein n is 0 or 1.

[0399] Embodiment 105. The composition of Embodiment 104 wherein n is 1.

[0400] Embodiment 106. The composition of Embodiment 104 wherein n is 0.

[0401] Embodiment 107. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 106 wherein in Formula 1, L is a direct bond, CH.sub.2, CH(Me) or CH.sub.2CH.sub.2.

[0402] Embodiment 108. The composition of Embodiment 107 wherein L is a direct bond, CH.sub.2 or CH.sub.2CH.sub.2.

[0403] Embodiment 109. The composition of Embodiment 108 wherein L is a direct bond or CH.sub.2.

[0404] Embodiment 110. The composition of Embodiment 109 wherein L is CH.sub.2.

[0405] Embodiment 111. The composition of Embodiment 109 wherein L is a direct bond.

[0406] Embodiment 112. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 111 wherein G is selected from G-1 through G-118 as shown in Exhibit A.

Exhibit A

##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025## [0407] wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3 and y is 0, 1, 2 or 3.

[0408] Embodiment 113. The composition of Embodiment 112 wherein G is G-1 through G-16, G-20, G-22 through G-30, G-36 through G-42, G-54 through G-60, G-85, G-86, G-108, G-110 or G-111.

[0409] Embodiment 114. The composition of Embodiment 113 wherein G is G-1 through G-16, G-20, G-22, G-24, G-25, G-26, G-28, G-29, G-30, G-36, G-37, G-38, G-41, G-42, G-54, G-57, G-58, G-59, G-60, G-85, G-86, G-108, G-110 or G-111.

[0410] Embodiment 115. The composition of Embodiment 114 wherein G is G-1 through G-13, G-20, G-22, G-24, G-25, G-26, G-28, G-29, G-41, G-42, G-54, G-57, G-58, G-59 or G-60.

[0411] Embodiment 116. The composition of Embodiment 115 wherein G is G-1, G-2, G-3, G-7, G-8, G-9, G-10, G-12, G-13, G-20, G-22, G-29, G-42, G-54 or G-58.

[0412] Embodiment 117. The composition of Embodiment 116 wherein G is G-1, G-3, G-12, G-13, G-20, G-22 or G-42.

[0413] Embodiment 118. The composition of Embodiment 117 wherein G is G-1, G-3, G-12, G-13 or G-20.

[0414] Embodiment 118a. The composition of Embodiment 117 wherein G is G-3.

[0415] Embodiment 119. The composition of Embodiment 118 wherein G is G-1, G-12, G-13 or G-20.

[0416] Embodiment 119a. The composition of Embodiment 118 wherein G is G-1, G-12 or G-20.

[0417] Embodiment 119b. The composition of Embodiment 118 wherein G is G-12 or G-20.

[0418] Embodiment 120. The composition of Embodiment 119 wherein G is G-1 or G-12.

[0419] Embodiment 121. The composition of Embodiment 120 wherein G is G-1.

[0420] Embodiment 122. The composition of Embodiment 121 wherein G is G-12.

[0421] Embodiment 123. The composition of Embodiment 122 wherein G is G-13.

[0422] Embodiment 124. The composition of Embodiment 123 wherein G is G-20.

[0423] Embodiment 125. The composition of Embodiment 121 wherein the 2-position of G-1 is connected to Z and the 4-position is connected to R.sup.9.

[0424] Embodiment 126. The composition of Embodiment 121 wherein the 2-position of G-1 is connected to Z and the 5-position is connected to R.sup.9.

[0425] Embodiment 127. The composition of Embodiment 118a wherein the 1-position of G-3 is connected to Z and the 4-position is connected to R.sup.9.

[0426] Embodiment 128. The composition of Embodiment 122 wherein the 1-position of G-12 is connected to Z and the 4-position is connected to R.sup.9.

[0427] Embodiment 129. The composition of Embodiment 122 wherein the 1-position of G-12 is connected to Z and the 3-position is connected to R.sup.9.

[0428] Embodiment 130. The composition of Embodiment 122 wherein the 1-position of G-12 is connected to Z, the 3-position is connected to R.sup.9 and the 5-position is connected to R.sup.10.

[0429] Embodiment 131. The composition of Embodiment 122 wherein the 1-position of G-12 is connected to Z and the 5-position is connected to R.sup.9.

[0430] Embodiment 132. The composition of Embodiment 123 wherein the 1-position of G-13 is connected to Z and the 4-position is connected to R.sup.9.

[0431] Embodiment 133. The composition of Embodiment 123 wherein the 1-position of G-13 is connected to Z and the 5-position is connected to R.sup.9.

[0432] Embodiment 134. The composition of Embodiment 124 wherein the 2-position of G-20 is connected to Z.

[0433] Embodiment 135. The composition of Embodiment 124 wherein the 4-position of G-20 is connected to Z.

[0434] Embodiment 136. The composition of Embodiment 124 wherein the 3-position of G-20 is connected to Z.

[0435] Embodiment 137. The composition of Embodiment 124 wherein the 2-position of G-20 is connected to Z and the 6-position is connected to R.sup.9.

[0436] Embodiment 138. The composition of Embodiment 124 wherein the 4-position of G-20 is connected to Z and the 2-position is connected to R.sup.9.

[0437] Embodiment 139. The composition of any one of Embodiments 112 through 138 wherein x is 1 or 2.

[0438] Embodiment 140. The composition of Embodiment 139 wherein x is 1.

[0439] Embodiment 141. The composition of Embodiment 140 wherein x is 2.

[0440] Embodiment 142. The composition of any one of Embodiments 112 through 141 wherein y is 0, 1 or 2.

[0441] Embodiment 143. The composition of Embodiment 142 wherein y is 0 or 1.

[0442] Embodiment 144. The composition of Embodiment 143 wherein y is 0.

[0443] Embodiment 145. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 144 wherein each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl).

[0444] Embodiment 145a. The composition of Embodiment 145 wherein each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b or C(R.sup.12e)NR.sup.12f.

[0445] Embodiment 145b. The composition of Embodiment 145a wherein each R.sup.9 is independently C(O)NR.sup.12aR.sup.12b or C(R.sup.12e)NR.sup.12f.

[0446] Embodiment 146. The composition of Embodiment 145 wherein each R.sup.9 is independently CH.sub.2R.sup.9a, CH.sub.2CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl).

[0447] Embodiment 147. The composition of Embodiment 146 wherein each R.sup.9 is independently CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl).

[0448] Embodiment 148. The composition of Embodiment 147 wherein each R.sup.9 is independently CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b or C(R.sup.12e)NR.sup.12f.

[0449] Embodiment 149. The composition of Embodiment 148 wherein each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b or C.sub.2-C.sub.4 alkoxy(thiocarbonyl).

[0450] Embodiment 150. The composition of Embodiment 149 wherein each R.sup.9 is independently C.sub.2-C.sub.4 alkoxy(thiocarbonyl).

[0451] Embodiment 151. The composition of Embodiment 149 wherein each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a.

[0452] Embodiment 152. The composition of Embodiment 149 wherein each R.sup.9 is independently CH.sub.2R.sup.9a.

[0453] Embodiment 153. The composition of Embodiment 149 wherein each R.sup.9 is independently C(O)NR.sup.12aR.sup.12b.

[0454] Embodiment 154. The composition of Embodiment 148 wherein each R.sup.9 is independently C(R.sup.12e)NR.sup.12f.

[0455] Embodiment 155. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 151 wherein each m is independently 1 or 2.

[0456] Embodiment 156. The composition of Embodiment 155 wherein each m is 1.

[0457] Embodiment 157. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 156 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl or C.sub.3-C.sub.8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0458] Embodiment 158. The composition of Embodiment 157 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0459] Embodiment 159. The composition of Embodiment 158 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0460] Embodiment 160. The composition of Embodiment 159 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonylalkoxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0461] Embodiment 161. The composition of Embodiment 160 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0462] Embodiment 162. The composition of Embodiment 161 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.13.

[0463] Embodiment 163. The composition of Embodiment 162 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13.

[0464] Embodiment 164. The composition of Embodiment 163 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0465] Embodiment 165. The composition of Embodiment 164 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.13.

[0466] Embodiment 166. The composition of Embodiment 165 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13.

[0467] Embodiment 167. The composition of Embodiment 166 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R.sup.13.

[0468] Embodiment 168. The composition of Embodiment 167 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.4 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R.sup.13.

[0469] Embodiment 169. The composition of Embodiment 168 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d, C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy.

[0470] Embodiment 170. The composition of Embodiment 169 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d.

[0471] Embodiment 171. The composition of Embodiment 170 wherein each R.sup.9a is independently C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy.

[0472] Embodiment 172. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 156 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl or C.sub.3-C.sub.8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13.

[0473] Embodiment 173. The composition of Embodiment 172 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.13.

[0474] Embodiment 173. The composition of Embodiment 173 wherein each R.sup.9a is independently R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.3-C.sub.6 alkenyloxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.13.

[0475] Embodiment 175. The composition of Embodiment 174 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy or C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13.

[0476] Embodiment 176. The composition of Embodiment 175 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy or C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13.

[0477] Embodiment 177. The composition of Embodiment 176 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy or C.sub.2-C.sub.8 alkoxycarbonyloxy, each optionally substituted with up to 1 substituent selected from R.sup.13.

[0478] Embodiment 178. The composition of Embodiment 177 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d, C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy or C.sub.2-C.sub.8 alkoxycarbonyloxy.

[0479] Embodiment 179. The composition of Embodiment 178 wherein each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d, C.sub.2-C.sub.4 alkylcarbonyloxy, C.sub.4-C.sub.5 cycloalkylcarbonyloxy or C.sub.2-C.sub.4 alkoxycarbonyloxy.

[0480] Embodiment 180. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 180 wherein each R.sup.10 is independently cyano, halogen, NR.sup.14aR.sup.14b, C(O)NR.sup.14aR.sup.14b, C(R.sup.15)NR.sup.16, NCR.sup.17NR.sup.18aR.sup.18b or UV-Q; or C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylsulfonyloxy, C.sub.1-C.sub.6 alkylsulfonylamino, C.sub.2-C.sub.6 alkylcarbonyl, C.sub.2-C.sub.6 alkoxycarbonyl, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.3-C.sub.6 alkynyloxycarbonyl, C.sub.4-C.sub.7 cycloalkoxycarbonyl, C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy, C.sub.4-C.sub.7 cycloalkoxycarbonyloxy, C.sub.2-C.sub.6 alkylaminocarbonyloxy, C.sub.2-C.sub.6 alkylcarbonylamino, C.sub.2-C.sub.6 alkoxycarbonylamino or C.sub.2-C.sub.6 alkylaminocarbonylamino, each optionally substituted with up to 3 substituents independently selected from R.sup.19.

[0481] Embodiment 181. The composition of Embodiment 180 wherein each R.sup.10 is independently cyano, halogen, C(O)NR.sup.14aR.sup.14b or UV-Q; or C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylsulfonyloxy, C.sub.1-C.sub.6 alkylsulfonylamino, C.sub.2-C.sub.6 alkylcarbonyl, C.sub.2-C.sub.6 alkoxycarbonyl, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.3-C.sub.6 alkynyloxycarbonyl, C.sub.4-C.sub.6 cycloalkoxycarbonyl or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.19.

[0482] Embodiment 182. The composition of Embodiment 181 wherein each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b or UV-Q; or C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.1-C.sub.6 alkylsulfonyl, C.sub.1-C.sub.6 alkylsulfonyloxy, C.sub.1-C.sub.6 alkylsulfonylamino, C.sub.2-C.sub.6 alkylcarbonyl, C.sub.2-C.sub.6 alkoxycarbonyl, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.3-C.sub.6 alkynyloxycarbonyl, C.sub.4-C.sub.6 cycloalkoxycarbonyl or C.sub.2-C.sub.6 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.19.

[0483] Embodiment 183. The composition of Embodiment 182 wherein each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b or UV-Q; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19.

[0484] Embodiment 184. The composition of Embodiment 183 wherein each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19.

[0485] Embodiment 185. The composition of Embodiment 184 wherein each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b or C.sub.2-C.sub.5 alkoxycarbonyl.

[0486] Embodiment 186. The composition of Embodiment 185 wherein each R.sup.10 is independently halogen or C.sub.2-C.sub.3 alkoxycarbonyl.

[0487] Embodiment 187. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 186 wherein each R.sup.11a and R.sup.11b is independently H, halogen, cyano, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl or C.sub.2-C.sub.3 haloalkoxycarbonyl.

[0488] Embodiment 188. The composition of Embodiment 187 wherein each R.sup.11a and R.sup.11b is independently H, methyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl or C.sub.2-C.sub.3 haloalkoxycarbonyl.

[0489] Embodiment 189. The composition of Embodiment 188 wherein each R.sup.11a and R.sup.11b is independently H, methyl or C.sub.2-C.sub.3 alkoxycarbonyl.

[0490] Embodiment 190. The composition of Embodiment 189 wherein each R.sup.11a and R.sup.11b is independently H, methyl or EtOC(O).

[0491] Embodiment 191. The composition of Embodiment 190 wherein each R.sup.11a and R.sup.11b is independently H or EtOC(O).

[0492] Embodiment 192. The composition of Embodiment 191 wherein each R.sup.11a and R.sup.11b is H.

[0493] Embodiment 193. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 192 wherein in Formula 1, each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl.

[0494] Embodiment 193a. The composition of Embodiment 193 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 alkenyloxy or C.sub.2-C.sub.6 alkynyloxy.

[0495] Embodiment 193b. The composition of Embodiment 193 wherein each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.2-C.sub.4 alkynyloxy.

[0496] Embodiment 194. The composition of Embodiment 193 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy.

[0497] Embodiment 195. The composition of Embodiment 194 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy.

[0498] Embodiment 196. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 192 wherein in Formula 1, each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl.

[0499] Embodiment 197. The composition of Embodiment 196 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl.

[0500] Embodiment 198. The composition of Embodiment 197 wherein each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 cyanoalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy, C.sub.2-C.sub.4 haloalkynyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl.

[0501] Embodiment 199. The composition of Embodiment 198 each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl.

[0502] Embodiment 200. The composition of Embodiment 199 wherein each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy or phenyl-CH.sub.2O.

[0503] Embodiment 201. The composition of Embodiment 200 wherein each R.sup.12a is independently C.sub.1-C.sub.3 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy or C.sub.2-C.sub.4 alkynyloxy.

[0504] Embodiment 202. The composition of Embodiment 197 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy C.sub.4-C.sub.8 cycloalkylalkoxy or phenyl-CH.sub.2O.

[0505] Embodiment 203. The composition of Embodiment 202 wherein each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy.

[0506] Embodiment 204. The composition of Embodiment 203 wherein each R.sup.12a is independently C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy or C.sub.2-C.sub.4 alkynyloxy.

[0507] Embodiment 205. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 204 wherein each R.sup.12b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl.

[0508] Embodiment 206. The composition of Embodiment 205 wherein each R.sup.12b is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl.

[0509] Embodiment 207. The composition of Embodiment 206 wherein each R.sup.12b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0510] Embodiment 208. The composition of Embodiment 207 wherein each R.sup.12b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0511] Embodiment 209. The composition of Embodiment 208 wherein each R.sup.12b is independently H, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl.

[0512] Embodiment 210. The composition of Embodiment 209 wherein each R.sup.12b is independently H or methyl.

[0513] Embodiment 211. The composition of Embodiment 210 wherein each R.sup.12b is H.

[0514] Embodiment 212. The composition of Embodiment 210 wherein each R.sup.12b is methyl.

[0515] Embodiment 213. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 212 wherein when each R.sup.12c is separate (i.e. not taken together with R.sup.12d to form a ring), then each R.sup.12c is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl.

[0516] Embodiment 214. The composition of Embodiment 213 wherein each R.sup.12c is independently C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0517] Embodiment 215. The composition of Embodiment 214 wherein each R.sup.12c is independently C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.4-C.sub.5 cycloalkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0518] Embodiment 216. The composition of Embodiment 215 wherein each R.sup.12c is independently H, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0519] Embodiment 217. The composition of Embodiment 216 wherein each R.sup.12c is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0520] Embodiment 218. The composition of Embodiment 217 wherein each R.sup.12c is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0521] Embodiment 219. The composition of Embodiment 218 wherein each R.sup.12c is independently C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl.

[0522] Embodiment 220. The composition of Embodiment 219 wherein each R.sup.12c is independently H or methyl.

[0523] Embodiment 221. The composition of Embodiment 220 wherein each R.sup.12c is independently H or C.sub.1-C.sub.3 alkoxy.

[0524] Embodiment 222. The composition of Embodiment 221 wherein each R.sup.12c is methoxy.

[0525] Embodiment 223. The composition of Embodiment 222 wherein each R.sup.12c is H.

[0526] Embodiment 224. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 223 wherein when each R.sup.12d is separate (i.e. not taken together with R.sup.12c to form a ring), then each R.sup.12d is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl.

[0527] Embodiment 225. The composition of Embodiment 224 wherein each R.sup.12d is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl.

[0528] Embodiment 226. The composition of Embodiment 225 wherein each R.sup.12d is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0529] Embodiment 227. The composition of Embodiment 226 wherein each R.sup.12d is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0530] Embodiment 228. The composition of Embodiment 227 wherein each R.sup.12d is independently H, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or cyclopropylmethyl.

[0531] Embodiment 229. The composition of Embodiment 228 wherein each R.sup.12d is independently H, methyl or cyclopropylmethyl.

[0532] Embodiment 230. The composition of Embodiment 229 wherein each R.sup.12d is methyl.

[0533] Embodiment 231. The composition of Embodiment 230 wherein each R.sup.12d is H.

[0534] Embodiment 232. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 231 wherein wherein when R.sup.12c and R.sup.12d are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0535] Embodiment 233. The composition of Embodiment 232 wherein R.sup.12c and R.sup.12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0536] Embodiment 234. The composition of Embodiment 233 wherein R.sup.12c and R.sup.12d are taken together to form an azetidinyl or pyrrolidinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0537] Embodiment 235. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 234 wherein each R.sup.12e is independently NH.sub.2, C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.3-C.sub.8 alkoxyalkoxyalkyl, C.sub.2-C.sub.6 alkylaminoalkyl, C.sub.3-C.sub.8 dialkylaminoalkyl or C.sub.3-C.sub.8 alkylcarbonyl.

[0538] Embodiment 236. The composition of Embodiment 235 wherein each R.sup.12e is independently C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.1-C.sub.6 hydroxyalkyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.6 alkoxyalkyl or C.sub.2-C.sub.6 haloalkoxyalkyl.

[0539] Embodiment 237. The composition of Embodiment 236 wherein each R.sup.12e is independently C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.5 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkyl.

[0540] Embodiment 238. The composition of Embodiment 237 wherein each R.sup.12e is independently C.sub.2-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy.

[0541] Embodiment 239. The composition of Embodiment 238 wherein each R.sup.12e is independently C.sub.2-C.sub.3 alkyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy.

[0542] Embodiment 240. The composition of 239 wherein each R.sup.12e is independently C.sub.2-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy.

[0543] Embodiment 241. The composition of Embodiment 240 wherein each R.sup.12e is independently C.sub.2-C.sub.4 alkoxy or C.sub.1-C.sub.3 haloalkoxy.

[0544] Embodiment 242. The composition of Embodiment 241 wherein each R.sup.12e is ethoxy.

[0545] Embodiment 243. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 242 wherein each R.sup.12f is independently hydroxy or NR.sup.20aR.sup.20b; or C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from cyano and halogen.

[0546] Embodiment 244. The composition of 243 wherein each R.sup.12f is independently C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen.

[0547] Embodiment 245. The composition of Embodiment 244 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen.

[0548] Embodiment 246. The composition of Embodiment 245 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy or C.sub.2-C.sub.4 alkylcarbonyloxy.

[0549] Embodiment 247. The composition of Embodiment 246 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.5 cycloalkylalkoxy.

[0550] Embodiment 248. The composition of Embodiment 247 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen.

[0551] Embodiment 249. The composition of Embodiment 248 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen.

[0552] Embodiment 250. The composition of Embodiment 249 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or cyclopropylmethoxy.

[0553] Embodiment 251. The composition of Embodiment 250 wherein each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy.

[0554] Embodiment 252. The composition of Embodiment 251 wherein each R.sup.12f is independently C.sub.3-C.sub.4 alkenyloxy.

[0555] Embodiment 253. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 252 wherein when each R.sup.12i and R.sup.12j is separate (i.e. not taken together to form a ring), then each R.sup.12i and R.sup.12j is independently H, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or C.sub.2-C.sub.4 alkylcarbonyl.

[0556] Embodiment 254. The composition of Embodiment 253 wherein each R.sup.12i and R.sup.12j is independently H, methyl or C.sub.2-C.sub.3 alkylcarbonyl.

[0557] Embodiment 255. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 254 wherein each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsufonyl or C.sub.3-C.sub.6 cycloalkyl.

[0558] Embodiment 256. The composition of Embodiment 255 wherein each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl.

[0559] Embodiment 257. The composition of Embodiment 256 wherein each R.sup.13 is independently halogen, cyano, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl.

[0560] Embodiment 258. The composition of Embodiment 257 wherein each R.sup.13 is independently Br, Cl, F, cyano, methoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.2 alkylthio or cyclopropyl.

[0561] Embodiment 259. The composition of Embodiment 258 wherein each R.sup.13 is independently Br, Cl, F, cyano, methoxy, CH.sub.3OC(O), CH.sub.3S or cyclopropyl.

[0562] Embodiment 260. The composition of Embodiment 259 wherein each R.sup.13 is independently Br, Cl, F, cyano, methoxy, CH.sub.3OC(O) or CH.sub.3S.

[0563] Embodiment 261. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 260 wherein when each R.sup.14a is separate (i.e. not taken together with R.sup.14b to form a ring), then each R.sup.14a is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 haloalkynyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl.

[0564] Embodiment 262. The composition of Embodiment 261 wherein each R.sup.14a is independently H, cyano, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl.

[0565] Embodiment 263. The composition of 262 wherein each R.sup.14a is independently H, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl.

[0566] Embodiment 264. The composition of Embodiment 263 wherein each R.sup.14a is independently H or C.sub.1-C.sub.2 alkyl.

[0567] Embodiment 265. The composition of 264 wherein each R.sup.14a is independently H or methyl.

[0568] Embodiment 266. The composition of Embodiment 265 wherein each R.sup.14a is H.

[0569] Embodiment 267. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 266 wherein when each R.sup.14b is separate (i.e. not taken together with R.sup.14a to form a ring), then each R.sup.14b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl.

[0570] Embodiment 268. The composition of Embodiment 267 wherein each R.sup.14b is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl.

[0571] Embodiment 269. A compound of Embodiment 226 wherein each R.sup.14b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0572] Embodiment 270. The composition of Embodiment 269 wherein each R.sup.14b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl.

[0573] Embodiment 271. The composition of Embodiment 270 wherein each R.sup.14b is independently H, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or cyclopropylmethyl.

[0574] Embodiment 272. The composition of Embodiment 271 wherein each R.sup.14b is independently H, methyl or cyclopropylmethyl.

[0575] Embodiment 273. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 272 wherein when R.sup.14a and R.sup.14b are taken together to form a 4- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0576] Embodiment 274. The composition of Embodiment 273 wherein R.sup.14a and R.sup.14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0577] Embodiment 275. The composition of Embodiment 274 wherein R.sup.14a and R.sup.14b are taken together to form an azetidinyl or pyrrolidinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl.

[0578] Embodiment 276. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 275 wherein in Formula 1, each R.sup.15 is independently H, cyano, halogen, methyl or methoxy.

[0579] Embodiment 277. The composition of Embodiment 276 wherein each R.sup.15 is independently H or methyl.

[0580] Embodiment 278. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 277 wherein in Formula 1, each R.sup.16 is independently hydroxy, NR.sup.20aR.sup.20b, C.sub.1-C.sub.2 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.4 alkoxycarbonyloxy.

[0581] Embodiment 279. The composition of Embodiment 278 wherein each R.sup.16 is independently hydroxy, NR.sup.20aR.sup.20b or C.sub.1-C.sub.4 alkoxy.

[0582] Embodiment 280. The composition of Embodiment 279 wherein each R.sup.16 is independently hydroxy, NR.sup.20aR.sup.20b or methoxy.

[0583] Embodiment 281. The composition of Embodiment 280 wherein each R.sup.16 is hydroxy.

[0584] Embodiment 282. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 281 wherein in Formula 1, each R.sup.17 is independently H or methyl.

[0585] Embodiment 283. The composition of Embodiment 282 wherein each R.sup.17 is H.

[0586] Embodiment 284. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 283 wherein in Formula 1, when each R.sup.18a and R.sup.18b is separate (i.e. not taken together to form a ring), then each R.sup.18a and R.sup.18b is independently H, methyl or ethyl.

[0587] Embodiment 285. The composition of Embodiment 284 wherein each R.sup.18a and R.sup.18b is independently H or methyl.

[0588] Embodiment 286. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 285 wherein in Formula 1, each R.sup.19 is independently cyano, halogen, hydroxy, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy, C.sub.2-C.sub.3 alkoxyalkoxy, C.sub.1-C.sub.3 alkylthio, C.sub.1-C.sub.3 alkylsulfinyl, C.sub.1-C.sub.3 alkylsulfonyl, C.sub.1-C.sub.3 haloalkylsulfonyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl, C.sub.2-C.sub.3 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl.

[0589] Embodiment 287. The composition of Embodiment 286 wherein each R.sup.19 is independently cyano, halogen, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.2 alkoxy, C.sub.1-C.sub.2 haloalkoxy, C.sub.1-C.sub.2 alkylthio, C.sub.1-C.sub.2 alkylsulfonyl, C.sub.1-C.sub.2 haloalkylsulfonyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl or C.sub.2-C.sub.3 alkylaminocarbonyl.

[0590] Embodiment 288. The composition of Embodiment 287 wherein each R.sup.19 is independently cyano, halogen, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.2 alkoxy, C.sub.1-C.sub.2 haloalkoxy, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl or C.sub.2-C.sub.3 alkoxycarbonyl.

[0591] Embodiment 289. The composition of Embodiment 288 wherein each R.sup.19 is independently cyano, halogen, cyclopropyl, cyclobutyl, methoxy, halomethoxy or methoxycarbonyl.

[0592] Embodiment 290. The composition of Embodiment 289 wherein each R.sup.19 is independently cyano, halogen, cyclopropyl or methoxy.

[0593] Embodiment 290a. The composition of Embodiment 290 wherein each R.sup.19 is independently halogen.

[0594] Embodiment 291. The composition of Embodiment 290 wherein each R.sup.19 is independently cyano, Cl, F, cyclopropyl or methoxy.

[0595] Embodiment 292. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 291 wherein in Formula 1, each U is independently a direct bond, C(O)O or C(O)N(R.sup.25).

[0596] Embodiment 293. The composition of Embodiment 292 wherein each U is independently a direct bond or C(O)O.

[0597] Embodiment 294. The composition of Embodiment 293 wherein each U is C(O)O.

[0598] Embodiment 295. The composition of Embodiment 293 wherein each U is a direct bond.

[0599] Embodiment 296. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 295 wherein in Formula 1, each V is independently a direct bond; or C.sub.1-C.sub.6 alkylene, C.sub.2-C.sub.6 alkenylene or C.sub.3-C.sub.6 alkynylene, each optionally substituted with up to 2 substituents independently selected from halogen, cyano, nitro, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy.

[0600] Embodiment 297. The composition of Embodiment 296 wherein each V is independently a direct bond; or C.sub.1-C.sub.3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy.

[0601] Embodiment 298. The composition of Embodiment 297 wherein each V is independently a direct bond or C.sub.1-C.sub.3 alkylene.

[0602] Embodiment 299. The composition of Embodiment 298 wherein each V is independently a direct bond or CH.sub.2.

[0603] Embodiment 300. The composition of Embodiment 299 wherein each V is a direct bond.

[0604] Embodiment 301. The composition of Embodiment 300 wherein each V is independently C.sub.1-C.sub.2 alkylene.

[0605] Embodiment 302. The composition of Embodiment 301 wherein each V is CH.sub.2.

[0606] Embodiment 303. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 301 wherein in Formula 1, each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or a 5- to 6-membered heteroaromatic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, each ring optionally substituted with up to 2 substituents independently selected from R.sup.27; or a 3- to 6-membered nonaromatic heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 2 ring members are independently selected from C(O), C(S), S(O) and S(O).sub.2, each ring optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0607] Embodiment 304. The composition of Embodiment 303wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, thienyl, isoxazolinyl, piperidinyl, morpholinyl or piperazinyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0608] Embodiment 305. The composition of Embodiment 304 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0609] Embodiment 306. The composition of Embodiment 305 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or pyridinyl or pyrazolyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0610] Embodiment 307. The composition of Embodiment 305 wherein each Q is independently phenyl or pyridinyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0611] Embodiment 308. The composition of Embodiment 307 wherein each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27.

[0612] Embodiment 309. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 308 wherein in Formula 1, when each R.sup.20a is separate (i.e. not taken together with R.sup.20b to form a ring), then each R.sup.20b is independently H, cyano, methyl, methylcarbonyl, methoxycarbonyl, methoxycarbonylmethyl, methylaminocarbonyl or dimethylaminocarbonyl.

[0613] Embodiment 310. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 215 wherein in Formula 1, when each R.sup.20b is separate (i.e. not taken together with R.sup.20a to form a ring), then each R.sup.20b is independently H, cyano, methyl, methylcarbonyl, methoxycarbonyl, methoxycarbonylmethyl, methylaminocarbonyl or dimethylaminocarbonyl.

[0614] Embodiment 311. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 310 wherein in Formula 1, when R.sup.20a and R.sup.20b are taken together to form a 5- to 6-membered fully saturated heterocyclic ring, then said ring contains ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to 1 heteroatom selected from up to 1 O, up to 1 S and up to 1 N atom, each ring optionally substituted with up to 2 methyl groups.

[0615] Embodiment 312. The composition of Embodiment 311 wherein R.sup.20a and R.sup.20b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 methyl groups.

[0616] Embodiment 313. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 312 wherein in Formula 1, each R.sup.21 and R.sup.23 is independently H, cyano, halogen, methyl or methoxy.

[0617] Embodiment 314. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 313 wherein in Formula 1, each R.sup.22 is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkylcarbonyl or C.sub.2-C.sub.3 alkoxycarbonyl; or phenyl optionally substituted with up to 2 substituents independently selected halogen and methyl; or a 5- to 6-membered fully saturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 2 O, up to 2 S and up to 2 N atoms, each ring optionally substituted with up to 2 substituents independently selected from halogen and methyl.

[0618] Embodiment 315. The composition of Embodiment 314 wherein R.sup.22 is independently H or C.sub.1-C.sub.2 alkyl.

[0619] Embodiment 316. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 315 wherein in Formula 1, each R.sup.24 is independently H, cyano or C.sub.1-C.sub.2 alkyl.

[0620] Embodiment 317. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 316 wherein in Formula 1, each R.sup.25 and R.sup.26 is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl or C.sub.1-C.sub.4 haloalkyl.

[0621] Embodiment 318. The composition of Embodiment 317 wherein each R.sup.25 and R.sup.26 is independently H, cyano, hydroxy or C.sub.1-C.sub.2 alkyl.

[0622] Embodiment 319. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 318 wherein in Formula 1, each R.sup.27 is independently halogen, cyano, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl or C.sub.1-C.sub.4 alkoxy.

[0623] Embodiment 320. The composition of Embodiment 319 wherein each R.sup.27 is independently halogen, cyano, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or C.sub.1-C.sub.2 alkoxy.

[0624] Embodiment 321. The composition of Embodiment 320 wherein each R.sup.27 is independently halogen, methyl or methoxy.

[0625] Embodiment 322. The composition of Embodiment 321 wherein each R.sup.27 is independently halogen.

[0626] Embodiment 323. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 322 wherein in Formula 1, Z is a direct bond, O, NH, C(O), C(O)NH, NHC(O), NHC(O)NH, OC(O)NH, NHC(O)O, S(O).sub.2NH, NHS(O).sub.2 or NHS(O).sub.2NH.

[0627] Embodiment 324. The composition of Embodiment 323 wherein Z is a direct bond, O, NH, C(O), C(O)NH or NHC(O).

[0628] Embodiment 325. The composition of Embodiment 324 wherein Z is a direct bond, O, NH or C(O).

[0629] Embodiment 326. The composition of Embodiment 325 wherein Z is a direct bond.

[0630] Embodiment 327. The composition of Formula 1 or any one of Embodiments 1 through 326 wherein each R.sup.28 is independently H or C.sub.1-C.sub.3 alkyl.

[0631] Embodiment 328. The composition of Embodiment 327 wherein each R.sup.28 is independently H or methyl.

[0632] Embodiment 329. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 328 wherein in Formula 1, p is 0 or 2.

[0633] Embodiment 330. The composition of Embodiment 329 wherein p is 2.

[0634] Embodiment 331. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 330 wherein component (a) does not comprise an N-oxide of a compound of Formula 1.

[0635] Embodiment 332. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 331 wherein component (a) comprises a compound selected from the group consisting of [0636] O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate (Compound 7); [0637] (Z)-(1-(4-((2-ethoxy-3,3,3-trifluoroprop-1-en-1-yl)oxy)benzyl)-1H-pyrazol-4-yl)methyl methoxy(methyl)carbamate (Compound 18); [0638] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate (Compound 21); [0639] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl acetate (Compound 22); [0640] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methoxyacetate (Compound 23); [0641] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-methylbutanoate (Compound 27); [0642] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpentanoate (Compound 30); [0643] 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(phenylmethoxy)-1H-pyrazole-4-carboxamide (Compound 31); [0644] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3,3,3-trifluoropropanoate (Compound 35); [0645] 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-1H-pyrazole-4-carboxamide (Compound 45); [0646] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpropanoate (Compound 46); [0647] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2,2-dimethylpropanoate (Compound 47); [0648] 1-[[1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl]2-methyl ethanedioate (Compound 48); [0649] [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-(methylthio)propanoate (Compound 50); [0650] 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl methyl carbonate (Compound 52). [0651] 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 105); [0652] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 108); [0653] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 109); [0654] 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-ethyl-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 119); [0655] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-N-methyl-6-pyridinecarboxamide (Compound 120); [0656] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 121); [0657] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-N-methyl-6-pyridinecarboxamide (Compound 123); [0658] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-6-pyridinecarboxamide (Compound 124); [0659] 2-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 125); [0660] 2-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-6-pyridinecarboxamide (Compound 127); [0661] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-2-pyridinecarboxamide (Compound 131); [0662] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-2-pyridinecarboxamide (Compound 132); and [0663] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-2-pyridinecarboxamide (Compound 133).

[0664] Embodiment 333. The composition of Embodiment 332 wherein component (a) comprises a compound selected from the group consisting of Compounds 7, 21, 22, 23, 27, 30, 31, 35, 45, 46, 47, 48, 50, 52, 105, 108, 109, 119, 120, 121, 123, 124, 125, 127, 132, and 133.

[0665] Embodiment 334. The composition of Embodiment 333 wherein component (a) comprises a compound selected from the group consisting of Compounds 7, 21, 22, 23, 27, 30, 31, 35, 45, 46, 47, 48, 52, 108, 120, 121 and 123.

[0666] Embodiment 335. The composition of Embodiment 334 wherein component (a) comprises a compound selected from the group consisting of Compounds 7, 21, 22, 23, 27, 30, 31, 35, 45, 46, 47, 52, 108, 120, 121 and 123.

[0667] Embodiment 336. The composition of Embodiment 335 wherein component (a) comprises a compound selected from the group consisting of Compounds 7, 21, 22, 23, 27, 30, 31, 45, 46, 47, 52, 108, 120 and 121.

[0668] Embodiment 337. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate, its (E)-isomer or a mixture thereof.

[0669] Embodiment 338. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is (Z)-(1-(4-((2-ethoxy-3,3,3-trifluoroprop-1-en-1-yl)oxy)benzyl)-1H-pyrazol-4-yl)methyl methoxy(methyl)carbamate, its (E)-isomer or a mixture thereof.

[0670] Embodiment 339. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate, its (E)-isomer or a mixture thereof.

[0671] Embodiment 340. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl acetate, its (E)-isomer or a mixture thereof.

[0672] Embodiment 341. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methoxyacetate, its (E)-isomer or a mixture thereof.

[0673] Embodiment 342. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-methylbutanoate, its (E)-isomer or a mixture thereof.

[0674] Embodiment 343. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpentanoate, its (E)-isomer or a mixture thereof.

[0675] Embodiment 344. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(phenylmethoxy)-1H-pyrazole-4-carboxamide, its (E)-isomer or a mixture thereof.

[0676] Embodiment 345. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3,3,3-trifluoropropanoate, its (E)-isomer or a mixture thereof.

[0677] Embodiment 346. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-1H-pyrazole-4-carboxamide, its (E)-isomer or a mixture thereof.

[0678] Embodiment 347. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2-methylpropanoate, its (E)-isomer or a mixture thereof.

[0679] Embodiment 348. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 2,2-dimethylpropanoate, its (E)-isomer or a mixture thereof.

[0680] Embodiment 349. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 1-[[1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl]2-methyl ethanedioate, its (E)-isomer or a mixture thereof.

[0681] Embodiment 350. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl 3-(methylthio)propanoate, its (E)-isomer or a mixture thereof.

[0682] Embodiment 351. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl methyl carbonate, its (E)-isomer or a mixture thereof.

[0683] Embodiment 352. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-2-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0684] Embodiment 353. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propen-1-yloxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0685] Embodiment 354. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0686] Embodiment 355. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-ethyl-N-(2-propen-1-yloxy)-2-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0687] Embodiment 356. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-N-methyl-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0688] Embodiment 357. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0689] Embodiment 358. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-N-methyl-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0690] Embodiment 359. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0691] Embodiment 360. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0692] Embodiment 361. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-6-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0693] Embodiment 362. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-2-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0694] Embodiment 363. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-2-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0695] Embodiment 364. The composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 332 wherein component (a) is 4-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-2-pyridinecarboxamide, its (E)-isomer or a mixture thereof.

[0696] Embodiments of this invention, including Embodiments 1-364 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments not only to the compositions comprising compounds of Formula 1 with at least one other fungicidal compound but also to compositions comprising compounds of Formula 1 with at least one invertebrate pest control compound or agent, and also to the compounds of Formula 1 and their compositions, and also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. In addition, embodiments of this invention, including Embodiments 1-364 above as well as any other embodiments described herein, and any combination thereof, pertain to the methods of the present invention. Therefore of note as a further embodiment is the composition disclosed above comprising (a) at least one compound selected from the compounds of Formula 1 described above, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.

[0697] Combinations of Embodiments 1-364 are illustrated by:

[0698] Embodiment A. The composition comprising components (a) and (b) described Summary of the Invention wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein in Formula 1, [0699] T is T-2 or T-3; [0700] R.sup.1 is CF.sub.3; [0701] X is O; [0702] Y is O; [0703] R.sup.2a and R.sup.2b are each independently H or C.sub.1-C.sub.2 alkyl; or [0704] R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5- to 6-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, wherein up to 1 carbon atom ring member is selected from C(O) and C(S), the ring optionally substituted with up to 2 substituents independently selected from halogen, cyano, methyl, halomethyl, methoxy and halomethoxy on carbon atom ring members; [0705] R.sup.2c is methyl or ethyl; [0706] R.sup.2d is H or methyl; [0707] A.sup.1 is CR.sup.5aR.sup.5b or O; [0708] A.sup.2 is a direct bond, CR.sup.5aR.sup.5b or O; [0709] each R.sup.5a and R.sup.5b is independently H or methyl; [0710] J is J-1, J-6 or J-14; [0711] each R.sup.7 is independently F, Cl or methyl; [0712] q is 0, 1 or 2; [0713] each R.sup.8a and R.sup.8b is independently H, halogen or methyl; [0714] n is 0, 1 or 2; [0715] G is selected from the group consisting of:

##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036## ##STR00037## ##STR00038## ##STR00039## [0716] wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring or ring system; x is 1, 2 or 3; and y is 0, 1, 2 or 3; [0717] each R.sup.9 is independently (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); [0718] each m is independently 1 or 2; [0719] each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl or C.sub.3-C.sub.8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13; [0720] each R.sup.10 is independently halogen, C(O)NR.sup.14aR.sup.14b or UV-Q; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19; [0721] each R.sup.11a and R.sup.11b is independently H, methyl, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 alkoxycarbonyl or C.sub.2-C.sub.3 haloalkoxycarbonyl; [0722] each R.sup.12a is independently C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; [0723] each R.sup.12b is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; [0724] each R.sup.12c is independently H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; [0725] each R.sup.12d is independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; or [0726] R.sup.12c and R.sup.12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; [0727] each R.sup.12e is independently C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.5 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkyl; [0728] each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; [0729] each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsufonyl or C.sub.3-C.sub.6 cycloalkyl; [0730] each R.sup.14a is independently H, C.sub.1-C.sub.2 alkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; [0731] each R.sup.14b is independently H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl; or [0732] R.sup.14a and R.sup.14b are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; [0733] each R.sup.19 is independently cyano, halogen, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.2 alkoxy, C.sub.1-C.sub.2 haloalkoxy, C.sub.2-C.sub.3 alkylcarbonyl, C.sub.2-C.sub.3 haloalkylcarbonyl or C.sub.2-C.sub.3 alkoxycarbonyl; [0734] each U is independently a direct bond, C(O)O or C(O)N(R.sup.25); [0735] each V is independently a direct bond; or C.sub.1-C.sub.3 alkylene, each optionally substituted with up to 2 substituents independently selected from halogen, hydroxy, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy; [0736] each Q is independently phenyl optionally substituted with up to 2 substituents independently selected from R.sup.27; or pyridinyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl or oxazolyl, each optionally substituted with up to 2 substituents independently selected from R.sup.27; [0737] each R.sup.25 is independently H, cyano, hydroxy or C.sub.1-C.sub.2 alkyl; [0738] each R.sup.27 is independently halogen, cyano, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl or C.sub.1-C.sub.4 alkoxy; and [0739] Z is a direct bond, 0, NH, C(O), C(O)NH, NHC(O), NHC(O)NH, OC(O)NH, NHC(O)O, S(O).sub.2NH, NHS(O).sub.2 or NHS(O).sub.2NH.

[0740] Embodiment AA. The composition of Embodiment A wherein in Formula 1, [0741] L is CH.sub.2; and [0742] Z is a direct bond.

[0743] Embodiment B. The composition of Embodiment A wherein in Formula 1, [0744] R.sup.2a and R.sup.2b are each independently H or methyl; or [0745] R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms, the ring optionally substituted with up to 2 substituents independently selected from halogen, methyl and halomethyl on a carbon atom ring member; [0746] A.sup.1 is O; [0747] A.sup.2 is a direct bond, CH.sub.2 or O; [0748] J is J-1; [0749] q is 0; [0750] each R.sup.8a and R.sup.8b is independently H or methyl; [0751] n is 0 or 1; [0752] G is G-1, G-3, G-12, G-13 or G-20; [0753] x is 1 or 2; [0754] y is 0 or 1; [0755] each R.sup.9a is independently OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 4 substituents independently selected from R.sup.13; [0756] R.sup.10 is halogen, C(O)NR.sup.14aR.sup.14b; or C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.3-C.sub.5 alkenyloxycarbonyl, C.sub.3-C.sub.5 alkynyloxycarbonyl or C.sub.4-C.sub.6 cycloalkoxycarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.19; [0757] each R.sup.11a and R.sup.11b is independently H, methyl or C.sub.2-C.sub.3 alkoxycarbonyl; [0758] each R.sup.12a is independently C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.2-C.sub.4 alkynyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy; or phenyl-CH.sub.2O, each phenyl ring optionally substituted with up to 2 substituents independently selected from halogen and methyl; [0759] each R.sup.12b is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl; [0760] each R.sup.12c is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; [0761] each R.sup.12d is independently H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 haloalkoxyalkyl, C.sub.2-C.sub.4 alkylaminoalkyl or C.sub.3-C.sub.5 dialkylaminoalkyl; [0762] each R.sup.12e is independently C.sub.2-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; [0763] each R.sup.12f is independently C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.6 cycloalkylalkoxy, each optionally substituted with up to 3 substituents independently selected from halogen; [0764] each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl; [0765] R.sup.14a is H or C.sub.1-C.sub.2 alkyl; [0766] R.sup.14b is H, C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 haloalkyl or cyclopropylmethyl; [0767] each R.sup.19 is independently halogen; and [0768] Z is a direct bond, O, NH or C(O).

[0769] Embodiment BB. The composition of Embodiment B wherein in Formula 1, [0770] L is CH.sub.2; [0771] G is G-1, G-12 or G-20; and [0772] Z is a direct bond.

[0773] Embodiment C. The composition of Embodiment B wherein in Formula 1, [0774] R.sup.2a and R.sup.2b are each H; or [0775] R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; [0776] R.sup.2c is ethyl; [0777] R.sup.2d is H; [0778] A.sup.2 is a direct bond; [0779] each R.sup.8a and R.sup.8b is H; [0780] n is 1; [0781] G is G-12 or G-20; [0782] x is 1; [0783] y is 0; [0784] R.sup.9 is CH.sub.2R.sup.9a, CH.sub.2CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); [0785] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 3 substituents independently selected from R.sup.13; [0786] R.sup.12a is C.sub.1-C.sub.4 haloalkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy or phenyl-CH.sub.2O; [0787] R.sup.12b is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl; [0788] R.sup.12c is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; [0789] R.sup.12d is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.3-C.sub.5 cycloalkyl, C.sub.4-C.sub.6 cycloalkylalkyl or C.sub.2-C.sub.4 alkoxyalkyl; [0790] R.sup.12e is C.sub.2-C.sub.3 alkyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; [0791] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or cyclopropylmethoxy, each optionally substituted with up to 3 substituents independently selected from halogen; [0792] each R.sup.13 is independently halogen, cyano, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl; and [0793] Z is a direct bond.

[0794] Embodiment CC. The composition of Embodiment C wherein in Formula 1, [0795] G is G-20; and [0796] Z is a direct bond.

[0797] Embodiment D. The composition of Embodiment C wherein in Formula 1, [0798] T is T-3; [0799] R.sup.9 is CH.sub.2R.sup.9a, C(O)NR.sup.12aR.sup.12b or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); [0800] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.3-C.sub.6 alkenylcarbonyloxy, C.sub.4-C.sub.6 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy or C.sub.3-C.sub.6 alkoxycarbonylcarbonyloxy, each optionally substituted with up to 2 substituents independently selected from R.sup.13; [0801] R.sup.12a is C.sub.2-C.sub.4 alkenyloxy, C.sub.2-C.sub.4 haloalkenyloxy, C.sub.4-C.sub.5 cycloalkylalkoxy or phenyl-CH.sub.2O; [0802] R.sup.12b is H, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl; [0803] R.sup.12c is H or C.sub.1-C.sub.3 alkoxy; [0804] R.sup.12d is H, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, cyclopropylmethyl or C.sub.2-C.sub.4 alkoxyalkyl; and [0805] each R.sup.13 is independently Br, Cl, F, cyano, methoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.2 alkylthio or cyclopropyl.

[0806] Embodiment E. The composition of Embodiment D wherein in Formula 1, [0807] G is G-12 connected at the 1-position to Z and the 4-position is connected to R.sup.9; or [0808] G is G-12 connected at the 1-position to Z and the 3-position is connected to R.sup.9; or [0809] G is G-12 connected at the 1-position to Z and the 5-position is connected to R.sup.9; or [0810] G is G-20 connected at the 2-position to Z; or [0811] G is G-20 connected at the 4-position to Z; [0812] R.sup.9 is CH.sub.2R.sup.9a; [0813] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy or C.sub.2-C.sub.6 alkoxycarbonyloxy each optionally substituted with up to 1 substituent selected from R.sup.13; [0814] R.sup.12c is methoxy; [0815] R.sup.12d is H, methyl or cyclopropylmethyl; and [0816] R.sup.13 is Br, Cl, F, cyano, methoxy, CH.sub.3OC(O), CH.sub.3S or cyclopropyl.

[0817] Embodiment EE. The composition of Embodiment E wherein in Formula 1, [0818] G is G-20 connected at the 2-position Z and the 6-position is connected to R.sup.9; or [0819] G is G-20 connected at the 4-position to Z and the 2-position is connected to R.sup.9.

[0820] Embodiment F. The composition comprising components (a) and (b) described Summary of the Invention wherein component (a) comprises a compound of Formula 1 or salt thereof, wherein in Formula 1, [0821] T is T-2 or T-3; [0822] R.sup.1 is CF.sub.3; [0823] X is O; [0824] Y is O; [0825] R.sup.2a and R.sup.2b are each H; or [0826] R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; [0827] R.sup.2c is methyl or ethyl; [0828] R.sup.2d is H; [0829] A.sup.1 is O; [0830] A.sup.2 is a direct bond; [0831] each R.sup.5a and R.sup.5b is H; [0832] J is J-1, J-6 or J-14; [0833] each R.sup.7 is F; [0834] q is 0, 1 or 2; [0835] each R.sup.8a and R.sup.8b is H; [0836] n is 1 or 2; [0837] G is selected from the group consisting of:

##STR00040## [0838] wherein the floating bond is connected to Z in Formula 1 through any available carbon or nitrogen atom of the depicted ring; x is 1; and y is 0 or 1; [0839] R.sup.9 is (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b, C(R.sup.12e)NR.sup.12f or C.sub.2-C.sub.4 alkoxy(thiocarbonyl); [0840] m is 1; [0841] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkylsufonylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.3-C.sub.9 alkenylcarbonylamino, C.sub.3-C.sub.9 alkynylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl, C.sub.3-C.sub.9 alkoxycarbonylcarbonyl or C.sub.3-C.sub.8 trialkylsilylalkoxy, each optionally substituted with up to 4 substituents independently selected from R.sup.13; [0842] R.sup.10 is halogen or C.sub.2-C.sub.3 alkoxycarbonyl; [0843] each R.sup.11a and R.sup.11b is independently H, methyl or C.sub.2-C.sub.3 alkoxycarbonyl; [0844] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; or phenyl-CH.sub.2O, the phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; [0845] R.sup.12b is H, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl; [0846] R.sup.12c is H, cyano, hydroxy, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl, C.sub.2-C.sub.5 alkoxycarbonyl, C.sub.2-C.sub.5 alkylaminocarbonyl or C.sub.3-C.sub.5 dialkylaminocarbonyl; [0847] R.sup.12d is H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.2-C.sub.6 haloalkynyl, C.sub.2-C.sub.6 cyanoalkyl, C.sub.3-C.sub.8 cycloalkyl, C.sub.3-C.sub.8 halocycloalkyl, C.sub.3-C.sub.8 cycloalkenyl, C.sub.3-C.sub.8 halocycloalkenyl, C.sub.4-C.sub.10 alkylcycloalkyl, C.sub.4-C.sub.10 cycloalkylalkyl, C.sub.4-C.sub.10 halocycloalkylalkyl, C.sub.2-C.sub.6 alkoxyalkyl, C.sub.2-C.sub.6 haloalkoxyalkyl, C.sub.2-C.sub.6 alkylthioalkyl, C.sub.2-C.sub.6 alkylsulfonylalkyl, C.sub.2-C.sub.6 alkylaminoalkyl or C.sub.3-C.sub.8 dialkylaminoalkyl, each optionally substituted with up to 1 substituent selected from cyano, hydroxy, nitro, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.4 alkoxycarbonyl; or [0848] R.sup.12c and R.sup.12d are taken together to form an azetidinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or thiomorpholinyl ring, each ring optionally substituted with up to 2 substituents independently selected from halogen or methyl; [0849] R.sup.12e is C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.5 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkyl; [0850] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; [0851] each R.sup.13 is independently halogen, cyano, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio, C.sub.1-C.sub.4 alkylsufonyl or C.sub.3-C.sub.6 cycloalkyl; and [0852] Z is a direct bond, O, NH or C(O).

[0853] Embodiment G. The composition of any one of Embodiment F wherein in Formula 1, [0854] R.sup.2c is ethyl; [0855] J is J-1; [0856] n is 1; [0857] G is G-12 or G-20; [0858] y is 0; [0859] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.3-C.sub.9 alkynylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.4-C.sub.9 cycloalkylalkylcarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 cyanoalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.2-C.sub.8 alkylcarbonylthio, C.sub.2-C.sub.8 alkylcarbonylamino, C.sub.5-C.sub.10 cycloalkylcarbonylamino, C.sub.2-C.sub.8 alkoxycarbonylamino, C.sub.3-C.sub.6 alkenyloxycarbonyl, C.sub.5-C.sub.10 cycloalkylalkoxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 3 substituents independently selected from R.sup.13; [0860] each R.sup.11a and R.sup.11b is independently H or EtOC(O); [0861] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; [0862] R.sup.12b is H or methyl; [0863] R.sup.12c is C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.5 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.2-C.sub.4 haloalkylcarbonyl, C.sub.4-C.sub.7 cycloalkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; [0864] R.sup.12d is H or methyl; [0865] R.sup.12e is C.sub.2-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.4 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; [0866] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy or C.sub.2-C.sub.4 alkylcarbonyloxy; [0867] each R.sup.13 is independently halogen, cyano, C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.4 alkylthio or C.sub.3-C.sub.5 cycloalkyl; and [0868] Z is a direct bond.

[0869] Embodiment H. The composition of any one of Embodiment G wherein in Formula 1, [0870] T is T-3; [0871] q is 0; [0872] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.8 alkylcarbonyloxy, C.sub.3-C.sub.9 alkenylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.8 alkoxycarbonyloxy, C.sub.2-C.sub.8 alkenyloxy, C.sub.2-C.sub.8 alkynyloxy, C.sub.4-C.sub.10 cycloalkoxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.8 alkoxycarbonylalkoxy, C.sub.3-C.sub.9 alkoxycarbonylcarbonyloxy, C.sub.3-C.sub.6 alkenyloxycarbonyl or C.sub.3-C.sub.9 alkoxycarbonylcarbonyl, each optionally substituted with up to 2 substituents independently selected from R.sup.13; [0873] each R.sup.11a and R.sup.11b is H; [0874] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; [0875] R.sup.12c is C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.2-C.sub.4 alkenyl, C.sub.2-C.sub.4 haloalkenyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl, C.sub.4-C.sub.5 cycloalkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; [0876] R.sup.12e is C.sub.2-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; [0877] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.5 cycloalkylalkoxy; and [0878] R.sup.13 is Br, Cl, F, cyano, methoxy, C.sub.2-C.sub.4 alkoxycarbonyl, C.sub.1-C.sub.2 alkylthio or cyclopropyl.

[0879] Embodiment I. The composition of any one of Embodiment H wherein in Formula 1, [0880] R.sup.9 is (CR.sup.11aR.sup.11b).sub.mR.sup.9a, C(O)NR.sup.12aR.sup.12b or C(R.sup.12e)NR.sup.12f; [0881] R.sup.9a is OC(O)NR.sup.12cR.sup.12d; or C.sub.2-C.sub.6 alkylcarbonyloxy, C.sub.4-C.sub.9 cycloalkylcarbonyloxy, C.sub.2-C.sub.6 alkoxycarbonyloxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.4-C.sub.10 cycloalkylalkoxy, C.sub.2-C.sub.6 alkoxycarbonylalkoxy or C.sub.3-C.sub.6 alkenyloxycarbonyl, each optionally substituted with up to 2 substituents independently selected from R.sup.13; [0882] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; [0883] R.sup.12b is H; [0884] R.sup.12c is C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.2-C.sub.4 alkoxyalkyl, C.sub.2-C.sub.4 alkylcarbonyl or C.sub.2-C.sub.5 alkoxycarbonyl; [0885] R.sup.12e is ethoxy; [0886] R.sup.12f is C.sub.1-C.sub.4 alkoxy; and [0887] R.sup.13 is Br, Cl, F, cyano, methoxy, CH.sub.3OC(O), CH.sub.3S or cyclopropyl.

[0888] Embodiment J. The composition any one of Embodiments A through I wherein component (a) comprises a compound selected from the group consisting of: Compound 7, Compound 18, Compound 21, Compound 22, Compound 23, Compound 27, Compound 30, Compound 31, Compound 35, Compound 45, Compound 46, Compound 47, Compound 48, Compound 50, Compound 52, Compound 105, Compound 108, Compound 109, Compound 119, Compound 120, Compound 121, Compound 123, Compound 124, Compound 125, Compound 127, Compound 131, Compound 132 and Compound 133.

[0889] Embodiment K. The composition of Embodiment J wherein component (a) comprises a compound selected from the group consisting of: Compound 7, Compound 21, Compound 22, Compound 23, Compound 27, Compound 30, Compound 31, Compound 45, Compound 46, Compound 47, Compound 52, Compound 108, Compound 120 and Compound 121.

[0890] Embodiment L. The composition of Embodiment K wherein component (a) comprises a Compound 108, Compound 120 and Compound 121.

[0891] Embodiment M. The composition of Embodiment L wherein component (a) comprises Compound 108.

[0892] Embodiment N. The composition of Embodiment L wherein component (a) comprises, Compound 120.

[0893] Embodiment O. The composition of Embodiment L wherein component (a) comprises Compound 121.

[0894] Embodiment B1. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b1) methyl benzimidazole carbamate fungicides such as benomyl, carbendazim, fuberidazole thiabendazole, thiophanate and thiophanate-methyl.

[0895] Embodiment B2. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b2) dicarboximide fungicides such as chlozolinate, dimethachlone, iprodione, procymidone and vinclozolin.

[0896] Embodiment B3. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b3) demethylation inhibitor fungicides such as triforine, buthiobate, pyrifenox, pyrisoxazole fenarimol, nuarimol, triarimol econazole, imazalil, oxpoconazole, pefurazoate, prochloraz, triflumizoleazaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, mefentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, ipfentrifluconazole, quinconazole, simeconazole, tebuconazole, tetraconazole triadimefon, triadimenol, triticonazole, uniconazole and uniconazole-P.

[0897] Embodiment B4. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b4) phenylamide fungicides such as metalaxyl, metalaxyl-M, benalaxyl, benalaxyl-M, furalaxyl, ofurace and oxadixyl.

[0898] Embodiment B5. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b5) amine/morpholine fungicides such as aldimorph, dodemorph, fenpropimorph, tridemorph, trimorphamide, fenpropidin, piperalin and spiroxamine.

[0899] Embodiment B6. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b6) phospholipid biosynthesis inhibitor fungicides such as edifenphos, iprobenfos, pyrazophos and isoprothiolane.

[0900] Embodiment B7. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b7) succinate dehydrogenase inhibitor fungicides such as benodanil, flutolanil, mepronil, isofetamid, fluopyram, fenfuram, carboxin, oxycarboxin thifluzamide, benzovindiflupyr, bixafen, fluindapyr, fluxapyroxad, furametpyr, inpyrfluxam, isopyrazam, penflufen, penthiopyrad, pyrapropoyne, sedaxane, flubeneteram, isoflucypram, pydiflumetofen, boscalid and pyraziflumid.

[0901] Embodiment B8. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b8) hydroxy(2-amino-)pyrimidine fungicides such as bupirimate, dimethirimol and ethirimol.

[0902] Embodiment B9. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b9) anilinopyrimidine fungicides such as cyprodinil, mepanipyrim and pyrimethanil.

[0903] Embodiment B10. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b10) N-phenyl carbamate fungicides such as diethofencarb.

[0904] Embodiment B11. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b11) fungicides quinone outside inhibitor fungicides such as azoxystrobin, coumoxystrobin, enoxastrobin, flufenoxystrobin, picoxystrobin, pyraoxystrobin, mandestrobin, pyraclostrobin, pyrametostrobin, triclopyricarb, kresoxim-methyl, trifloxystrobin, dimoxystrobin, fenaminstrobin, metominostrobin, orysastrobin, fluoxastrobin, famoxadone, fenamidone and pyribencarb.

[0905] Embodiment B12. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b12) phenylpyrrole fungicides compound such as fenpiclonil and fludioxonil.

[0906] Embodiment B13. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b13) azanaphthalene fungicides such as quinoxyfen and proquinazid.

[0907] Embodiment B14. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b14) cell peroxidation inhibitor fungicides such as biphenyl, chloroneb, dicloran, quintozene, tecnazene, tolclofos-methyl and etridiazole.

[0908] Embodiment B15. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b15) melanin biosynthesis inhibitors-reductase fungicides such as fthalide, pyroquilon and tricyclazole.

[0909] Embodiment B16a. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b16a) melanin biosynthesis inhibitors-dehydratase fungicides such as carpropamid, diclocymet, and fenoxanil.

[0910] Embodiment B16b. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b16b) melanin biosynthesis inhibitor-polyketide synthase fungicides such as tolprocarb.

[0911] Embodiment B17. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b17) keto reductase inhibitor fungicides such as fenhexamid, fenpyrazamine, quinofumelin and ipflufenoquin.

[0912] Embodiment B18. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b18) squalene-epoxidase inhibitor fungicides such as pyributicarb, naftifine and terbinafine.

[0913] Embodiment B19. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b19) polyoxin fungicides such as polyoxin.

[0914] Embodiment B20. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b20) phenylurea fungicides such as pencycuron.

[0915] Embodiment B21. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b21) quinone inside inhibitor fungicides such as cyazofamid, amisulbrom, fenpicoxamid (Registry Number 517875-34-2) and metarylpicoxamid.

[0916] Embodiment B22. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b22) benzamide and thiazole carboxamide fungicides such as zoxamide and ethaboxam.

[0917] Embodiment B23. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b23) enopyranuronic acid antibiotic fungicides such as blasticidin-S.

[0918] Embodiment B24. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b24) hexopyranosyl antibiotic fungicides such as kasugamycin.

[0919] Embodiment B25. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b25) glucopyranosyl antibiotic: protein synthesis fungicides such as streptomycin.

[0920] Embodiment B26. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b26) glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides such as validamycin.

[0921] Embodiment B27. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b27) cyanoacetylamideoxime fungicides such as cymoxanil.

[0922] Embodiment B28. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b28) carbamate fungicides such as propamacarb, prothiocarb and iodocarb.

[0923] Embodiment B29. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b29) oxidative phosphorylation uncoupling fungicides such as fluazinam, binapacryl, meptyldinocap and dinocap.

[0924] Embodiment B30. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b30) organo tin fungicides such as fentin acetate, fentin chloride and fentin hydroxide.

[0925] Embodiment B31. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b31) carboxylic acid fungicides such as oxolinic acid.

[0926] Embodiment B32. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b32) heteroaromatic fungicides such as hymexazole and octhilinone.

[0927] Embodiment B33. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b33) phosphonate fungicides such as phosphorous acid and its various salts, including fosetyl-aluminum.

[0928] Embodiment B34. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b34) phthalamic acid fungicides such as teclofthalam.

[0929] Embodiment B35. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b35) benzotriazine fungicides such as triazoxide.

[0930] Embodiment B36. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b36) benzene-sulfonamide fungicides such as flusulfamide.

[0931] Embodiment B37. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b37) pyridazinone fungicides such as diclomezine.

[0932] Embodiment B38. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b38) thiophene-carboxamide fungicides such as silthiofam.

[0933] Embodiment B39. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b39) complex I NADH oxidoreductase inhibitor fungicides such as diflumetorim, tolfenpyrad and fenazaquin.

[0934] Embodiment B40. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b40) carboxylic acid amide fungicides such as dimethomorph, benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, valifenalate, mandipropamid, flumorph, dimethomorph, flumorph, pyrimorph, benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, tolprocarb, valifenalate and mandipropamid.

[0935] Embodiment B41. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b41) tetracycline antibiotic fungicides such as oxytetracycline.

[0936] Embodiment B42. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b42) thiocarbamate fungicides such as methasulfocarb.

[0937] Embodiment B43. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b43) benzamide fungicides such as fluopicolide and fluopimomide.

[0938] Embodiment B44. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b44) microbial fungicides such as Bacillus amyloliquefaciens strains QST713, FZB24, MB1600, D747, F727, TJ100 (also called strain 1 BE; known from EP2962568) and the fungicidal lipopeptides which they produce.

[0939] Embodiment B45. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b45) quinone outside inhibitor, stigmatellin binding fungicides such as ametoctradin.

[0940] Embodiment B46. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b46) plant extract fungicides such as Melaleuca alternifolia, eugenol, geraniol and thymol.

[0941] Embodiment B47. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b47) cyanoacrylate fungicides such as phenamacril.

[0942] Embodiment B48. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b48) polyene fungicides such as natamycin.

[0943] Embodiment B49. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b49) oxysterol binding protein inhibitor fungicides such as oxathiapiprolin and fluoxapiprolin.

[0944] Embodiment B50. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b50) aryl-phenyl-ketone fungicides such as metrafenone and pyriofenone.

[0945] Embodiment B51. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b51) host plant defense induction fungicides such as acibenzolar-S-methyl, probenazole, tiadinil, isotianil, laminarin, extract from Reynoutria sachalinensis and Bacillus mycoides isolate J and cell walls of Saccharomyces cerevisiae strain LAS117.

[0946] Embodiment B52. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b52) multi-site activity fungicides such as copper oxychloride, copper sulfate, copper hydroxide, Bordeaux composition (tribasic copper sulfide), elemental sulfur, ferbam, mancozeb, maneb, metiram, propineb, thiram, zinc thiazole, zineb, ziram, folpet, captan, captafol, chlorothalonil, dichlofluanid, tolyfluanid, guazatine, iminoctadine albesilate, iminoctadine triacetate, anilazine, dithianon, quinomethionate and fluoroimide.

[0947] Embodiment B53. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b53) biological fungicides with multiple modes of action such as extract from the cotyledons of lupine plantlets.

[0948] Embodiment B54. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b54) fungicides other than fungicides of component (a) and components (b1) through (b53), such as cyflufenamid, bethoxazin, neo-asozin, pyrrolnitrin, tebufloquin, dodine, flutianil, ferimzone, picarbutrazox, dichlobentiazox (Registry Number 957144-77-3), dipymetitrone (Registry Number 16114-35-5), flometoquin, tolnifanide (Registry Number 304911-98-6), N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimid-amide, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine and 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate (XR-539).

[0949] Embodiment B55. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes (1S)-2,2-bis(4-fluorophenyl)-1-methylethyl N-[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]-L-alaninate (provisional common name florylpicoxamid).

[0950] Embodiment B56. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes 1-[2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-3-methylphenyl]-1,4-dihydro-4-methyl-5H-tetrazol-5-one (provisional common name metyltetraprole).

[0951] Embodiment B57. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine (provisional common name pyridachlometyl).

[0952] Embodiment B58. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate (provisional common name aminopyrifen).

[0953] Embodiment B59. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b54.11) (i.e Formula b54.11)

##STR00041## [0954] wherein [0955] R.sup.b10 and R.sup.b11 are each independently halogen; and [0956] R.sup.6 is H, halogen, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl or C.sub.3-C.sub.6 cycloalkyl.

[0957] Embodiment B60. The composition of Embodiment B59 wherein component (b) includes at least one fungicidal compound selected from the group consisting of methyl N-[[5-[1-(2,6-difluoro-4-formylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-(4-cyclopropyl-2,6-dichlorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]-carbamate, methyl N-[[5-[1-(4-chloro-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-(4-cyclopropyl-2,6-difluorophenyl)-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl) phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate and methyl N-[[5-[1-[2,6-di fluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate.

[0958] Embodiment B61. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b54.12) (i.e Formula b54.12)

##STR00042##

wherein [0959] R.sup.b4 is

##STR00043## [0960] R.sup.b6 is C.sub.2-C.sub.4 alkoxycarbonyl or C.sub.2-C.sub.4 haloalkylaminocarbonyl; [0961] L is CH.sub.2 or CH.sub.2O, wherein the atom to the right is connected to the phenyl ring in Formula b54.12; and [0962] R.sup.b5 is

##STR00044##

[0963] Embodiment B62. The composition of Embodiment B61 wherein component (b) includes at least one fungicidal compound selected from the group consisting of N-(2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide and ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl]-1H-pyrazole-4-carboxylate.

[0964] Embodiment B63. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one compound selected from (b54.13) (i.e Formula b54.13)

##STR00045## [0965] wherein [0966] R.sup.b7, R.sup.b8 and R.sup.b9 are each independently H, halogen or cyano; and [0967] R.sup.b10 and R.sup.b11 are each independently H, halogen, C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 methoxy

[0968] Embodiment B64. The composition of Embodiment B63 wherein component (b) includes at least one fungicidal compound selected from the group consisting of 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-benzonitrile and N-(2-chloro-4-fluoro-6-nitrophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine.

[0969] Embodiment B65. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes N-(2-fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (common name flufenoxadiazam, Registry Number 1839120-27-2).

[0970] Embodiment B66. The composition described in the Summary of the Invention (including but not limited to the composition of any one of Embodiments 1 through 364 and A through O) wherein component (b) includes at least one fungicidal compound (fungicide) selected from the group consisting of azoxystrobin, benzovindiflupyr, boscalid (nicobifen), bixafen, bromuconazole, carbendazim, chlorothalonil, copper hydroxide, cyflufenamid, cyproconazole, difenoconazole, dimoxystrobin, epoxiconazole, famoxadone, fenbuconazole, fenpropidin, fenpropimorph, fluindapyr, flusilazole, flutriafol, fluxapyroxad, hexaconazole, ipconazole kresoxim-methyl, manzate, metarylpicoxamid, metconazole, metominostrobin, metrafenone, myclobutanil, penconazole, penthiopyrad, picoxystrobin, prochloraz, propiconazole, proquinazid, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone quinoxyfen, tebuconazole, trifloxystrobin, triticonazole, methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, N-(2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl]-1H-pyrazole-4-carboxylate, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-benzonitrile.

[0971] Embodiment B67. The composition of Embodiment B66 wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil, copper hydroxide, cyflufenamid, cyproconazole, difenoconazole, dimoxystrobin, epoxiconazole, famoxadone, fenpropidin, fenpropimorph, fluindapyr, flusilazole, flutriafol, fluxapyroxad, kresoxim-methyl, manzate, metarylpicoxamid, metconazole, metominostrobin, metrafenone, myclobutanil, penthiopyrad, picoxystrobin, propiconazole, proquinazid, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone, quinoxyfen, tebuconazole, trifloxystrobin, triticonazole, methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, N-(2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl]-1H-pyrazole-4-carboxylate, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-benzonitrile.

[0972] Embodiment B68. The composition of Embodiment B67 wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil, copper hydroxide, cyproconazole, difenoconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindapyr, flutriafol, fluxapyroxad, manzate, metarylpicoxamid, metominostrobin, picoxystrobin, prothioconazole, pydiflumetofen, pyraclostrobin, tebuconazole, trifloxystrobin, methyl N-[[5-[1-[2,6-difluoro-4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, methyl N-[[5-[1-[2,6-difluoro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-2-methylphenyl]methyl]carbamate, N-(2,2,2-trifluoroethyl)-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-4-oxazolecarboxamide, ethyl 1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy]methyl]-1H-pyrazole-4-carboxylate, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-4-methyl-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, 4-(2-chloro-4-fluorophenyl)-N-(2-fluoro-6-nitrophenyl)-1,3-dimethyl-1H-pyrazol-5-amine and 3,5-difluoro-4-[5-[(4-methoxy-2-nitrophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-benzonitrile.

[0973] Embodiment B69. The composition of Embodiment B68 wherein component (b) includes at least one compound selected from the group consisting of azoxystrobin, benzovindiflupyr, bixafen, chlorothalonil, copper hydroxide, cyproconazole, epoxiconazole, fenpropidin, fenpropimorph, fluindapyr, flutriafol, fluxapyroxad, manzate, metarylpicoxamid, metominostrobin, picoxystrobin, prothioconazole, pydiflumetofen, pyraclostrobin, tebuconazole, trifloxystrobin.

[0974] Of note is the composition of any one of the embodiments described herein, including any Embodiments 1 through 364, A through O, and B1 through B69, wherein reference to Formula 1 includes salts thereof but not N-oxides thereof; therefore the phrase a compound of Formula 1 can be replaced by the phrase a compound of Formula 1 or a salt thereof. In this composition of note, component (a) comprises a compound of Formula 1 or a salt thereof.

[0975] Also noteworthy as embodiments are fungicidal compositions of the present invention comprising a fungicidally effective amount of a composition of Embodiments 1 through 364, A through O, and B1 through B69, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

[0976] Embodiments of the invention further include methods for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed or seedling, a fungicidally effective amount of a composition any one of Embodiments 1 through 364, A through O, and B1 through B69 (e.g., as a composition including formulation ingredients as described herein). Embodiments of the invention also include methods for protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying a fungicidally effective amount of a composition of any one of Embodiments 1 through 364, A through O, and B1 through B69 to the plant or plant seed.

[0977] Some embodiments of the invention involve control of a plant disease or protection from a plant disease that primarily afflicts plant foliage and/or applying the composition of the invention to plant foliage (i.e. plants instead of seeds). The preferred methods of use include those involving the above preferred compositions; and the diseases controlled with particular effectiveness include plant diseases caused by fungal plant pathogens. Combinations of fungicides used in accordance with this invention can facilitate disease control and retard resistance development.

[0978] Method embodiments further include:

[0979] Embodiment C1. A method for protecting a plant from a disease selected from rust, powdery mildew and Septoria diseases comprising applying to the plant a fungicidally effective amount of the composition comprising components (a) and (b) described in the Summary of the Invention or any one of Embodiments 1 through 364.

[0980] Embodiment C2. The method of Embodiment C1 wherein the disease is a rust disease and component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b5) amine/morpholine fungicides, (b7) succinate dehydrogenase inhibitor fungicides, (b11) quinone outside inhibitor (QoI) fungicides, (b13) methyl benzimidazole carbamate fungicides and (b52) multi-site activity fungicides.

[0981] Embodiment C3. The method of Embodiment C2 wherein component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b7) succinate dehydrogenase inhibitor fungicides and (b11) quinone outside inhibitor (QoI) fungicides.

[0982] Embodiment C4. The method of Embodiment C3 wherein component (b) of the composition includes at least one fungicidal compound selected from the group consisting of azoxystrobin, cyproconazole, difenoconazole, epoxiconazole, fluindapyr, flutriafol, fluxapyroxad, picoxystrobin, prothioconazole, pyraclostrobin, tebuconazole and trifloxystrobin.

[0983] Embodiment C5. The method of Embodiments C2 through C4 wherein the disease is Asian soybean rust caused by Puccinia recondite.

[0984] Embodiment C6. The method of Embodiments C2 through C4 wherein the disease is wheat leaf rust caused by Phakopsora pachyrhizi.

[0985] Embodiment C7. The method of Embodiment C1 wherein the disease is a powdery mildew disease and component (b) of the composition includes at least one fungicidal compound selected from (b3) demethylation inhibitor (DMI) fungicides, (b11) quinine outside inhibitor (QoI) fungicides and (b13) azanaphthalene fungicides.

[0986] Embodiment C8. The method of Embodiment C7 wherein the disease is wheat powdery mildew.

[0987] Embodiment C9. The method of Embodiment C7 wherein the disease is grape downy mildew.

[0988] Embodiment C10. The method of Embodiments C7 through C9 wherein component (b) includes at least one fungicidal compound selected from (b3) DMI fungicides.

[0989] Embodiment C11. The method of Embodiment C10 wherein component (b) includes at least one fungicidal compound selected from the group consisting of cyproconazole, difenoconazole, epoxiconazole, prothioconazole and tebuconazole.

[0990] Embodiment C12. The method of Embodiment C11 wherein component (b) includes at least one fungicidal compound selected from the group consisting of cyproconazole, difenoconazole and prothioconazole.

[0991] Embodiment C13. The method of Embodiments C8 through C10 wherein component (b) includes at least one fungicidal compound selected from (b11) QoI fungicides.

[0992] Embodiment C14. The method of Embodiment C12 wherein component (b) includes at least one fungicidal compound selected from the group consisting of azoxystrobin, picoxystrobin and pyraclostrobin.

[0993] Embodiment C15. The method of Embodiment C1 wherein the disease is a Septoria disease and component (b) of the composition includes at least one fungicidal compound selected from the group consisting of epoxiconazole, metalaxyl (including metalaxyl-M), iprovalicarb and fenpropimorph.

[0994] Embodiment C16. The method of Embodiment C15 wherein the disease is wheat leaf blotch.

[0995] Embodiment C17. The method of any one of Embodiments C1 through C16 wherein components (a) and (b) are applied in synergistically effective amounts (and in a synergistic ratio relative to each other).

[0996] Of note are embodiments that are counterparts of Embodiments C1 through C17 relating to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, a fungicidally effective amount of a fungicidal composition of the invention.

[0997] As noted in the Summary of the Invention, this invention also relates to a compound of Formula 1, or an N-oxide or salt thereof. Also noted is that the embodiments of this invention, including Embodiments 1-364, relate also to compounds of Formula 1. Accordingly, combinations of Embodiments 1-364 are further illustrated by: Embodiment D1. A compound of Formula 1, or an N-oxide or salt thereof, wherein [0998] T is selected from the group consisting of:

##STR00046## [0999] wherein the bond extending to the left is attached to A; [1000] R.sup.1 is CF.sub.3; [1001] X is O; [1002] Y is O; [1003] R.sup.2a and R.sup.2b are taken together with the atoms X and Y to which they are attached to form a 5-membered saturated ring containing ring members, in addition to the atoms X and Y, selected from carbon atoms; [1004] R.sup.2c is methyl or ethyl; [1005] R.sup.2d is H; [1006] when T is T-2, then A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b, wherein A.sup.1 is connected to J, and CR.sup.5aR.sup.5b is connected to T; [1007] when T is T-3, then A is A.sup.1-A.sup.2, wherein A.sup.1 is connected to J, and A.sup.2 is connected to T; [1008] A.sup.1 is O; [1009] A.sup.2 is a direct bond; [1010] each R.sup.5a and R.sup.5b is H; [1011] J is:

##STR00047## [1012] each R.sup.7 is F; [1013] q is 0, 1 or 2; [1014] L is (CR.sup.8aR.sup.8b).sub.n; [1015] each R.sup.8a and R.sup.8b is H; [1016] n is 1; [1017] G is

##STR00048## [1018] wherein the floating bond is connected to Z in Formula 1 through any available carbon atom of the depicted ring; x is 1; and y is 0 or 1; [1019] R.sup.9 is C(O)NR.sup.12aR.sup.12b or C(R.sup.12e)NR.sup.12f; [1020] R.sup.10 is halogen or C.sub.2-C.sub.3 alkoxycarbonyl; [1021] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.6 hydroxyalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.2-C.sub.6 haloalkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; or phenyl-CH.sub.2O, the phenyl ring optionally substituted with up to 3 substituents independently selected from halogen and methyl; [1022] R.sup.12b is H, C.sub.1-C.sub.2 alkyl or C.sub.1-C.sub.2 haloalkyl; [1023] R.sup.12e is C.sub.2-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 haloalkenyl, C.sub.2-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkoxy, C.sub.4-C.sub.5 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkyl; [1024] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy, C.sub.4-C.sub.6 cycloalkylalkoxy, C.sub.2-C.sub.4 alkylcarbonyloxy or C.sub.2-C.sub.5 alkoxycarbonyloxy, each optionally substituted with up to 3 substituents independently selected from halogen; and [1025] Z is a direct bond;
provided that the compound of Formula 1 is other than: [1026] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 105). [1027] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 108) [1028] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-6-pyridinecarboxamide (Compound 109).

[1029] Embodiment D2. A compound of Embodiment D1 wherein [1030] T is T-3; [1031] R.sup.2c is ethyl; [1032] q is 0; [1033] y is 0; [1034] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 cyanoalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 haloalkenyloxy, C.sub.2-C.sub.6 alkynyloxy, C.sub.4-C.sub.8 cycloalkylalkoxy or C.sub.2-C.sub.6 alkoxyalkoxy; [1035] R.sup.12b is H or methyl; [1036] R.sup.12e is C.sub.2-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy or C.sub.4-C.sub.5 cycloalkylalkoxy; and [1037] R.sup.12f is C.sub.1-C.sub.4 alkoxy, C.sub.2-C.sub.4 alkenyloxy or C.sub.4-C.sub.5 cycloalkylalko.

[1038] Embodiment D3. A compound of Embodiment D2 wherein [1039] R.sup.9 is C(O)NR.sup.12aR.sup.12b; [1040] R.sup.12a is C.sub.1-C.sub.6 haloalkoxy, C.sub.2-C.sub.6 alkenyloxy, C.sub.2-C.sub.6 alkynyloxy or C.sub.4-C.sub.8 cycloalkylalkoxy; and [1041] R.sup.12b is H.

[1042] Embodiment D4. A compound of Embodiment D3 wherein [1043] G is G-20 connected at the 2-position Z and the 6-position is connected to R.sup.9; or [1044] G is G-20 connected at the 4-position to Z and the 2-position is connected to R.sup.9.

[1045] Embodiment D5. A compound of Embodiment D4 wherein [1046] G is G-20 connected at the 2-position Z and the 6-position is connected to R.sup.9.

[1047] Specific embodiments include compounds of Formula 1 selected from the group consisting of: [1048] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-ethyl-N-(2-propen-1-yloxy)-2-pyridinecarboxamide (Compound 119); [1049] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-N-methyl-6-pyridinecarboxamide (Compound 120); [1050] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methyl-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 121); [1051] 2-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-N-methyl-6-pyridinecarboxamide (Compound 123); [1052] 2-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-6-pyridinecarboxamide (Compound 124); [1053] 2-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-6-pyridinecarboxamide (Compound 125); [1054] 2-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-6-pyridinecarboxamide (Compound 127); [1055] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propyn-1-yloxy)-2-pyridinecarboxamide (Compound 131); [1056] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(cyclopropylmethoxy)-2-pyridinecarboxamide (Compound 132); and [1057] 4-[[4-1[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2,2,2-trifluoroethoxy)-2-pyridinecarboxamide (Compound 133).

[1058] Additional embodiments include a fungicidal composition comprising: (1) a compound of any one of Embodiments D1 through D5; and (2) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Additional embodiments also include a method for protecting a plant or plant seed from diseases caused by fungal pathogens comprising applying a fungicidally effective amount of the compound of any one of Embodiments D1 through D5 to the plant (or portion thereof) or plant seed (directly or through the environment (e.g., growing medium) of the plant or plant seed). Of note are embodiments relating to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, a fungicidally effective amount of a compound of any one of Embodiments D1 through D5.

[1059] This invention also provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, N-oxides, and salts thereof) (i.e. in a fungicidally effective amount), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.

[1060] One or more of the following methods and variations as described in Schemes 1-23 can be used to prepare the compounds of Formula 1. The definitions of G, Z, L, A, A.sup.1, A.sup.2, J, T, X, Y, R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.2d, R.sup.5a and R.sup.5b in the compounds of Formulae 1-23a below are as defined above in the Summary of the Invention unless otherwise noted. Compounds of Formulae 1a-1a.sup.1, 1b-1b.sup.4, 1c-1c.sup.1 and 1d-1.sup.d1 are various subsets of Formula 1, and all substituents for Formulae 1a-1a.sup.1, 1b-1b.sup.4, 1c-1c.sup.1 and 1d-1.sup.d1 are as defined above for Formula 1 unless otherwise noted. As the synthetic literature includes many halomethyl ketone and hydrate-forming methods, which can readily be adapted to prepare compounds of the present invention, the following methods in Schemes 1-23 are representative examples of a wide variety of procedures useful for the preparation of compounds of Formula 1. For reviews of ketone and hydrate-forming methods, see, for example, Tetrahedron 1991, 47, 3207-3258 and Chem. Communications 2013, 49(95), 11133-11148, and references cited therein. Also see the methods outlined in U.S. Pat. No. 6,350,892, and PCT publications WO 2018/080859, WO 2018/118781, WO 2018/187553, WO 2019/010192 and WO 2020/056090.

[1061] Compounds of Formula 1 wherein G is a heterocyclic ring or ring system (e.g., pyrazole) linked to L via a nitrogen atom, and Z is a direct bond, can be prepared by displacement of an appropriate leaving group L.sup.a of compounds of Formula 2 with nitrogen-containing heterocycles of Formula 3 in the presence of a base, as depicted in Scheme 1. Suitable bases include inorganic bases such as alkali or alkaline earth metal (e.g., lithium, sodium, potassium and cesium) hydrides, alkoxides, carbonates, phosphates and hydroxides. A variety of solvents are suitable for this method including, for example, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone, acetonitrile and acetone. Particularly useful reaction conditions include using cesium carbonate or potassium carbonate as the base, and N,N-dimethylformamide or acetonitrile as the solvent at temperatures ranging between about 0 to 80 C. Suitable leaving groups in the compounds of Formula 2 include bromide, chlorine, iodide, mesylate (OS(O).sub.2CH.sub.3), triflate (OS(O).sub.2CF.sub.3), and the like. For reaction conditions, see PCT publication WO 2018/187553 (Example 1, Step C, Examples 2-9, and Example 11, Step C). The method of Scheme 1 is also illustrated in present Example 1, Step F; Example 4, Step D; and Example 5, Step C.

##STR00049##

[1062] Compounds of Formula 2 can be prepared by conversion of the corresponding alcohols of Formula 4 to an appropriate leaving group (i.e. L.sup.a), as shown in Scheme 2. For example, alkyl chlorides of Formula 2 can be prepared by treating the corresponding alcohols with thionyl chloride, oxalyl chloride or phosphorus trichloride (for conditions, see present Example 5, Step B). Alkyl bromides can similarly be prepared using phosphorus tribromide or phosphorus oxybromide, or carbon tetrabromide or N-bromosuccinimide in the presence of triphenylphosphine (for conditions, see present Example 1, Step E and Example 4, Step C). Sulfonates can be prepared by reaction of a compound of Formula 4 with a sulfonating agent such as methanesulfonyl chloride, typically in the presence of a base, under conditions well known to one skilled in the art of organic synthesis.

##STR00050##

[1063] General methods useful for preparing compounds of Formula 4 are well known in the literature. For example, as shown in Scheme 3, reduction of carboxylic esters of Formula 5 using a reducing agent such as lithium aluminum hydride or a borane/tetrahydrofuran complex in an aprotic solvent such as tetrahydrofuran or diethyl ether at temperatures from 78 C. to 25 C. provides compounds of Formula 4. For relevant literature references, see, for example, March and Smith, March's Advanced Organic Chemistry, 5.sup.th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 19; and Bulletin of the Chemical Society of Japan 1991, 64(9), 2730-2745. The method of Scheme 3 is also illustrated in present Example 1, Step D; and Example 4, Step B.

##STR00051##

[1064] Alternatively, compounds of Formula 1 wherein G is an N-linked heterocycle can be prepared by reaction of primary or secondary alcohols of Formula 6 with nitrogen-containing heterocycles of Formula 3 using Mitsunobu coupling reaction conditions, as shown in Scheme 4. Mitsunobu reactions are typically run in tetrahydrofuran with triphenylphosphine and diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD) at room temperature. Polymer supported triphenylphosphine can be used to ease purification. For a review of the Mitsunobu reaction, see Mitsunobu, O. Comprehensive Organic Synthesis; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 6, pages 65-101. For reaction conditions, see PCT publication WO 2018/187553 (Example 12, Step C).

##STR00052##

[1065] Compounds of Formula 1 can also be prepared by reaction of suitably functionalized compounds of Formula 7 with suitably functionalized compounds of Formula 8 as shown in Scheme 5. The functional groups Y.sup.1 and Y.sup.2 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amide oximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates (triflate), boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow for the construction of the various G rings. For example, reaction of a compound of Formula 7 where Y.sup.1 is a chlorooxime moiety with a compound of Formula 8 where Y.sup.2 is a vinyl or acetylene group in the presence of a base will give a compound of Formula 1 where G is an isoxazoline or isoxazole ring, respectively. For typical reaction conditions, see WO 2018/118781 (Examples 1, 2 and 6) and WO 2018/187553 (Example 13). The synthetic literature describes many general methods for forming heterocyclic rings and ring systems, such as those illustrated in G-1 through G-118 of Embodiment 20; see, for example, Comprehensive Heterocyclic Chemistry, Volumes 4-6, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984; Comprehensive Heterocyclic Chemistry II, Volumes 2-4, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996; and the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York. One skilled in the art knows how to select the appropriate functional groups Y.sup.1 and Y.sup.2 to construct the desired G rings.

##STR00053##

[1066] As shown in Scheme 6, Compounds of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) wherein R.sup.1 is CF.sub.3 can be prepared by trifluoroacetylation of organometallic compounds of Formula 9. Typically, the ethyl ester of trifluoroacetic acid (i.e. ethyl trifluoroacetate) is used as the source of the trifluoroacetyl group in this method, but trifluoroacetonitrile and various trifluoroacetate salts can also be used. Depending on the reaction conditions, double addition on the trifluoroacetyl compound can occur. Conducting the reaction at 65 C., or more preferably at 78 C., can reduce the occurrence of double addition adducts to trace amounts, particularly when using organometallic species of Formula 9 wherein M is Li or MgBr. Many other organometallic species yield similar results. For reaction conditions useful in the method of Scheme 6, as well as other well-established routes for the synthesis of trifluoromethyl ketones see, for example, Journal of Organic Chemistry 1987, 52(22), 5026-5030; Chemical Communications 2013, 49(95), 11133-11148; and Journal of Fluorine Chemistry 1981, 18, 117-129. Conditions described in these references can easily be modified to prepare compounds of Formula 1a wherein R.sup.1 is other than CF.sub.3 (e.g., difluor- or trichloro-moieties).

##STR00054##

[1067] Alternatively, compounds of Formula 1a can be prepared via alkylation of ethyl 4,4,4-trifluoroacetoacetate (ETFAA) with compounds of Formula 10 wherein L.sup.a is a leaving group such as halogen (e.g., Cl, Br) or sulfonate (e.g., mesylate), and the like, as illustrated in Scheme 7. In this method ETFAA is first treated with a base such as sodium hydride in a polar aprotic solvent such as tetrahydrofuran, tetrahydrofuran/hexamethylphosphoramide (HMPA) or acetone. The ETFAA anion then displaces the leaving group in compounds of Formula 10 to give an intermediate ester which undergoes hydrolysis and decarboxylation in the presence of lithium chloride (LiCl) and N,N-dimethylformamide to provide ketones of Formula 1a. For reaction conditions see Journal of the Chemical Society, Chemical Communications 1989, (2), 83-84; Chemical Communications 2013, 49(95), 11133-11148; and Journal of Fluorine Chemistry 1989, 44, 377-394.

##STR00055##

[1068] As shown in Scheme 8, compounds of Formula 1a can also be prepared by trifluoromethylation of an ester of Formula 11 with trifluoromethyltrimethylsilane (TMS-CF.sub.3). The reaction is run in the presence of a fluoride initiator such as tetrabutylammonium fluoride, and in an anhydrous solvent such as toluene or dichloromethane at about 78 C. (for reaction conditions see, for example, Angew. Chem., Int. Ed. 1998, 37(6), 820-821). Cesium fluoride can also be used as an initiator in a solvent such as 1,2-dimethoxyethane (glyme) at room temperature (for reaction conditions see, for example, J. Org. Chem. 1999, 64, 2873). The reaction proceeds through a trimethylsilicate intermediate, which is hydrolyzed with aqueous acid to give the desired trifluoromethyl ketone compound of Formula 1a. Weinreb amides may also be used in place of the starting esters (for reaction conditions see, for example, Chem. Commun. 2012, 48, 9610).

##STR00056##

[1069] As shown in Scheme 9, compounds of Formula 1a.sup.1 (i.e. Formula 1a wherein A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b) wherein R.sup.1 is CF.sub.3 and at least one R.sup.5a or R.sup.5b is H can be prepared by reacting acid chlorides of Formula 12 with trifluoroacetic anhydride (TFAA) and pyridine in a solvent such as dichloromethane or toluene at temperatures between about 0 to 80 C., followed by aqueous hydrolysis (for reaction conditions see, for example, Tetrahedron 1995, 51, 2573-2584). Compounds of Formula 12 can be prepared from compounds of Formula 11 by ester hydrolysis to the corresponding carboxylic acid and treatment with oxalyl chloride, as known to one skilled in the art.

##STR00057##

[1070] As shown in Scheme 10, compounds of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R.sup.2aX and R.sup.2bY are OH can be prepared by reacting phenyl ketones of Formula 13 with trifluoroacetic esters (e.g., ethyl trifluoroacetate) in the presence of a base such as sodium hydride and in a solvent such as tetrahydrofuran, at a temperature between about 0 to 70 C. The target compounds of Formula 1b are typically isolated as their ketone hydrates (i.e. dihydroxy) upon aqueous hydrolysis. For reaction conditions see, for example, Tetrahedron 2014, 70, 4668-4674; and Journal of Organic Chemistry 2013, 52, 4171-4176

##STR00058##

[1071] The method of Scheme 10 is also useful for preparing intermediates of Formula 5, which can subsequently be converted to compounds of Formula 1 using the methods of Schemes 1-3. Scheme 11 illustrates a specific example wherein a phenyl ketone of Formula 14 is reacted with ethyl trifluoroacetate in the presence of sodium hydride in tetrahydrofuran to provide a compound of Formula 5a (i.e. Formula 5 wherein A is OCH.sub.2, R.sup.2aX and R.sup.2bY are OH and R.sup.1 is CF.sub.3). For reaction conditions, see present Example 1, Step B. Compounds of Formula 14 are available from commercial sources and can easily be prepared using commercial precursors and known methods. Present Example 1, Step A illustrates the preparation of a compound of Formula 14.

##STR00059##

[1072] As shown in Scheme 12, compounds of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R.sup.2aX and R.sup.2bY are OH can also be prepared by oxidation of alcohols of Formula 15 to the corresponding dihydroxy. The oxidation reaction can be performed by a variety of means, such as by treatment of the alcohols of Formula 15 with manganese dioxide, Dess-Martin periodinane, pyridinium chlorochromate or pyridinium dichromate. For typical reaction conditions, see PCT publication WO 2020/056090 (Example 6, Step F and Example 8, Step F).

##STR00060##

[1073] As illustrated in Scheme 13, ketones of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) may exist in equilibrium with their corresponding ketone hydrates (i.e. dihydroxy) of Formula 1b (i.e. Formula 1 wherein T is T-2) wherein R.sup.2aX and R.sup.2bY are OH. The predominance of Formula 1a or Formula 1b is dependent upon several factors, such as environment and structure. For example, in an aqueous environment ketones of Formula 1a can react with water to give ketone hydrates (also known as 1,1-geminal diols) of Formula 1b. Conversion back to the keto-form can usually be achieved by treatment with a dehydrating agent such as magnesium sulfate or molecular sieves. When the ketone moiety is in close proximity to an electron-withdrawing group, such as when R.sup.1 is a trifluoromethyl group, the equilibrium typically favors the dihydrate form. In these cases, conversion back to the keto-form may require a strong dehydrating agent, such as phosphorus pentoxide (P.sub.2O.sub.5). For reaction conditions see, for example, Eur. J. Org. Chem. 2013, 3658-3661; and Chemical Communications 2013, 49(95), 11133-11148, and references cited therein.

##STR00061##

[1074] As shown in Scheme 14, ketones of Formula 1a may also exist in equilibrium with their hemiketals, hemithioketals and hemiaminals of Formula 1b.sup.1 (i.e. Formula 1b wherein R.sup.2bY is OH and R.sup.2a is other than H) along with their ketals, thioketals aminals of Formula 1b wherein R.sup.2a and R.sup.2b are other than H. Compounds of Formula 1b.sup.1 can be prepared by reacting a compound of Formula 1a with a compound of formula R.sup.2a XH (e.g., alcohols for X being 0, thiols for X being S or amines for X being NR.sup.4a), usually in the presence of a catalyst, such as a Bronsted (i.e. protic) acid or Lewis acid (e.g. BF.sub.3), (see, for example, Master Organic Chemistry (Online), On Acetals and Hemiacetals, May 28, 2010, www.masterorganic-chemistry.com/2010/05/28/on-acetals-and-hemiacetals). In a subsequent step, compounds of Formula 1b.sup.1 can be treated with a compound of formula R.sup.2bYH (e.g., alcohols for Y being O, thiols for Y being S or amines for Y being NR.sup.4b) under dehydrating conditions, or other means of water removal that will drive the equilibrium in the reaction to the right, to provide compounds of Formula 1b wherein R.sup.2a and R.sup.2b are other than H. Alternatively, ketones of Formula 1a can initially be treated with two equivalents (or an excess amount) of an alcohol, thiol or amine typically in the presence of a catalyst together with a dehydrating agent to provide compounds of Formula 1b directly (see, for example, the preparation of dimethylketals using methanol and trimethyl orthoformate in U.S. Pat. No. 6,350,892).

##STR00062##

[1075] As shown in Scheme 15, cyclic ketals of Formula 1b.sup.2 (i.e. Formula 1b wherein X and Y are O, and R.sup.2a and R.sup.2b are taken together to form a 5- to 7-membered ring) can be prepared by treating the corresponding ketones of Formula 1a with haloalcohols (e.g., 2-chloroethanol or 2-bromopropanol) in the presence of a base such as potassium carbonate or potassium tert-butoxide and in as solvent such as acetonitrile or N,N-dimethylformamide. For reaction conditions see, Organic Letters 2006 8(17), 3745-3748, and PCT publication WO 2020/056090 (Example 2).

##STR00063##

[1076] The method of Scheme 15 is also useful for preparing cyclic ketals starting from the corresponding ketone hydrate intermediate of Formula 5. Scheme 16 illustrates a specific example wherein the ketone hydrate of Formula 5a (i.e. Formula 5 wherein A is OCH2, R.sup.2aX and R.sup.2bY are OH and R.sup.1 is CF.sub.3) is reacted with 2-chloroethanol in the presence of potassium carbonate in acetonitrile to provide a compound of Formula 5b (i.e. Formula 5 wherein A is OCH.sub.2, X and Y are O, R.sup.2a and R.sup.2b are taken together to form a 5-membered ring and R.sup.1 is CF.sub.3). The method of Scheme 16 is illustrated in present Example 1, Step C.

##STR00064##

[1077] As shown in Scheme 17, Compounds of Formula 1b.sup.3 (i.e. compounds of Formula 1b wherein A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b) wherein A.sup.1 is N(R.sup.6), O or S and A.sup.2 is a direct bond, or wherein A.sup.1 is CR.sup.5aR.sup.5b and A.sup.2 is N(R.sup.6), O or S can be prepared by reacting compounds of Formula 16 wherein A.sup.1 is O, S or N(R.sup.6) and A.sup.2 is a direct bond, or where A.sup.1 is CR.sup.5aR.sup.5b and A.sup.2 is O, S or N(R.sup.6) with compounds of Formula 17 wherein L.sup.b is a leaving group (e.g., mesylate, triflate tosylate). The reaction is typically run in a solvent such as N,N-dimethylformamide or dimethyl sulfoxide with a base such as cesium or potassium carbonate or sodium hydride at temperatures between about 20 to 80 C. The method of Scheme 17 is illustrated in PCT application WO 2020/056090 (Example 4, Step D).

##STR00065##

[1078] Compounds of Formula 17 can be prepared using commercial precursors and known methods. For example, as shown in Scheme 18, compounds of Formula 17a (i.e. Formula 17 wherein R.sup.5a and R.sup.5b are H, X and Y are O and R.sup.2a and R.sup.2b are taken together to form a 5-membered ring) can be prepared by reacting compounds of Formula 18 with haloalcohols (e.g., 2-chloroethanol or 3-bromopropanol) under basic conditions (e.g., potassium tert-butoxide in a solvent such as N,N-dimethylformamide or tetrahydrofuran) to provide compounds of Formula 19. A variety of methods are disclosed in the chemical literature for the conversion of ketones to cyclic ketals and can be readily adapted to prepare compounds of Formula 19 (see, for example, G. Hilgetag and A. Martini, Ed., Preparative Organic Chemistry, pp 381-387: Wiley, New York, 1972, and references sited therein; also see PCT application WO 2020/056090, Example 4, Step A). The ester moiety of the resulting cyclic ketal of Formula 19 can be reduced to the corresponding alcohol of Formula 20 by standard methods known to one skilled in the art (PCT publication WO 2020/056090, Example 4, Step B illustrates a typical procedure). The hydroxy moiety in the compounds of Formula 20 can then be converted to a variety of L.sup.b groups to provide compounds of Formula 17a. For example, a mesylate or tosylate group can be installed by treating the alcohol with methanesulfonyl chloride (mesyl chloride) or 4-toluenesulfonyl chloride (tosyl chloride) in the presence of a base such as triethylamine at a temperature between about 0 to 40 C. and in a solvent such as dichloromethane. A triflate group can be installed by treating the alcohol with triflic anhydride (CF.sub.3SO.sub.2).sub.2O as illustrated in PCT publication WO 2020/056090 (Example 4, Step C). Compounds of Formula 18 are known and can be prepared by methods known to one skilled in the art.

##STR00066##

[1079] Compounds of Formula 1c (i.e. Formula 1 wherein T is T-3 and X is O) can be prepared by reacting a compound of Formula 1a (i.e. Formula 1 wherein T is T-1 and W is O) wherein A is A.sup.1-A.sup.2-CR.sup.5aR.sup.5b and at least one of R.sup.5a and R.sup.5b is H with a compound of Formula 21 in the presence of a base, as illustrated in Scheme 19. Suitable bases include cesium or potassium carbonate in a solvent such as N,N-dimethylformamide or dimethyl sulfoxide at temperatures from about 20 to 80 C. In some cases, the method of Scheme 19 results in a mixture of O-alkylated product (typically as a mixture of (E)- and (Z)-isomers), along with C-alkylated product. Purification can be achieved using standard techniques such as column chromatography (see Magnetic Resonance in Chemistry 1991, 29, 675-678). Compounds of Formula 21 are commercially available and can be easily synthesized by general methods known to one skilled in the art.

##STR00067##

[1080] The method of Scheme 19 is also useful for preparing compounds of Formula 1c starting from the corresponding ketone hydrates. Scheme 20 illustrates a specific example where a ketone hydrate of Formula 1b.sup.4 (i.e. Formula 1b wherein L is CH.sub.2, J is phenyl, A is OCH.sub.2, R.sup.2aX and R.sup.2bY are OH and R.sup.1 is CF.sub.3) is reacted with iodoethane in the presence of cesium carbonate in dimethyl sulfoxide at a temperature between about 25 to 75 C. to provide a compound of Formula 1c.sup.1 (i.e. Formula 1c wherein L is CH.sub.2, J is phenyl, A is O, R.sup.2d is H, XR.sup.2c is OCH.sub.2CH.sub.3 and R.sup.1 is CF.sub.3). PCT publication WO 2020/056090, Example 5, illustrates the method of Scheme 20.

##STR00068##

[1081] The method of Scheme 20 can also be performed starting from the corresponding ketone hydrate of Formula 5a (i.e. Formula 5 wherein A is OCH.sub.2, R.sup.2aX and R.sup.2bY are OH and R.sup.1 is CF.sub.3), as shown in Scheme 21. For reaction conditions, see present Example 4, Step A.

##STR00069##

[1082] One skilled in the art will recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents. In particular, certain R.sup.9 substituents attached to the G ring may be obtained via functional group interconversion reactions. For example, as shown in Scheme 22, compounds of Formula 1d (i.e. Formula 1 wherein the G ring is substituted with R.sup.9, and R.sup.9 is (CR.sup.11aR.sup.11b).sub.mR.sup.9a and R.sup.9a is alkylcarbonyloxy, alkenylcarbonyloxy, cycloalkylcarbonyloxy, alkoxycarbonyloxy, and the like) can be prepared by reacting a carboxylic acid of Formula 22 with an alcohol of Formula 23. The reaction proceeds via activation of the carboxylic acid of Formula 22 followed by coupling with the alcohol of Formula 23. Activation of the carboxylic acid takes place with the aid of a coupling reagent, or alternatively by conversion of the carboxylic acid to the acid halide. For example, compounds of Formulae 23 and 22 can be reacted in the presence of a carbodiimide coupling reagent, such as N,N-dicyclehexylcarbodiimide (DCC), N-ethyl-N-(3-dimethylaminopropyl)carbodiimide (EDC) or N,N-diisopropylcarbodimide (DIC). In some instances, addition of a catalyst such as N,N-dimethyl-4-pyridinamine (DMAP) can aid in reducing the formation of undesired products (e.g., N-acylurea side products). A wide variety of other methods are available for formation of esters from carboxylic acids and alcohols, including use of coupling reagents such as benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP), O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-fluorophosphate (HBTU). The reaction is typically run in a polar aprotic solvent such as N,N-dimethylformamide, tetrahydrofuran or dichloromethane and in the presence of a base such as pyridine, triethylamine or N,N-diisopropylethylamine. In certain instances it can be advantageous to use polymer-supported coupling reagents, such as polymer bound dicyclohexyl carbodiimide (DCC). Alternatively, a carboxylic acid of Formula 22 can be reacted with a halogenating reagent such as thionyl chloride, oxalyl chloride, phosphorus trichloride, phosphorus oxychloride or phosphorus pentachloride in a solvent such as dichloromethane or toluene and optionally in the presence of a catalytic amount of N,N-dimethylformamide to provide the corresponding acid chloride. When using an acid chloride of Formula 22, the coupling step typically includes a base such as triethylamine, N,N-diisopropylethylamine and pyridine (for reaction conditions see Example 4, Step F). A wide variety of synthetic methods are known in the art to enable the formation of esters from carboxylic acids and alcohols; for an extensive review of coupling conditions, including solid-supported strategies, see Natural Product Reports 2015, 32(4), 605-632; Chemical Society Review 2009, 38, 606-631; Chemical Society Review 2014, 00, 1-29; Journal of Saudi Chemical Society 2012, 16, 97-116; Organic Letters 2011, 13(12), 2988-2991; and Tetrahedron 2005, 61, 10827-10852.

##STR00070##

[1083] General methods useful for preparing compounds of Formula 23 are well known in the art. For example, reduction of ketones using a reducing agent such as lithium aluminum hydride or a borane/tetrahydrofuran complex in an aprotic solvent, analogous to the method described in Scheme 3. For reaction conditions, see present Example 1, Step G; Example 2, Step A; and Example 4, Step E. Carboxylic acids of Formula 22 are commercially available and can be prepared by known literature methods.

[1084] Scheme 23 illustrates a specific example of the general method of Scheme 22 for the preparation of a compound of Formula 1d.sup.1 (i.e. Formula 1d wherein G is pyrazole, L is CH.sub.2, J is phenyl and R.sup.9 is cyclopentyl-C(O)OCH.sub.2). Present Example 1, Step H illustrates the method of Scheme 23.

##STR00071##

[1085] One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described above wherein W is O can be converted to the corresponding thiolates wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (Lawesson's reagent). Reactions of this type are well-known in the chemistry literature, see, for example, Heterocycles 1995, 40, 271-278; Journal of Medicinal Chemistry 2008, 51, 8124-8134; Journal of Medicinal Chemistry 1990, 33, 2697-706; Synthesis 1989, (5), 396-3977; J. Chem. Soc., Perkin Trans. 1, 1988, 1663-1668; Tetrahedron 1988 44, 3025-3036; and Journal of Organic Chemistry 1988 53(6), 1323-1326. For relevant reaction conditions, see present Example 3.

[1086] It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2.sup.nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula 1.

[1087] Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other examples or steps. Ambient or room temperature is defined as about 20-25 C. Unless otherwise indicated, the following examples are conducted under a nitrogen atmosphere with stirring. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. MPLC refers to medium pressure liquid chromatography on silica gel. .sup.1H NMR spectra are reported in ppm downfield from tetramethylsilane; s means singlet, d means doublet, t means triplet, q means quartet, m means multiplet, br s means broad singlet, br d means broad doublet, t d means a triplet of doublets and q d means a quartet of doublets. .sup.19F NMR spectra are reported in ppm using trichlorofluoromethane as the reference. Mass spectra (MS) are reported as the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of H.sup.+ (molecular weight of 1) to the molecule, or (M1) formed by the loss of H.sup.+ (molecular weight of 1) from the molecule, observed by using liquid chromatography coupled to a mass spectrometer (LCMS) using either atmospheric pressure chemical ionization (AP.sup.+) or electrospray ionization (ESI.sup.+).

Example 1

Preparation of [1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl cyclopentanecarboxylate (Compound 4)

Step A: Preparation of ethyl 4-(2-oxo-2-phenylethoxy)benzoate

[1088] To a mixture of ethyl 4-hydroxybenzoate (100 g, 0.60 mol) in acetone (3 L) was added portionwise 2-bromo-1-phenylethanone (132 g, 0.66 mol) and potassium carbonate (249 g, 1.80 mol). The reaction mixture was heated at 60 C. for 3 h, and then cooled and filtered, rinsing with acetone (250 mL). The filtrate was concentrated under reduced pressure and the resulting solid was triturated with pentane (500 mL) to provide the title compound as a white solid (159 g).

[1089] .sup.1H NMR (CDCl.sub.3): 8.00-7.99 (d, 4H), 7.64-7.62 (t, 1H), 7.54-7.50 (t, 2H), 6.97-6.94 (d, 2H), 5.35 (s, 2H), 4.37-4.32 (q, 2H), 1.39-1.36 (t, 3H).

[1090] MS m/z: 284 [M+H].sup.+

Step B: Preparation of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate

[1091] To a mixture of ethyl 2,2,2-trifluoroacetate (31.8 g, 0.22 mol) in tetrahydrofuran (750 mL) was added sodium hydride (60% in oil, 8.94 g, 0.22 mol). After 15 minutes, the reaction mixture was cooled to 0 C., and then ethyl 4-(2-oxo-2-phenylethoxy)benzoate (i.e. the product of Step A) (53 g, 0.19 mol) was added portionwise. The reaction mixture was heated at 70 C. for 2.5 h, and then cooled to 0 C. and diluted with hydrochloric acid (1 N solution in water, 140 mL). After stirring for 15 minutes, saturated aqueous sodium bicarbonate solution (250 mL) was added, and the resulting mixture was extracted with ethyl acetate (2380 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was triturated with pentane (100 mL) to provide the title compound as an off-white solid (43 g).

[1092] .sup.1H NMR (DMSO-d6): 7.92-7.90 (d, 2H), 7.36 (s, 2H), 7.09-7.07 (d, 2H), 4.30-4.25 (q, 2H), 4.13 (s, 2H), 1.32-1.28 (t, 3H),

[1093] MS m/z: 295 [M+H].sup.+

Step C: Preparation of ethyl 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzoate

[1094] To a mixture of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate (i.e. the product of Step B) (42 g, 0.14 mol) in N,N-dimethylformamide (80 mL) was added potassium carbonate (58.9 g, 0.43 mol). After 10 minutes, 2-chloroethanol (34.5 g, 0.43 mol) was added dropwise to the reaction mixture and stirring was continued for 16 h. The reaction mixture was cooled to 0 C. and ice-cold water (250 mL) was added. The resulting mixture was extracted with ethyl acetate (2300 mL), and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 1% ethyl acetate in petroleum ether) to provide the title compound as a colorless oil (31 g).

[1095] .sup.1H NMR (CDCl.sub.3): 8.02-7.98 (d, 2H), 6.98-6.94 (d, 2H), 4.38-4.33 (q, 2H), 4.29 (s, 2H), 4.21 (s, 4H), 1.40-1.36 (t, 3H).

[1096] MS m/z: 321 [M+H].sup.+

Step D: Preparation of 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]-benzenemethanol

[1097] To a mixture of ethyl 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzoate (i.e. the product of Step C) (25 g, 78.1 mmol) in tetrahydrofuran (120 mL) at 0 C. was added lithium aluminum hydride (2 M solution in tetrahydrofuran, 58.5 mL, 117 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 3 h, and then cooled to 0 C. and diluted with ethyl acetate (180 mL) and water (100 mL). The resulting mixture was filtered through a pad of Celite, rinsing with ethyl acetate (100 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solid was triturated with petroleum ether to provide the title compound as an off-white solid (20 g).

[1098] .sup.1H NMR (DMSO-d6): 7.24-7-22 (d, 2H), 6.96-6.93 (d, 2H), 5.08-5.05 (t, 1H), 4.42-4.41 (d, 2H), 4.23-4.11 (m, 6H).

Step E: Preparation of 2-[[4-(bromomethyl)phenoxy]methyl]-2-(trifluoromethyl)-1,3-dioxolane

[1099] To a mixture of 4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]benzenemethanol (i.e. the product of Step D) (36 g, 0.13 mol) in dichloromethane (300 mL) at 0 C. was added tetrabromomethane (47.1 g, 0.14 mol) and triphenylphosphine (37.3 g, 0.14 mol). The reaction mixture was allowed to warm to room temperature and stirred for 2 h, and then cooled to 0 C., diluted with ice-cold water (80 mL) and extracted with dichloromethane (2150 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 5% ethyl acetate in petroleum ether) to provide the title compound as a pale-yellow oil (37.2 g).

[1100] .sup.1H NMR (CDCl.sub.3): 7.34-7.31 (d, 2H), 6.92-6.89 (d, 2H), 4.49-4.46 (s, 2H), 4.23-4.20 (m, 6H).

Step F: Preparation of ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]-phenyl]methyl]-1H-pyrazole-4-carboxylate

[1101] To a mixture of ethyl 1H-pyrazole-4-carboxylate (12.3 g, 87.9 mmol) in acetonitrile (220 mL) was added cesium carbonate (57.3 g, 0.18 mol). After 10 minutes, 2-[[4-(bromomethyl)phenoxy]methyl]-2-(trifluoromethyl)-1,3-dioxolane (i.e. the product of Step E) (30 g, 87.9 mmol) was added to the reaction mixture and stirring was continued for 7 h. The reaction mixture was filtered through a frit funnel, rinsing with acetonitrile (50 mL), and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 15% ethyl acetate in petroleum ether) to provide the title compound as an off-white solid (26.2 g).

[1102] .sup.1H NMR (CDCl.sub.3): 7.92 (s, 1H), 7.81 (s, 1H), 7.22-7.19 (d, 2H), 6.95-6.93 (d, 2H), 5.24 (s, 2H), 4.28-4.26 (q, 2H), 4.23-4.20 (m, 6H), 1.34-1.31 (t, 3H).

[1103] MS m/z: 401 [M+H].sup.+

Step G: Preparation of 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-methyl]-1H-pyrazole-4-methanol

[1104] To a mixture of ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-methyl]-1H-pyrazole-4-carboxylate (i.e. the product of Step F) (30 g, 74.9 mmol) in tetrahydrofuran (200 mL) at 0 C. was added dropwise lithium aluminum hydride (1 M solution in tetrahydrofuran, 112 mL, 112 mmol). The reaction mixture was stirred at 0 C. for 2 h, and then diluted with ethyl acetate (300 mL) and water (200 mL). The resulting mixture was filtered through a pad of Celite, rinsing with ethyl acetate (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 35% ethyl acetate in petroleum ether) to provide the title compound as a pale yellow solid (24.5 g).

[1105] .sup.1H NMR (DMSO-d6): 7.53 (s, 1H), 7.35 (s, 1H), 7.20-7.18 (d, 2H), 6.93-6.91 (d, 2H), 5.21 (s, 2H), 4.56 (s, 2H), 4.22-4.20 (m, 6H).

[1106] MS m/z: 359 [M+H].sup.+

Step H: Preparation of [1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-methyl]-1H-pyrazol-4-yl]methyl cyclopentanecarboxylate

[1107] To a mixture of cyclopentanecarboxylic acid (111 mg, 0.97 mmol) in tetrahydrofuran (10 mL) at 0 C. was added N,N-dimethyl-4-pyridinamine (355 mg, 2.91 mmol), followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (ECD) (558 mg, 2.91 mmol). The reaction mixture was stirred at 0 C. for 10 minutes, and then 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]-1H-pyrazole-4-methanol (i.e. the product of Step G) (350 mg, 0.97 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for 16 h, and then diluted with water (10 mL). The resulting mixture was extracted with ethyl acetate (220 mL) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 20% ethyl acetate in petroleum ether) to provide the title compound, a compound of the present invention, as a colorless oil (210 mg).

[1108] .sup.1H NMR (CDCl.sub.3): 7.53 (s, 1H), 7.38 (s, 1H), 7.19-7.16 (d, 2H), 6.93-6.90 (d, 2H), 5.21 (s, 2H), 4.97 (s, 2H), 4.22-4.20 (m, 6H), 2.71-2.68 (m, 1H), 1.86-1.53 (m, 8H).

[1109] MS m/z: 455 [M+H].sup.+

Example 2

Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-methoxy-N-methyl-1H-pyrazole-4-acetamide (Compound 5)

Step A: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-methanol

[1110] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-carboxylate (10 g, 26.0 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in tetrahydrofuran (100 mL) at 0 C. was added dropwise lithium aluminum hydride (1 M solution in tetrahydrofuran, 31.2 mL, 31.2 mmol). The reaction mixture was stirred at 0 C. for 1 h, and then diluted with water (1.2 mL) and sodium hydroxide (10% aqueous solution, 2.4 mL), followed by more water (1.2 mL). After stirring for 15 minutes, the mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure to provide the title compound as an oil (8 g).

Step B: Preparation of 4-(chloromethyl)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole

[1111] To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-methanol (i.e. the product of Step A) (3.0 g, 8.8 mmol) in dichloromethane (30 mL) at 0 C. was added dropwise N,N-dimethylformamide (0.068 mL, 0.88 mmol) and thionyl chloride (1.28 mL, 17.53 mmol). The reaction mixture was heated at 45 C. for 1 h, cooled to room temperature, and then diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as an oil (3 g).

[1112] .sup.1H NMR (CDCl.sub.3): 7.54 (s, 1H), 7.40 (s, 1H), 7.23 (d, 2H), 7.02 (d, 2H), 6.76 (s, 1H), 5.23 (s, 2H), 4.51 (s, 2H), 4.17 (q, 2H), 1.33 (t, 3H)

Step C: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-acetonitrile

[1113] To a mixture of 4-(chloromethyl)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole (i.e. the product of Step B) (3.0 g, 8.3 mmol), and trimethylsilyl cyanide (1.66 mL, 12.47 mmol) in acetonitrile (40 mL) was added tetrabutylammonium fluoride solution (1 M solution in tetrahydrofuran, 12.5 mL, 12.5 mmol). After 16 h, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 50 to 55% ethyl acetate in hexanes) to provide the title compound as an oil (2 g).

[1114] .sup.1H NMR (CDCl.sub.3): 7.47 (s, 1H), 7.30 (s, 1H), 7.23 (m, 2H), 7.03 (m, 2H), 6.76 (s, 1H), 5.24 (s, 2H), 4.25-4.15 (m, 2H), 3.56 (s, 2H), 1.32 (t, 3H).

[1115] MS m/z: 352 [M+H].sup.+

Step D: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-acetic acid

[1116] To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetonitrile (i.e. the product of Step C) (1.0 g, 2.9 mmol) in water (5 mL) was added acetic acid (5 mL, 2.9 mmol) and sulfuric acid (5 mL, 2.9 mmol). The reaction mixture was heated at 100 C. for 4 h, and then cooled to room temperature and diluted with water. The resulting mixture was extracted with ethyl acetate, and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as an oil (0.7 g).

[1117] MS m/z: 371 [M+H].sup.+

Step E: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-N-methoxy-N-methyl-1H-pyrazole-4-acetamide

[1118] To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetic acid (i.e. the product of Step D) (150 mg, 0.41 mmol) and N,O-dimethylhydroxylamine hydrochloride (27 mg, 0.45 mmol) in dichloromethane (10 mL) was added propanephosphonic acid anhydride (T3P) (50% in ethyl acetate, 0.18 mL, 0.61 mmol) and triethylamine (0.11 mL, 0.81 mmol). The reaction mixture was stirred for 3 h, and then diluted with water and extracted with dichloromethane. The organic extract was dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 60 to 70% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as an oil (50 mg).

[1119] .sup.1H NMR (CDCl.sub.3): 7.47 (s, 1H), 7.41 (s, 1H), 7.22 (d, 2H), 6.99 (d, 2H), 6.74 (s, 1H), 5.21 (s, 2H), 4.15 (q, 2H), 3.67 (s, 3H), 3.60 (s, 2H), 3.17 (s, 3H), 1.32 (t, 3H).

[1120] MS m/z: 414 [M+H].sup.+

Example 3

Preparation of O-ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carbothioate (Compound 7)

[1121] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-carboxylate (0.2 g, 0.52 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in xylenes (10 mL) was added 2,4-bis(4-methoxy-phenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide (Lawesson's reagent) (0.421 g, 1.04 mmol). The reaction mixture was heated at 150 C. for 16 h, cooled to room temperature and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 25 to 30% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a light yellow oil (0.1 g).

[1122] .sup.1H NMR (CDCl.sub.3): 7.97 (s, 1H), 7.93 (s, 1H), 7.27 (d, 2H), 7.04 (d, 2H), 6.76 (s, 1H), 5.25 (s, 2H), 4.64 (q, 2H), 4.17 (q, 2H), 1.44 (t, 3H), 1.34 (t, 3H).

[1123] MS m/z: 401 [M+H].sup.+

Example 4

Preparation of [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate (Compound 21)

Step A: Preparation of ethyl 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzoate

[1124] To a mixture of ethyl 4-(3,3,3-trifluoro-2,2-dihydroxypropoxy)benzoate (i.e. the product of Example 1, Step B) (7.55 g, 25.7 mmol) in dimethyl sulfoxide (64 mL) was added cesium carbonate (16.8 g, 51.4 mmol) and iodoethane (27.2 g, 0.18 mol). The reaction mixture was heated at 50 C. for 3 h, cooled to room temperature, and then poured into ice-cold water (100 mL). The resulting mixture was extracted with ethyl acetate (3100 mL) and the combined organic extracts were washed with saturated aqueous sodium chloride solution (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 10% ethyl acetate in hexanes) to give the title compound as a colorless oil (6.96 g).

[1125] .sup.1H NMR (CDCl.sub.3): 8.08-8.05 (m, 2H), 7.10-7.06 (m, 2H), 6.83 (s, 1H), 4.37 (q, 2H), 4.20 (q, 2H), 1.42-1.33 (m, 6H).

[1126] .sup.19F NMR (CDCl.sub.3): -70.20 (s, 3F).

Step B: Preparation of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzenemethanol

[1127] To a mixture of ethyl 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzoate (i.e. the product of Step A) (12.3 g, 40.4 mmol) in tetrahydrofuran (202 mL) at 0 C. was added dropwise lithium aluminum hydride (2 M solution in tetrahydrofuran, 50.5 mL, 0.10 mol). The reaction mixture was stirred for 1 h, and then water (3.8 mL) was slowly added, followed by sodium hydroxide (15% aqueous solution, 3.8 mL), and more water (11.4 mL). To the resulting mixture was added magnesium sulfate, the mixture was stirred for 15 minutes and then filtered. The filtrate was concentrated under reduced pressure and the resulting material was purified by silica gel chromatography (eluting with 10-50% ethyl acetate in hexanes) to provide the title compound as a yellow oil (9.3 g).

[1128] .sup.1H NMR (CDCl.sub.3): 7.37-7.35 (m, 2H), 7.06-7.02 (m, 2H), 6.80-6.77 (m, 1H), 4.68-4.66 (m, 2H), 4.18 (q, 2H), 1.35 (t, 3H).

[1129] .sup.19F NMR (CDCl.sub.3): -70.03 (s, 3F).

Step C: Preparation of 1-(bromomethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzene

[1130] A mixture of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzenemethanol (i.e. the product of Step B) (9.3 g, 35.5 mmol) and triphenylphosphine (15.8 g, 60.3 mmol) in dichloromethane (236 mL) was cooled to 0 C., and then N-bromosuccinimide (9.47 g, 53.2 mmol) was added portionwise over 5 minutes. After 30 minutes, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, and the aqueous layer was separated and extracted with dichloromethane. The combined organics were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (eluting with 0-5% ethyl acetate in hexanes) to provide the title compound as a colorless oil (6.98 g).

[1131] .sup.1H NMR (CDCl.sub.3): 7.42-7.33 (m, 2H), 7.06-6.99 (m, 2H), 6.79-6.76 (m, 1H), 4.49 (s, 2H), 4.18 (q, 2H), 1.34 (t, 3H).

[1132] .sup.19F NMR (CDCl.sub.3): -70.11 (s, 3F).

Step D: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-phenyl]methyl]-1H-pyrazole-4-carboxylate

[1133] To a mixture of 1-(bromomethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzene (i.e. the product of Step C) (6.98 g, 21.5 mmol) in N,N-dimethylformamide (85.9 mL) was added ethyl 1H-pyrazole-4-carboxylate (3.61 g, 25.8 mmol) followed by cesium carbonate (17.5 g, 53.7 mmol). The reaction mixture was heated at 65 C. overnight, and then cooled to room temperature and diluted with water (100 mL) and ethyl acetate (200 mL). The aqueous layer was separated and extracted with ethyl acetate. The combined organics were washed with saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with a gradient of 0-50% ethyl acetate in hexanes) to provide the title compound as a white solid (5.96 g).

[1134] .sup.1H NMR (CDCl.sub.3): 7.94 (s, 1H), 7.86 (s, 1H), 7.29 (m, 2H), 7.05 (m, 2H), 6.78 (q, 1H), 5.28 (s, 2H), 4.27 (q, 2H), 4.17 (q, 2H), 1.30-1.40 (m, 6H).

[1135] .sup.19F NMR (CDCl.sub.3): -70.13 (s, 3F).

Step E: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-phenyl]methyl]-1H-pyrazole-4-methanol

[1136] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-phenyl]methyl]-1H-pyrazole-4-carboxylate (i.e. the product of Step D) (5.96 g, 15.5 mmol) in tetrahydrofuran (78 mL) at 0 C. was added dropwise lithium aluminum hydride (2 M in tetrahydrofuran, 15.5 mL, 31.0 mmol). The reaction mixture was stirred for 1 h, and then water (1.2 mL) was slowly added, followed by sodium hydroxide (15% aqueous solution, 1.2 mL) and more water (3.6 mL). The reaction mixture was allowed to warm to room temperature, stirred for 15 minutes, and then dried over magnesium sulfate, filtered and concentrated under reduce pressure. The resulting material was purified by silica gel column chromatography to provide the title compound as a white solid (4.52 g).

[1137] .sup.1H NMR (CDCl.sub.3): 7.53 (s, 1H), 7.27-7.22 (m, 3H), 7.03 (d, 2H), 6.75 (s, 1H), 5.25 (s, 2H), 4.57 (d, 2H), 4.17 (q, 2H), 1.58-1.46 (m, 1H), 1.34 (t, 3H).

[1138] .sup.19F NMR (CDCl.sub.3): -70.09 (s, 3F).

[1139] MS m/z: 343 [M+H].sup.+

Step F: Preparation of [1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-phenyl]methyl]-1H-pyrazol-4-yl]methyl propanoate

[1140] To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-methanol (i.e. the product of Step E) (0.15 g, 0.44 mmol) in dichloromethane (2.2 mL) at 0 C. was added pyridine (0.053 mL, 0.657 mmol) followed by propionyl chloride (0.057 mL, 0.657 mmol). The reaction mixture was stirred for 30 minutes, and then diluted with water and dichloromethane. The aqueous layer was separated and extracted with dichloromethane. The combined organics were washed with saturated sodium chloride, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (eluting with 10% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a colorless oil (0.167 g).

[1141] .sup.1H NMR (CDCl.sub.3): 7.55 (s, 1H), 7.42 (s, 1H), 7.27-7.22 (m, 2H), 7.03 (d, 2H), 6.76 (q, 1H), 5.24 (s, 2H), 4.98 (s, 2H), 4.17 (q, 2H), 2.31 (q, 2H), 1.34 (t, 3H), 1.12 (t, 3H).

[1142] .sup.19F NMR (CDCl.sub.3): -70.11 (s, 3F).

[1143] MS m/z: 399 [M+H].sup.+

Example 5

Preparation of ethyl -(acetyloxy)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetate (Compound 54)

Step A: Preparation of ethyl 2-oxo-2-(1H-pyrazol-4-yl)acetate

[1144] A mixture of 4-bromo-1H-pyrazole (1.0 g, 6.80 mmol) in tetrahydrofuran (15 mL) was cooled to 78 C., and then n-butyllithium (1.6 M in hexanes, 6.4 mL, 10.2 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 1 h, and then cooled to 78 C., and diethyl oxalate (1.4 mL, 10.2 mmol) was added. After 30 minutes, the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 45 to 50% ethyl acetate in hexanes) to provide the title compound as an oil (0.3 g).

[1145] .sup.1H NMR (CDCl.sub.3): 8.40 (s, 2H), 4.41 (q, 2H), 1.42 (t, 3H).

[1146] MS m/z: 169 [M+H].sup.+

Step B: Preparation of 1-(chloromethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzene

[1147] A mixture of 4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzenemethanol (i.e. the product of Example 4, Step B) (7.0 g, 26.7 mmol) in dichloromethane (70 mL) at 0 C. was added N,N-dimethylformamide (0.21 mL, 2.67 mmol) and thionyl chloride (3.90 mL, 53.39 mmol). The reaction mixture was heated at 45 C. for 1 h, and then cooled to room temperature and diluted with saturated aqueous sodium bicarbonate solution. The resulting mixture was extracted with ethyl acetate (100 mL2) and the combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 5-10% ethyl acetate in hexanes) to provide the title compound as a yellow oil (6 g).

[1148] .sup.1H NMR (CDCl.sub.3): 7.33-7.49 (m, 2H), 7.01-7.13 (m, 2H), 6.79 (s, 1H), 4.58 (s, 2H), 4.06-4.30 (m, 2H), 1.24-1.44 (m, 3H).

Step C: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]--oxo-1H-pyrazole-4-acetate

[1149] To a mixture 1-(chloromethyl)-4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]benzene (i.e. the product of Step B) (0.50 g, 1.78 mmol) and ethyl 2-oxo-2-(1H-pyrazol-4-yl)acetate (i.e. the product of Step A) (0.359 g, 2.14 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.369 g, 2.67 mmol). The reaction mixture was heated at 70 C. for 4 h, cooled to room temperature, and then diluted with water. The resulting mixture was extracted with ethyl acetate, and the organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 25-30% ethyl acetate in hexanes) to provide the title compound as an oil (0.5 g).

[1150] .sup.1H NMR (CDCl.sub.3): 8.25 (s, 1H), 8.21 (s, 1H), 7.29 (d, 2H), 7.06 (d, 2H), 6.76 (s, 1H), 5.33-5.30 (m, 2H), 4.37 (q, 2H), 4.17 (q, 2H), 1.40 (t, 3H), 1.33 (t, 3H).

[1151] MS m/z: 413 [M+H].sup.+

Step D: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]--hydroxy-1H-pyrazole-4-acetate

[1152] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]--oxo-1H-pyrazole-4-acetate (i.e. the product of Step C) (150 mg, 0.364 mmol) in methanol (10 mL) at 0 C. was added sodium borohydride (0.021 g, 0.546 mmol). After 3 h, the reaction mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 50-55% ethyl acetate in hexanes) to provide the title compound as an oil (0.08 g).

[1153] .sup.1H NMR (CDCl.sub.3): 7.53 (s, 1H), 7.40 (s, 1H), 7.21 (d, 2H), 7.00 (d, 2H), 6.75 (s, 1H), 5.21 (s, 2H), 5.18-5.13 (m, 1H), 4.25 (q, 2H), 4.16 (q, 2H), 3.44 (br d, 1H), 1.32 (t, 3H), 1.25 (t, 3H).

[1154] MS m/z: 415 [M+H].sup.+

Step E: Preparation of ethyl -(acetyloxy)-1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-acetate

[1155] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]--hydroxy-1H-pyrazole-4-acetate (i.e. the product of Step D) (0.10 g, 0.24 mmol) in dichloromethane (10 mL) at 0 C. was added triethylamine (0.05 mL, 0.36 mmol) and acetyl chloride (0.023 g, 0.29 mmol). The reaction mixture was allowed to warm to room temperature, stirred for 1 h, and then diluted with water and extracted with dichloromethane. The organic extracts were dried over sodium sulphate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (eluting with 20-25% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as an oil (55 mg).

[1156] .sup.1H NMR (CDCl.sub.3): 7.58 (s, 1H), 7.46 (s, 1H), 7.24 (d, 2H), 7.02 (d, 2H), 6.75 (s, 1H), 5.91 (s, 1H), 5.24 (s, 2H), 4.31-4.10 (m, 4H), 2.13 (s, 3H), 1.32 (t, 3H), 1.23 (t, 3H).

[1157] MS m/z: 457 [M+H].sup.+

Example 6

Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboxamide (Compound 55)

Step A: Preparation of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-carboxylic acid

[1158] To a mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-1H-pyrazole-4-carboxylate (1.35 g, 3.51 mmol) (prepared according to the procedure disclosed in WO 2020/056090, Example 5) in ethanol (12 mL) and tetrahydrofuran (35 mL) was added lithium hydroxide (1 M in water, 6.30 mL, 6.30 mmol). After 2 days, the reaction mixture was concentrated under reduce pressure. The resulting mixture was diluted with water and saturated aqueous sodium bicarbonate solution, and then washed with ethyl acetate (35 mL). The resulting aqueous layer was acidified with hydrochloric acid (1N) to a pH of about 2, and then extracted with ethyl acetate (310 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to provide the title compound as a white solid (1.22 g).

[1159] .sup.1H NMR (DMSO-d6): 12.33 (br s, 1H), 8.37 (d, 1H), 7.81 (d, 1H), 7.34 (d, 2H), 7.26 (d, 1H), 7.20 (d, 2H), 5.34 (s, 2H), 4.11 (q, 2H), 1.24 (t, 3H).

Step B: Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]-phenyl]methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboxamide

[1160] To a mixture of 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-1H-pyrazole-4-carboxylic acid (i.e. the product of Step B) (1.30 g, 3.65 mmol) in N,N-dimethylformamide (10 mL) was added hydroxy-1H-benzotriazole (HOBT) (0.542 g, 4.01 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (ECD) (0.77 g, 4.01 mmol), triethylamine (0.66 mL, 4.74 mmol) and O-2-propenylhydroxylamine (0.32 g, 4.38 mmol). The reaction mixture was stirred overnight, and then diluted with water (30 mL), and extracted with ethyl acetate (35 mL). The combined organic extracts were dried over sodium sulfate and filtered. To the filtrate was added Celite and the resulting mixture was concentrated under reduce pressure, then purified by MPLC (eluting with a gradient of 0 to 100% ethyl acetate in hexanes) to provide the title compound, a compound of the present invention, as a solid (1.17 g).

[1161] .sup.1H NMR (CDCl.sub.3): 7.90 (s, 1H), 7.87 (br s, 1H), 7.28-7.26 (m, 2H), 7.05 (d, 2H), 6.76 (d, 1H), 6.04-5.92 (m, 1H), 5.43-5.32 (m, 2H), 5.28 (s, 2H), 4.43 (d, 2H), 4.17 (q, 2H), 1.34 (t, 3H).

Example 7

Preparation of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboximidate (Compound 40)

[1162] A mixture of ethyl 1-[[4-[[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy]phenyl]-methyl]-N-(2-propen-1-yloxy)-1H-pyrazole-4-carboxamide (i.e. the product of Example 6) (300 mg, 0.73 mmol), triphenylphosphine (0.21 g, 0.80 mmol) and ethanol (0.047 mL, 0.80 mmol) in tetrahydrofuran (1.2 mL) was cooled to 0 C., and then diethyl azodicarboxylate (DEAD) (0.13 mL, 0.80 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 3 h, and then dichloromethane and Celite (5 g) were added. The resulting mixture was concentrated under reduce pressure, and then purified by MPLC using a RediSep Gold column (eluting with a gradient of 10 to 40% ethyl acetate in heptane over 16 minutes) to afford the title compound, a compound of the present invention, as a colorless oil (0.18 g).

[1163] .sup.1H NMR (CDCl.sub.3): 7.71 (s, 1H), 7.59 (s, 1H), 7.26-7.23 (m, 2H), 7.04-7.02 (m, 2H), 6.76 (d, 1H), 6.06-5.98 (m, 1H), 5.31 (q d, 1H), 5.25 (s, 2H), 5.21 (q d, 1H), 4.50 (t d, 2H), 4.33 (q, 2H), 4.17 (q, 2H), 1.35-1.32 (m, 6H).

[1164] MS m/z: 440 [M+H].sup.30

Formulation/Utility

[1165] A compound of Formula 1 of this invention (including N-oxides and salts thereof), or a mixture (i.e. composition) comprising the compound with at least one additional fungicidal compound as described in the Summary of the Invention, will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serve as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.

[1166] The mixtures of component (a) (i.e. at least one compound of Formula 1, N-oxides, or salts thereof) with component (b) (e.g., selected from (b1) to (b54) and salts thereof as described above) and/or one or more other biologically active compound or agent (i.e. insecticides, other fungicides, nematocides, acaricides, herbicides and other biological agents) can be formulated in a number of ways, including: [1167] (i) component (a), component (b) and/or one or more other biologically active compounds or agents can be formulated separately and applied separately or applied simultaneously in an appropriate weight ratio, e.g., as a tank mix; or [1168] (ii) component (a), component (b) and/or one or more other biologically active compounds or agents can be formulated together in the proper weight ratio.

[1169] Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in-water emulsions, flowable concentrates and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil-in-water emulsion, flowable concentrate and suspoemulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

[1170] The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (wettable) or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or overcoated). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation.

[1171] Of note is a composition embodiment wherein granules of a solid composition comprising a compound of Formula 1 (or an N-oxide or salt thereof) is mixed with granules of a solid composition comprising component (b). These mixtures can be further mixed with granules comprising additional agricultural protectants. Alternatively, two or more agricultural protectants (e.g., a component (a) (Formula 1) compound, a component (b) compound, an agricultural protectant other than component (a) or (b)) can be combined in the solid composition of one set of granules, which is then mixed with one or more sets of granules of solid compositions comprising one or more additional agricultural protectants. These granule mixtures can be in accordance with the general granule mixture disclosure of PCT Patent Publication WO 94/24861 or more preferably the homogeneous granule mixture teaching of U.S. Pat. No. 6,022,552.

[1172] Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water, but occasionally another suitable medium like an aromatic or paraffinic hydrocarbon or vegetable oil. Spray volumes can range from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.

[1173] The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.

TABLE-US-00001 Weight Percent Active Ingredient Diluent Surfactant Water-Dispersible and Water- 0.001-90 0-99.999 0-15 soluble Granules, Tablets and Powders Oil Dispersions, Suspensions, 1-50 40-99 0-50 Emulsions, Solutions (including Emulsifiable Concentrates) Dusts 1-25 70-99 0-5 Granules and Pellets 0.001-95 5-99.999 0-15 High Strength Compositions 90-99 0-10 0-2

[1174] Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey.

[1175] Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N-methylpyrrolidinone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and -butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C.sub.6-C.sub.22), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950.

[1176] The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as surface-active agents) generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents.

[1177] Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides; alkyl polysaccharides; and glucamides such as mixtures of octyl-N-methylglucamide and decyl-N-methylglucamide (e.g., products is obtainable under the Synergen GA name from Clariant).

[1178] Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as N,N-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.

[1179] Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

[1180] Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.

[1181] Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.

[1182] The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 m can be wet milled using media mills to obtain particles with average diameters below 3 m. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. Pat. No. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 m range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, Agglomeration, Chemical Engineering, Dec. 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pp 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. Pat. No. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. Pat. Nos. 4,144,050, 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. Pat. Nos. 5,180,587, 5,232,701 and 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. Pat. No. 3,299,566.

[1183] One embodiment of the present invention relates to a method for controlling fungal pathogens, comprising diluting the fungicidal composition of the present invention (a compound of Formula 1 formulated with surfactants, solid diluents and liquid diluents or a formulated mixture of a compound of Formula 1 and at least one other fungicide) with water, and optionally adding an adjuvant to form a diluted composition, and contacting the fungal pathogen or its environment with an effective amount of said diluted composition.

[1184] Although a spray composition formed by diluting with water a sufficient concentration of the present fungicidal composition can provide sufficient efficacy for controlling fungal pathogens, separately formulated adjuvant products can also be added to spray tank mixtures. These additional adjuvants are commonly known as spray adjuvants or tank-mix adjuvants, and include any substance mixed in a spray tank to improve the performance of a pesticide or alter the physical properties of the spray mixture. Adjuvants can be anionic or nonionic surfactants, emulsifying agents, petroleum-based crop oils, crop-derived seed oils, acidifiers, buffers, thickeners or defoaming agents. Adjuvants are used to enhancing efficacy (e.g., biological availability, adhesion, penetration, uniformity of coverage and durability of protection), or minimizing or eliminating spray application problems associated with incompatibility, foaming, drift, evaporation, volatilization and degradation. To obtain optimal performance, adjuvants are selected with regard to the properties of the active ingredient, formulation and target (e.g., crops, insect pests).

[1185] The amount of adjuvants added to spray mixtures is generally in the range of about 0.1% to 2.5% by volume. The application rates of adjuvants added to spray mixtures are typically between about 1 to 5 L per hectare. Representative examples of spray adjuvants include: Adigor (Syngenta) 47% methylated rapeseed oil in liquid hydrocarbons, Silwet (Helena Chemical Company) polyalkyleneoxide modified heptamethyltrisiloxane and Assist (BASF) 17% surfactant blend in 83% paraffin based mineral oil.

[1186] One method of seed treatment is by spraying or dusting the seed with a compound of the invention (i.e. as a formulated composition) before sowing the seeds. Compositions formulated for seed treatment generally comprise a film former or adhesive agent. Therefore typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1 and a film former or adhesive agent. Seeds can be coated by spraying a flowable suspension concentrate directly into a tumbling bed of seeds and then drying the seeds. Alternatively, other formulation types such as wetted powders, solutions, suspoemulsions, emulsifiable concentrates and emulsions in water can be sprayed on the seed. This process is particularly useful for applying film coatings on seeds. Various coating machines and processes are available to one skilled in the art. Suitable processes include those listed in P. Kosters et al., Seed Treatment: Progress and Prospects, 1994 BCPC Mongraph No. 57, and references listed therein.

[1187] For further information regarding the art of formulation, see T. S. Woods, The Formulator's ToolboxProduct Forms for Modern Agriculture in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. Also see U.S. Pat. No. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. Pat. No. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. Pat. No. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, U K, 2000.

[1188] In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Active ingredient refers to the compounds in Index Tables A-E disclosed herein. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be constructed as merely illustrative, and not limiting of the disclosure in any way whatsoever.

Example A

TABLE-US-00002 High Strength Concentrate Compound 7 98.5% silica aerogel 0.5% synthetic amorphous fine silica 1.0%

Example B

TABLE-US-00003 Wettable Powder Compound 105 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0%

Example C

TABLE-US-00004 Granule Compound 108 10.0% attapulgite granules (low volatile 90.0% matter, 0.71/0.30 mm; U.S.S. No. 25-50 sieves)

Example D

TABLE-US-00005 Extruded Pellet Compound 109 25.0% anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0% calcium/magnesium bentonite 59.0%

Example E

TABLE-US-00006 Emulsifiable Concentrate Compound 120 10.0% polyoxyethylene sorbitol hexoleate 20.0% C.sub.6-C.sub.10 fatty acid methyl ester 70.0%

Example F

TABLE-US-00007 Microemulsion Compound 121 5.0% polyvinylpyrrolidone-vinyl acetate copolymer 30.0% alkylpolyglycoside 30.0% glyceryl monooleate 15.0% water 20.0%

Example G

TABLE-US-00008 Seed Treatment Compound 123 20.00% polyvinylpyrrolidone-vinyl acetate copolymer 5.00% montan acid wax 5.00% calcium ligninsulfonate 1.00% polyoxyethylene/polyoxypropylene block copolymers 1.00% stearyl alcohol (POE 20) 2.00% polyorganosilane 0.20% colorant red dye 0.05% water 65.75%

Example H

TABLE-US-00009 Fertilizer Stick Compound 124 2.50% pyrrolidone-styrene copolymer 4.80% tristyrylphenyl 16-ethoxylate 2.30% talc 0.80% corn starch 5.00% slow-release fertilizer 36.00% kaolin 38.00% water 10.60%

Example I

TABLE-US-00010 Suspension Concentrate Compound 125 35% butyl polyoxyethylene/polypropylene block copolymer 4.0% stearic acid/polyethylene glycol copolymer 1.0% styrene acrylic polymer 1.0% xanthan gum 0.1% propylene glycol 5.0% silicone based defoamer 0.1% 1,2-benzisothiazolin-3-one 0.1% water 53.7%

Example J

TABLE-US-00011 Emulsion in Water Compound 127 10.0% butyl polyoxyethylene/polypropylene block copolymer 4.0% stearic acid/polyethylene glycol copolymer 1.0% styrene acrylic polymer 1.0% xanthan gum 0.1% propylene glycol 5.0% silicone based defoamer 0.1% 1,2-benzisothiazolin-3-one 0.1% aromatic petroleum based hydrocarbon 20.0 water 58.7%

Example K

TABLE-US-00012 Oil Dispersion Compound 131 25% polyoxyethylene sorbitol hexaoleate 15% organically modified bentonite clay 2.5% fatty acid methyl ester 57.5%.sup.

Example L

TABLE-US-00013 Suspoemulsion Compound 132 10.0% imidacloprid 5.0% butyl polyoxyethylene/polypropylene block copolymer 4.0% stearic acid/polyethylene glycol copolymer 1.0% styrene acrylic polymer 1.0% xanthan gum 0.1% propylene glycol 5.0% silicone based defoamer 0.1% 1,2-benzisothiazolin-3-one 0.1% aromatic petroleum based hydrocarbon 20.0% water 53.7%

[1189] Water-soluble and water-dispersible formulations are typically diluted with water to form aqueous compositions before application. Aqueous compositions for direct applications to the plant or portion thereof (e.g., spray tank compositions) typically contain at least about 1 ppm or more (e.g., from 1 ppm to 100 ppm) of the compound(s) of this invention.

[1190] Seed is normally treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (i.e. from about 0.0001 to 1% by weight of the seed before treatment). A flowable suspension formulated for seed treatment typically comprises from about 0.5 to about 70% of the active ingredient, from about 0.5 to about 30% of a film-forming adhesive, from about 0.5 to about 20% of a dispersing agent, from 0 to about 5% of a thickener, from 0 to about 5% of a pigment and/or dye, from 0 to about 2% of an antifoaming agent, from 0 to about 1% of a preservative, and from 0 to about 75% of a volatile liquid diluent.

[1191] The compositions of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Ascomycota, Basidiomycota, Zygomycota phyla, and the fungal-like Oomycota class. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include but are not limited to those listed in Table 1-1. For Ascomycetes and Basidiomycetes, names for both the sexual/teleomorph/perfect stage as well as names for the asexual/anamorph/imperfect stage (in parentheses) are listed where known. Synonymous names for pathogens are indicated by an equal sign. For example, the sexual/teleomorph/perfect stage name Phaeosphaeria nodorum is followed by the corresponding asexual/anamorph/imperfect stage name Stagnospora nodorum and the synonymous older name Septoria nodorum.

TABLE-US-00014 TABLE 1-1 Ascomycetes in the order Pleosporales including Alternaria solani, A. alternata and A. brassicae, Guignardia bidwellii, Venturia inaequalis, Pyrenophora tritici-repentis (Dreschlera tritici-repentis = Helminthosporium tritici-repentis) and Pyrenophora teres (Dreschlera teres = Helminthosporium teres), Corynespora cassiicola, Phaeosphaeria nodorum (Stagonospora nodorum = Septoria nodorum), Cochliobolus carbonum and C. heterostrophus, Leptosphaeria biglobosa and L. maculans; Ascomycetes in the order Mycosphaerellales including Mycosphaerella graminicola (Zymoseptoria tritici = Septoria tritici), M. berkeleyi (Cercosporidium personatum), M. arachidis (Cercospora arachidicola), Passalora sojina (Cercospora sojina), Cercospora zeae-maydis and C. beticola; Ascomycetes in the order Erysiphales (the powdery mildews) such as Blumeria graminis f. sp. tritici and Blumeria graminis f. sp. hordei, Erysiphe polygoni, E. necator (=Uncinula necator), Podosphaera fuliginea (=Sphaerotheca fuliginea), and Podosphaera leucotricha (=Sphaerotheca fuliginea); Ascomycetes in the order Helotiales such as Botryotinia fuckeliana (Botrytis cinerea), Oculimacula yallundae (=Tapesia yallundae; anamorph Helgardia herpotrichoides = Pseudocercosporella herpetrichoides), Monilinia fructicola, Sclerotinia sclerotiorum, Sclerotinia minor, and Sclerotinia homoeocarpa; Ascomycetes in the order Hypocreales such as Giberella zeae (Fusarium graminearum), G. monoliformis (Fusarium moniliforme), Fusarium solani and Verticillium dahliae; Ascomycetes in the order Eurotiales such as Aspergillus flavus and A. parasiticus; Ascomycetes in the order Diaporthales such as Cryptosphorella viticola (=Phomopsis viticola), Phomopsis longicolla, and Diaporthe phaseolorum; Other Ascomycete pathogens including Magnaporthe grisea, Gaeumannomyces graminis, Rhynchosporium secalis, and anthracnose pathogens such as Glomerella acutata (Colletotrichum acutatum), G. graminicola (C. graminicola) and G. lagenaria (C. orbiculare); Basidiomycetes in the order Urediniales (the rusts) including Puccinia recondita, P. striiformis, Puccinia hordei, P. graminis and P. arachidis), Hemileia vastatrix and Phakopsora pachyrhizi; Basidiomycetes in the order Ceratobasidiales such as Thanatophorum cucumeris (Rhizoctonia solani) and Ceratobasidium oryzae-sativae (Rhizoctonia oryzae); Basidiomycetes in the order Polyporales such as Athelia rolfsii (Sclerotium rolfsii); Basidiomycetes in the order Ustilaginales such as Ustilago maydis; Zygomycetes in the order Mucorales such as Rhizopus stolonifer; Oomycetes in the order Pythiales, including Phytophthora infestans, P. megasperma, P. parasitica, P. sojae, P. cinnamomi and P. capsici, and Pythium pathogens such as Pythium aphanidermatum, P. graminicola, P. irregulare, P. ultimum and P. dissoticum; Oomycetes in the order Peronosporales such as Plasmopara viticola, P. halstedii, Peronospora hyoscyami (=Peronospora tabacina), P. manshurica, Hyaloperonospora parasitica (=Peronospora parasitica), Pseudoperonospora cubensis and Bremia lactucae; and other genera and species closely related to all of the above pathogens.

[1192] In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and other related species. By controlling harmful microorganisms, the compositions of this invention are useful for improving (i.e. increasing) the ratio of beneficial to harmful microorganisms in contact with crop plants or their propagules (e.g., seeds, corms, bulbs, tubers, cuttings) or in the agronomic environment of the crop plants or their propagules.

[1193] Compositions of this invention are useful in treating all plants, plant parts and seeds. Plant and seed varieties and cultivars can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants or seeds (transgenic plants or seeds) are those in which a heterologous gene (transgene) has been stably integrated into the plant's or seed's genome. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

[1194] Genetically modified plant cultivars which can be treated according to the invention include those that are resistant against one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, cold temperature, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits of, for example, herbicide tolerance, insect-resistance, modified oil profiles or drought tolerance.

[1195] Treatment of genetically modified plants and seeds with compounds of the invention may result in super-additive or enhanced effects. For example, reduction in application rates, broadening of the activity spectrum, increased tolerance to biotic/abiotic stresses or enhanced storage stability may be greater than expected from just simple additive effects of the application of compounds of the invention on genetically modified plants and seeds.

[1196] Compounds and compositions of this invention are useful in seed treatments for protecting seeds from plant diseases. In the context of the present disclosure and claims, treating a seed means contacting the seed with a biologically effective amount of a compound of this invention, which is typically formulated as a composition of the invention. This seed treatment protects the seed from soil-borne disease pathogens and generally can also protect roots and other plant parts in contact with the soil of the seedling developing from the germinating seed. The seed treatment may also provide protection of foliage by translocation of the compound of this invention or a second active ingredient within the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants genetically transformed to express specialized traits will germinate. Representative examples include those expressing proteins toxic to invertebrate pests, such as Bacillus thuringiensis toxin or those expressing herbicide resistance such as glyphosate acetyltransferase, which provides resistance to glyphosate. Seed treatments with compounds and compositions of this invention can also increase vigor of plants growing from the seed.

[1197] Compounds and compositions of this invention are particularly useful in seed treatment for crops including, but not limited to, maize or corn, soybeans, cotton, cereal (e.g., wheat, oats, barley, rye and rice), potatoes, vegetables and oilseed rape.

[1198] Furthermore, the compounds and compositions of this invention are useful in treating postharvest diseases of fruits and vegetables caused by fungi, oomycetes and bacteria. These infections can occur before, during and after harvest. For example, infections can occur before harvest and then remain dormant until some point during ripening (e.g., host begins tissue changes in such a way that infection can progress or conditions become conducive for disease development); also infections can arise from surface wounds created by mechanical or insect injury. In this respect, the compositions of this invention can reduce losses (i.e. losses resulting from quantity and quality) due to postharvest diseases which may occur at any time from harvest to consumption. Treatment of postharvest diseases with compounds of the invention can increase the period of time during which perishable edible plant parts (e.g., fruits, seeds, foliage, stems, bulbs, tubers) can be stored refrigerated or un-refrigerated after harvest, and remain edible and free from noticeable or harmful degradation or contamination by fungi or other microorganisms. Treatment of edible plant parts before or after harvest with compounds of the invention can also decrease the formation of toxic metabolites of fungi or other microorganisms, for example, mycotoxins such as aflatoxins.

[1199] Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruits, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants. Control of postharvest pathogens which infect the produce before harvest is typically accomplished by field application of a compound of this invention, and in cases where infection occurs after harvest the compounds can be applied to the harvested crop as dips, sprays, fumigants, treated wraps and box liners.

[1200] The compounds and compositions of this invention can also be applied using an unmanned aerial vehicle (UAV) for the dispension of the compositions disclosed herein over a planted area. In some embodiments the planted area is a crop-containing area. In some embodiments, the crop is selected from a monocot or dicot. In some embodiments, the crop is selected form rice, corn, barley, sobean, wheat, vegetable, tobacco, tea tree, fruit tree and sugar cane. In some embodiments, the compositions disclosed herein are formulated for spraying at an ultra-low volume. Products applied by drones may use water or oil as the spray carrier. Typical spray volume (including product) used for drone applications globally. 5.0 liters/ha-100 liters/ha (approximately 0.5-10 gpa). This includes the range of ultra low spray volume (ULV) to low spray volume (LV). Although not common there may be situations where even lower spray volumes could be used as low as 1.0 liter/ha (0.1 gpa).

[1201] Suitable rates of application (e.g., fungicidally effective amounts) of component (a) (i.e. at least one compound selected from compounds of Formula 1, N-oxides and salts thereof) as well as suitable rates of application (e.g., biologically effective amounts, fungicidally effective amounts or insecticidally effective amounts) for the mixtures and compositions comprising component (a) according to this invention can be influenced by factors such as the plant diseases to be controlled, the plant species to be protected, the population structure of the pathogen to be controlled, ambient moisture and temperature and should be determined under actual use conditions. One skilled in the art can easily determine through simple experimentation the fungicidally effective amount necessary for the desired level of plant disease control. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed. One skilled in the art can easily determine through simple experimentation the application rates of component (a), and mixtures and compositions thereof, containing particular combinations of active ingredients according to this invention needed to provide the desired spectrum of plant protection and control of plant diseases and optionally other plant pests.

[1202] Compounds and compositions of the present invention may also be useful for increasing vigor of a crop plant. This method comprises contacting the crop plant (e.g., foliage, flowers, fruit or roots) or the seed from which the crop plant is grown with a composition comprising a compound of Formula 1 in amount sufficient to achieve the desired plant vigor effect (i.e. biologically effective amount). Typically the compound of Formula 1 is applied in a formulated composition. Although the compound of Formula 1 is often applied directly to the crop plant or its seed, it can also be applied to the locus of the crop plant, i.e. the environment of the crop plant, particularly the portion of the environment in close enough proximity to allow the compound of Formula 1 to migrate to the crop plant. The locus relevant to this method most commonly comprises the growth medium (i.e. medium providing nutrients to the plant), typically soil in which the plant is grown. Treatment of a crop plant to increase vigor of the crop plant thus comprises contacting the crop plant, the seed from which the crop plant is grown or the locus of the crop plant with a biologically effective amount of a compound of Formula 1.

[1203] Increased crop vigor can result in one or more of the following observed effects: (a) optimal crop establishment as demonstrated by excellent seed germination, crop emergence and crop stand; (b) enhanced crop growth as demonstrated by rapid and robust leaf growth (e.g., measured by leaf area index), plant height, number of tillers (e.g., for rice), root mass and overall dry weight of vegetative mass of the crop; (c) improved crop yields, as demonstrated by time to flowering, duration of flowering, number of flowers, total biomass accumulation (i.e. yield quantity) and/or fruit or grain grade marketability of produce (i.e. yield quality); (d) enhanced ability of the crop to withstand or prevent plant disease infections and arthropod, nematode or mollusk pest infestations; and (e) increased ability of the crop to withstand environmental stresses such as exposure to thermal extremes, suboptimal moisture or phytotoxic chemicals.

[1204] The compounds and compositions of the present invention may increase the vigor of treated plants compared to untreated plants by preventing and/or curing plant diseases caused by fungal plant pathogens in the environment of the plants. In the absence of such control of plant diseases, the diseases reduce plant vigor by consuming plant tissues or sap, or transmitting plant pathogens such as viruses. Even in the absence of fungal plant pathogens, the compounds of the invention may increase plant vigor by modifying metabolism of plants. Generally, the vigor of a crop plant will be most significantly increased by treating the plant with a compound of the invention if the plant is grown in a nonideal environment, i.e. an environment comprising one or more aspects adverse to the plant achieving the full genetic potential it would exhibit in an ideal environment.

[1205] Of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment comprising plant diseases caused by fungal plant pathogens. Also of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment not comprising plant diseases caused by fungal plant pathogens. Also of note is a method for increasing vigor of a crop plant wherein the crop plant is grown in an environment comprising an amount of moisture less than ideal for supporting growth of the crop plant.

[1206] Compounds and compositions of this invention can also be mixed with one or more other biologically active compounds or agents including fungicides, insecticides, nematicides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Thus the present invention also pertains to a composition comprising a compound of Formula 1 (in a fungicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount) and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of the present invention, one or more other biologically active compounds or agents can be formulated together with a compound of Formula 1, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1, and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.

[1207] As mentioned in the Summary of the Invention, one aspect of the present invention is a fungicidal composition comprising (i.e. a mixture or combination of) a compound of Formula 1, an N-oxide, or a salt thereof (i.e. component (a)), and at least one other fungicide (i.e. component (b)). Of note is such a combination where the other fungicidal active ingredient has different site of action from the compound of Formula 1. In certain instances, a combination with at least one other fungicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise a fungicidally effective amount of at least one additional fungicidal active ingredient having a similar spectrum of control but a different site of action.

[1208] Examples of component (b) fungicides include acibenzolar-S-methyl, aldimorph, ametoctradin, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl-M), benodanil, benomyl, benthiavalicarb (including benthiavalicarb-isopropyl), benzovindiflupyr, bethoxazin, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, buthiobate, captafol, captan, carbendazim, carboxin, carpropamid, chloroneb, chlorothalonil, chlozolinate, clotrimazole, copper hydroxide, copper oxychloride, copper sulfate, coumoxystrobin, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole (including diniconazole-M), dinocap, dithianon, dithiolanes, dodemorph, dodine, dipymetitrone, econazole, edifenphos, enoxastrobin (also known as enestroburin), epoxiconazole, etaconazole, ethaboxam, ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenaminstrobin, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, flometoquin, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, flumorph, fluopicolide, fluopimomide, fluopyram, flouroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fthalide, fuberidazole, furalaxyl, furametpyr, guazatine, hexaconazole, hymexazole, imazalil, imibenconazole, iminoctadine albesilate, iminoctadine triacetate, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isofetamid, isoprothiolane, isoflucypram, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandepropamid, mandestrobin, maneb, mepanipyrim, mepronil, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), mefentrifluconazole, metconazole, methasulfocarb, metiram, metominostrobin, metrafenone, miconazole, myclobutanil, naftifine, neo-asozin, nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxathiapiprolin, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, pefurazoate, penconazole, pencycuron, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picarbutrazox, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinconazole, quinofumelin (Registry Number 861647-84-9) quinomethionate, quinoxyfen, quintozene, sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquin, teclofthalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolnifanide, tolprocarb, tolyfluanid, triadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole, triclopyricarb, tridemorph, trifloxystrobin, triflumizole, triforine, trimorphamide, uniconazole, uniconazole-P, validamycin, valifenalate (also known as valiphenal), vinclozolin, zineb, ziram, zoxamide, N-[2-(1S,2R)-[1,1-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, -(1-chlorocyclopropyl)--[2-(2,2-dichlorocyclopropyl)-ethyl]-1H-1,2,4-triazole-1-ethanol, (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)-amino]butanamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide, N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, N-(3,4-difluoro[1,1-biphenyl]-2-yl)-3-(trifluoromethyl)-2-pyrazinecarboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, 5,8-di-fluoro-N-[2-[3-methoxy-4-[[4-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]ethyl]-4-quinazo-linamine, 1-[4-[4-[5R-[(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperdinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)-methoxy]-4-pyrimidinamine, -(methoxyimino)-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]-ethoxy]imino]methyl]benzeneacetamide, and [[4-methoxy-2-[[[(3S,7R,8R,9S)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl 2-methylpropanoate. Therefore of note is a fungicidal composition comprising as component (a) a compound of Formula 1 (or an N-oxide or salt thereof) and as component (b) at least one fungicide selected from the preceding list.

[1209] Of particular note are combinations of compounds of Formula 1 (or an N-oxide or salt thereof) (i.e. Component (a) in compositions) with component (b) compounds selected from aminopyrifen (Registry Number 1531626-08-0), azoxystrobin, benzovindiflupyr, bixafen, captan, carpropamid, chlorothalonil, copper hydroxide, copper oxychloride, copper sulfate, cymoxanil, cyproconazole, cyprodinil, dichlobentiazox (Registry Number 957144-77-3), diethofencarb, difenoconazole, dimethomorph, dipymetitrone, epoxiconazole, ethaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluindapyr, fluopyram, flusilazole, flutianil, flutriafol, fluxapyroxad, folpet, ipflufenoquin (Registry Number 1314008-27-9), iprodione, isofetamid, isoflucypram, isopyrazam, kresoxim-methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), mefentrifluconazole, metconazole, metrafenone, metyltetraprole (Registry Number 1472649-01-6), myclobutanil, oxathiapiprolin, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyridachlometyl (Registry Number 1358061-55-8), pyraclostrobin, pyrapropoyne (Registry Number 1803108-03-3), pyrimethanil, sedaxane spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, -(1-chlorocyclopropyl)--[2-(2,2-dichlorocyclopropyl)ethyl]-1H-1,2,4-triazole-1-ethanol, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, 3-(difluoromethyl)-N-(2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, 1-[4-[4-[5R-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1,1-di-methylethyl N-[6-[[[[(1-methyl-1H-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1H-1,2,4-triazole, rel-2-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-thione, and rel-1-[[(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1H-1,2,4-triazole (i.e. as Component (b) in compositions).

[1210] Generally preferred for better control of plant diseases caused by fungal plant pathogens (e.g., lower use rate or broader spectrum of plant pathogens controlled) or resistance management are mixtures of a compound of Formula 1, an N-oxide, or salt thereof, with a fungicidal compound selected from the group: amisulbrom, azoxystrobin, benzovindiflupyr, bixafen, boscalid, carbendazim, carboxin, chlorothalonil, copper hydroxide, cymoxanil, cyproconazole, difenoconazole, dimethomorph, dimoxystrobin, epoxiconazole, fenpropidin, fenpropimorph, florylpicoxamid, fluazinam, fludioxonil, flufenoxystrobin, fluindapyr, fluquinconazole, fluopicolide, fluoxastrobin, flutriafol, fluxapyroxad, ipconazole, ipfentrifluconazole, iprodione, kresoxim-methyl, mancozeb, metalaxyl, mefenoxam, mefentrifluconazole, metconazole, metominostrobin, myclobutanil, paclobutrazole, penflufen, picoxystrobin, prothioconazole, pydiflumetofen, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyriofenone, sedaxane, silthiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole.

[1211] In the fungicidal compositions of the present invention, component (a) (i.e. at least one compound selected from compounds of Formula 1, N-oxides, and salts thereof) and component (b) are present in fungicidally effective amounts. The weight ratio of component (a) to component (b) (i.e. one or more additional fungicidal compounds) is generally between about 1:3000 to about 3000:1, and more typically between about 1:500 and about 500:1. Table B1 lists typical, more typical and most typical ranges of ratios involving particular fungicidal compounds of component (b). Tables A1 through A28 and C1 through C28 exemplify weight ratios for particular combinations of fungicidal compounds. Of note are compositions where in the weight ratio of component (a) to component (b) is from about 125:1 to about 1:125. With many fungicidal compounds of component (b), these compositions are particularly effective for controlling plant diseases caused by fungal plant pathogens. Of particular note are compositions wherein the weight ratio of component (a) to component (b) is from about 25:1 to about 1:25, or from about 5:1 to about 1:5. One skilled in the art can easily determine through simple experimentation the weight ratios and application rates of fungicidal compounds necessary for the desired spectrum of fungicidal protection and control. It will be evident that including additional fungicidal compounds in component (b) may expand the spectrum of plant diseases controlled beyond the spectrum controlled by component (a) alone.

[1212] Specific mixtures (compound numbers refer to compounds in Index Tables A through E) are listed in Tables A1 through A28. In Table A1, each line below the column headings Component (a) and Component (b) specifically discloses a mixture of Component (a), (i.e. Compound 7), with a Component (b) fungicidal compound. The entries under the heading Illustrative Ratios disclose three specific weight ratios of Component (a) to Component (b) for the disclosed mixture. For example, the first line of Table A1 discloses a mixture of Compound 7 with acibenzolar-S-methyl and lists weight ratios of Compound 7 relative to acibenzolar-S-methyl of 1:1, 1:4 or 1:18.

TABLE-US-00015 TABLE A1 Component (a) Component (b) Illustrative Ratios(*) Compound 7 acibenzolar-S-methyl 1:1 1:4 1:18 Compound 7 aldimorph 7:1 3:1 1:1 Compound 7 ametoctradin 3:1 1:1 1:3 Compound 7 amisulbrom 1:1 1:2 1:6 Compound 7 anilazine 22:1 8:1 4:1 Compound 7 azaconazole 2:1 1:2 1:4 Compound 7 azoxystrobin 3:1 1:1 1:3 Compound 7 benalaxyl 1:1 1:2 1:6 Compound 7 benalaxyl-M 1:1 1:3 1:8 Compound 7 benodanil 4:1 2:1 1:2 Compound 7 benomyl 11:1 4:1 1:1 Compound 7 benthiavalicarb 1:1 1:4 1:12 Compound 7 benthiavalicarb-isopropyl 1:1 1:4 1:12 Compound 7 bethoxazin 15:1 5:1 2:1 Compound 7 binapacryl 15:1 5:1 2:1 Compound 7 biphenyl 15:1 5:1 2:1 Compound 7 bitertanol 3:1 1:1 1:2 Compound 7 bixafen 2:1 1:1 1:3 Compound 7 blasticidin-S 1:4 1:12 1:30 Compound 7 Bordeaux mixture (tribasic copper sulfate) 45:1 15:1 5:1 Compound 7 boscalid 4:1 2:1 1:2 Compound 7 bromuconazole 3:1 1:1 1:3 Compound 7 bupirimate 1:3 1:10 1:30 Compound 7 captafol 15:1 5:1 2:1 Compound 7 captan 15:1 5:1 2:1 Compound 7 carbendazim 11:1 4:1 2:1 Compound 7 carboxin 4:1 2:1 1:2 Compound 7 carpropamid 3:1 1:1 1:3 Compound 7 chloroneb 100:1 35:1 14:1 Compound 7 chlorothalonil 15:1 5:1 2:1 Compound 7 chlozolinate 11:1 4:1 2:1 Compound 7 clotrimazole 3:1 1:1 1:3 Compound 7 copper hydroxide 45:1 15:1 5:1 Compound 7 copper oxychloride 45:1 15:1 5:1 Compound 7 cyazofamid 1:1 1:2 1:6 Compound 7 cyflufenamid 1:2 1:6 1:24 Compound 7 cymoxanil 1:1 1:2 1:5 Compound 7 cyproconazole 1:1 1:2 1:6 Compound 7 cyprodinil 4:1 2:1 1:2 Compound 7 dichlofluanid 15:1 5:1 2:1 Compound 7 diclocymet 15:1 5:1 2:1 Compound 7 diclomezine 3:1 1:1 1:3 Compound 7 dicloran 15:1 5:1 2:1 Compound 7 diethofencarb 7:1 2:1 1:2 Compound 7 difenoconazole 1:1 1:3 1:12 Compound 7 diflumetorim 15:1 5:1 2:1 Compound 7 dimethirimol 1:3 1:8 1:30 Compound 7 dimethomorph 3:1 1:1 1:2 Compound 7 dimoxystrobin 2:1 1:1 1:4 Compound 7 diniconazole 1:1 1:3 1:8 Compound 7 diniconazole-M 1:1 1:3 1:12 Compound 7 dinocap 2:1 1:1 1:3 Compound 7 dithianon 5:1 2:1 1:2 Compound 7 dodemorph 7:1 3:1 1:1 Compound 7 dodine 10:1 4:1 2:1 Compound 7 edifenphos 3:1 1:1 1:3 Compound 7 enestroburin 2:1 1:1 1:4 Compound 7 epoxiconazole 1:1 1:3 1:7 Compound 7 etaconazole 1:1 1:3 1:7 Compound 7 ethaboxam 2:1 1:1 1:3 Compound 7 ethirimol 7:1 3:1 1:1 Compound 7 etridiazole 7:1 2:1 1:2 Compound 7 famoxadone 2:1 1:1 1:4 Compound 7 fenamidone 2:1 1:1 1:4 Compound 7 fenaminstrobin 3:1 1:1 1:3 Compound 7 fenarimol 1:2 1:7 1:24 Compound 7 fenbuconazole 1:1 1:3 1:10 Compound 7 fenfuram 4:1 1:1 1:2 Compound 7 fenhexamid 10:1 4:1 2:1 Compound 7 fenoxanil 15:1 4:1 1:1 Compound 7 fenpiclonil 15:1 5:1 2:1 Compound 7 fenpropidin 7:1 2:1 1:1 Compound 7 fenpropimorph 7:1 2:1 1:1 Compound 7 fenpyrazamine 3:1 1:1 1:3 Compound 7 fentin salt such as fentin acetate, 3:1 1:1 1:3 fentin chloride or fentin hydroxide Compound 7 ferbam 30:1 10:1 4:1 Compound 7 ferimzone 7:1 2:1 1:2 Compound 7 fluazinam 3:1 1:1 1:2 Compound 7 fludioxonil 2:1 1:1 1:4 Compound 7 flumetover 3:1 1:1 1:2 Compound 7 flumorph 3:1 1:1 1:3 Compound 7 fluopicolide 1:1 1:2 1:6 Compound 7 fluopyram 3:1 1:1 1:3 Compound 7 fluoroimide 37:1 14:1 5:1 Compound 7 fluoxastrobin 1:1 1:2 1:6 Compound 7 fluquinconazole 1:1 1:2 1:4 Compound 7 flusilazole 3:1 1:1 1:3 Compound 7 flusulfamide 15:1 5:1 2:1 Compound 7 flutianil 1:1 1:2 1:6 Compound 7 flutolanil 4:1 1:1 1:2 Compound 7 flutriafol 1:1 1:2 1:4 Compound 7 fluxapyroxad 2:1 1:1 1:3 Compound 7 folpet 15:1 5:1 2:1 Compound 7 fosetyl-aluminum 30:1 12:1 5:1 Compound 7 fuberidazole 11:1 4:1 2:1 Compound 7 furalaxyl 1:1 1:2 1:6 Compound 7 furametpyr 15:1 5:1 2:1 Compound 7 guazatine 15:1 5:1 2:1 Compound 7 hexaconazole 1:1 1:2 1:5 Compound 7 hymexazol 75:1 25:1 9:1 Compound 7 imazalil 1:1 1:2 1:5 Compound 7 imibenconazole 1:1 1:2 1:5 Compound 7 iminoctadine 15:1 4:1 1:1 Compound 7 iodocarb 15:1 5:1 2:1 Compound 7 ipconazole 1:1 1:2 1:5 Compound 7 iprobenfos 15:1 5:1 2:1 Compound 7 iprodione 15:1 5:1 2:1 Compound 7 iprovalicarb 2:1 1:1 1:3 Compound 7 isoprothiolane 45:1 15:1 5:1 Compound 7 isopyrazam 2:1 1:1 1:3 Compound 7 isotianil 2:1 1:1 1:3 Compound 7 kasugamycin 1:2 1:7 1:24 Compound 7 kresoxim-methyl 2:1 1:1 1:4 Compound 7 mancozeb 22:1 7:1 3:1 Compound 7 mandipropamid 2:1 1:1 1:4 Compound 7 maneb 22:1 7:1 3:1 Compound 7 mepanipyrim 6:1 2:1 1:1 Compound 7 mepronil 1:1 1:2 1:6 Compound 7 meptyldinocap 2:1 1:1 1:3 Compound 7 metalaxyl 1:1 1:2 1:6 Compound 7 metalaxyl-M 1:1 1:4 1:12 Compound 7 metconazole 1:1 1:2 1:6 Compound 7 methasulfocarb 15:1 5:1 2:1 Compound 7 metiram 15:1 5:1 2:1 Compound 7 metominostrobin 3:1 1:1 1:3 Compound 7 metrafenone 2:1 1:1 1:4 Compound 7 myclobutanil 1:1 1:3 1:8 Compound 7 naftifine 15:1 5:1 2:1 Compound 7 neo-asozin (ferric methanearsonate) 15:1 5:1 2:1 Compound 7 nuarimol 3:1 1:1 1:3 Compound 7 octhilinone 15:1 4:1 1:1 Compound 7 ofurace 1:1 1:2 1:6 Compound 7 orysastrobin 3:1 1:1 1:3 Compound 7 oxadixyl 1:1 1:2 1:6 Compound 7 oxolinic acid 7:1 2:1 1:2 Compound 7 oxpoconazole 1:1 1:2 1:5 Compound 7 oxycarboxin 4:1 1:1 1:2 Compound 7 oxytetracycline 3:1 1:1 1:3 Compound 7 pefurazoate 15:1 5:1 2:1 Compound 7 penconazole 1:2 1:6 1:15 Compound 7 pencycuron 11:1 4:1 2:1 Compound 7 penflufen 2:1 1:1 1:3 Compound 7 penthiopyrad 2:1 1:1 1:3 Compound 7 phosphorous acid or a salt thereof 15:1 6:1 2:1 Compound 7 phthalide 15:1 6:1 2:1 Compound 7 picoxystrobin 1:1 1:2 1:5 Compound 7 piperalin 3:1 1:1 1:3 Compound 7 polyoxin 3:1 1:1 1:3 Compound 7 probenazole 3:1 1:1 1:3 Compound 7 prochloraz 7:1 2:1 1:2 Compound 7 procymidone 11:1 4:1 2:1 Compound 7 propamocarb or propamocarb-hydrochloride 10:1 4:1 2:1 Compound 7 propiconazole 1:1 1:2 1:5 Compound 7 propineb 11:1 4:1 2:1 Compound 7 proquinazid 1:1 1:3 1:12 Compound 7 prothiocarb 3:1 1:1 1:3 Compound 7 prothioconazole 1:1 1:2 1:5 Compound 7 pyraclostrobin 2:1 1:1 1:4 Compound 7 pyrametostrobin 2:1 1:1 1:4 Compound 7 pyraoxystrobin 2:1 1:1 1:4 Compound 7 pyrazophos 15:1 4:1 1:1 Compound 7 pyribencarb 4:1 1:1 1:2 Compound 7 pyributicarb 15:1 4:1 1:1 Compound 7 pyrifenox 3:1 1:1 1:3 Compound 7 pyrimethanil 3:1 1:1 1:2 Compound 7 pyriofenone 2:1 1:1 1:4 Compound 7 pyrisoxazole 3:1 1:1 1:3 Compound 7 pyroquilon 3:1 1:1 1:3 Compound 7 pyrrolnitrin 15:1 5:1 2:1 Compound 7 quinconazole 1:1 1:2 1:4 Compound 7 quinomethionate 15:1 5:1 2:1 Compound 7 quinoxyfen 1:1 1:2 1:6 Compound 7 quintozene 15:1 5:1 2:1 Compound 7 silthiofam 2:1 1:1 1:4 Compound 7 simeconazole 1:1 1:2 1:5 Compound 7 spiroxamine 5:1 2:1 1:2 Compound 7 streptomycin 3:1 1:1 1:3 Compound 7 sulfur 75:1 25:1 9:1 Compound 7 tebuconazole 1:1 1:2 1:5 Compound 7 tebufloquin 3:1 1:1 1:3 Compound 7 tecloftalam 15:1 5:1 2:1 Compound 7 tecnazene 15:1 5:1 2:1 Compound 7 terbinafine 15:1 5:1 2:1 Compound 7 tetraconazole 1:1 1:2 1:5 Compound 7 thiabendazole 11:1 4:1 2:1 Compound 7 thifluzamide 3:1 1:1 1:3 Compound 7 thiophanate 11:1 4:1 2:1 Compound 7 thiophanate-methyl 11:1 4:1 2:1 Compound 7 thiram 37:1 14:1 5:1 Compound 7 tiadinil 2:1 1:1 1:3 Compound 7 tolclofos-methyl 37:1 14:1 5:1 Compound 7 tolnifanide 3:1 1:1 1:3 Compound 7 tolylfluanid 15:1 5:1 2:1 Compound 7 triadimefon 1:1 1:2 1:5 Compound 7 triadimenol 1:1 1:2 1:5 Compound 7 triarimol 1:2 1:7 1:24 Compound 7 triazoxide 15:1 5:1 2:1 Compound 7 tricyclazole 3:1 1:1 1:3 Compound 7 tridemorph 7:1 2:1 1:1 Compound 7 trifloxystrobin 2:1 1:1 1:4 Compound 7 triflumizole 3:1 1:1 1:3 Compound 7 triforine 3:1 1:1 1:3 Compound 7 trimorphamide 7:1 2:1 1:2 Compound 7 triticonazole 1:1 1:2 1:5 Compound 7 uniconazole 1:1 1:2 1:5 Compound 7 validamycin 3:1 1:1 1:3 Compound 7 valifenalate 2:1 1:1 1:4 Compound 7 vinclozolin 15:1 6:1 2:1 Compound 7 zineb 37:1 14:1 5:1 Compound 7 ziram 37:1 14:1 5:1 Compound 7 zoxamide 2:1 1:1 1:4 Compound 7 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin- 1:1 1:2 1:6 1-yl)[1,2,4]triazolo[1,5-a]pyrimidine (DPX-BAS600F) Compound 7 N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxy- 2:1 1:1 1:4 phenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]- butanamide Compound 7 N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxy- 2:1 1:1 1:4 phenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide Compound 7 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]- 2:1 1:1 1:4 methyl]propyl]carbamate Compound 7 N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)- 1:2 1:7 1:24 2,3-difluorophenyl]methylene]benzeneacetamide Compound 7 -[methoxyimino]-N-methyl-2-[[[1-[3-(trifluoromethyl)- 3:1 1:1 1:3 phenyl]ethoxylimino]methyl]benzeneacetamide Compound 7 N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethyl- 3:1 1:1 1:3 phenyl]-N-ethyl-N-methylmethanimidamide (*)Ratios of Component (a) relative to Component (b) by weight.

[1213] Tables A2 through A29 are each constructed the same as Table A1 above except that entries below the Component (a) column heading are replaced with the respective Component (a) Column Entry shown below. Thus, for example, in Table A2 the entries below the Component (a) column heading all recite Compound 18, and the first line below the column headings in Table A2 specifically discloses a mixture of Compound 18 with acibenzolar-S-methyl. Tables A3 through A28 are constructed similarly.

TABLE-US-00016 Table Number Component (a) Column Entry A2 Compound 18 A3 Compound 21 A4 Compound 22 A5 Compound 23 A6 Compound 27 A7 Compound 30 A8 Compound 31 A9 Compound 35 A10 Compound 45 A11 Compound 46 A12 Compound 47 A13 Compound 48 A14 Compound 50 A15 Compound 52 A16 Compound 105 A17 Compound 108 A18 Compound 109 A19 Compound 119 A20 Compound 120 A21 Compound 121 A22 Compound 123 A23 Compound 124 A24 Compound 125 A25 Compound 127 A26 Compound 131 A27 Compound 132 A28 Compound 133 A29 Compound 135

[1214] Table B1 lists specific combinations of a Component (b) compound with Component (a) illustrative of the mixtures, compositions and methods of the present invention. The first column of Table B1 lists the specific Component (b) compound (e.g., acibenzolar-S-methyl in the first line). The second, third and fourth columns of Table B1 lists ranges of weight ratios for rates at which the Component (a) compound is typically applied to a field-grown crop relative to Component (b). Thus, for example, the first line of Table B1 discloses the combination of a compound of Component (a) with acibenzolar-S-methyl is typically applied in a weight ratio of the Component (a) to Component (b) of between 2:1 to 1:180. The remaining lines of Table B1 are to be construed similarly. Of particular note is a composition comprising a mixture of any one of the compounds listed in Embodiment 332 as Component (a) with a compound listed in the Component (b) column of Table B1 according to the weight ratios disclosed in Table B1. Table B1 thus supplements the specific ratios disclosed in Tables A1 through A28 with ranges of ratios for these combinations.

TABLE-US-00017 TABLE B1 Typical Typical Most Typical Component (b) Weight Ratio Weight Ratio Weight Ratio acibenzolar-S-methyl 2:1 to 1:180 1:1 to 1:60 1:1 to 1:18 aldimorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 ametoctradin 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 amisulbrom 6:1 to 1:18 2:1 to 1:6 1:1 to 1:6 anilazine 90:1 to 2:1 30:1 to 4:1 22:1 to 4:1 azaconazole 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 azoxystrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 benalaxyl 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 benalaxyl-M 4:1 to 1:36 1:1 to 1:12 1:1 to 1:8 benodanil 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 benomyl 45:1 to 1:4 15:1 to 1:1 11:1 to 1:1 benthiavalicarb or benthiavalicarb-isopropyl 2:1 to 1:36 1:1 to 1:12 1:1 to 1:12 bethoxazin 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 binapacryl 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 biphenyl 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 bitertanol 15:1 to 1:5 5:1 to 1:2 3:1 to 1:2 bixafen 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 blasticidin-S 3:1 to 1:90 1:1 to 1:30 1:4 to 1:30 boscalid 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 bromuconazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 bupirimate 3:1 to 1:90 1:1 to 1:30 1:3 to 1:30 captafol 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 captan 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 carbendazim 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 carboxin 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 carpropamid 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 chloroneb 300:1 to 2:1 100:1 to 4:1 100:1 to 14:1 chlorothalonil 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 chlozolinate 45:1 to 1:2 15:1 to 2:1 11:1 to 2:1 clotrimazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 copper salts such as Bordeaux mixture 450:1 to 1:1 150:1 to 4:1 45:1 to 5:1 (tribasic copper sulfate), copper oxychloride, copper sulfate and copper hydroxide cyazofamid 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 cyflufenamid 1:1 to 1:90 1:2 to 1:30 1:2 to 1:24 cymoxanil 6:1 to 1:18 2:1 to 1:6 1:1 to 1:5 cyproconazole 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 cyprodinil 22:1 to 1:9 7:1 to 1:3 4:1 to 1:2 dichlofluanid 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 diclocymet 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 diclomezine 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 dicloran 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 diethofencarb 22:1 to 1:9 7:1 to 1:3 7:1 to 1:2 difenoconazole 4:1 to 1:36 1:1 to 1:12 1:1 to 1:12 diflumetorim 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 dimethirimol 3:1 to 1:90 1:1 to 1:30 1:3 to 1:30 dimethomorph 9:1 to 1:6 3:1 to 1:2 3:1 to 1:2 dimoxystrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 diniconazole 3:1 to 1:36 1:1 to 1:12 1:1 to 1:8 diniconazole M 3:1 to 1:90 1:1 to 1:30 1:1 to 1:12 dinocap 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 dithianon 15:1 to 1:4 5:1 to 1:2 5:1 to 1:2 dodemorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 dodine 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 edifenphos 30:1 to 1:9 10:1 to 1:3 3:1 to 1:3 enestroburin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 epoxiconazole 3:1 to 1:36 1:1 to 1:12 1:1 to 1:7 etaconazole 3:1 to 1:36 1:1 to 1:12 1:1 to 1:7 ethaboxam 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 ethirimol 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 etridiazole 30:1 to 1:9 10:1 to 1:3 7:1 to 1:2 famoxadone 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 fenamidone 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 fenaminstrobin 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 fenarimol 3:1 to 1:90 1:1 to 1:30 1:2 to 1:24 fenbuconazole 3:1 to 1:30 1:1 to 1:10 1:1 to 1:10 fenfuram 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 fenhexamid 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 fenoxanil 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 fenpiclonil 75:1 to 1:9 25:1 to 1:3 15:1 to 2:1 fenpropidin 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 fenpropimorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 fenpyrazamine 100:1 to 1:100 10:1 to 1:10 3:1 to 1:3 fentin salt such as the acetate, chloride or 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 hydroxide ferbam 300:1 to 1:2 100:1 to 2:1 30:1 to 4:1 ferimzone 30:1 to 1:5 10:1 to 1:2 7:1 to 1:2 fluazinam 22:1 to 1:5 7:1 to 1:2 3:1 to 1:2 fludioxonil 7:1 to 1:12 2:1 to 1:4 2:1 to 1:4 flumetover 9:1 to 1:6 3:1 to 1:2 3:1 to 1:2 flumorph 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 fluopicolide 3:1 to 1:18 1:1 to 1:6 1:1 to 1:6 fluopyram 15:1 to 1:90 5:1 to 1:30 3:1 to 1:3 fluoromide 150:1 to 2:1 50:1 to 4:1 37:1 to 5:1 fluoxastrobin 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 fluquinconazole 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 flusilazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 flusulfamide 90:1 to 1:2 30:1 to 2:1 15:1 to 2:1 flutianil 7:1 to 1:36 2:1 to 1:12 1:1 to 1:6 flutolanil 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 flutriafol 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 fluxapyroxad 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 folpet 90:1 to 1:4 30:1 to 1:2 15:1 to 2:1 fosetyl-aluminum 225:1 to 2:1 75:1 to 5:1 30:1 to 5:1 fuberidazole 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 furalaxyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 furametpyr 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 guazatine or iminoctadine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 hexaconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 hymexazol 225:1 to 2:1 75:1 to 4:1 75:1 to 9:1 imazalil 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 imibenconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 iodocarb 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 ipconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 iprobenfos 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 iprodione 120:1 to 1:2 40:1 to 2:1 15:1 to 2:1 iprovalicarb 9:1 to 1:9 3:1 to 1:3 2:1 to 1:3 isoprothiolane 150:1 to 2:1 50:1 to 4:1 45:1 to 5:1 isopyrazam 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 isotianil 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 kasugamycin 7:1 to 1:90 2:1 to 1:30 1:2 to 1:24 kresoxim-methyl 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 mancozeb 180:1 to 1:3 60:1 to 2:1 22:1 to 3:1 mandipropamid 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 maneb 180:1 to 1:3 60:1 to 2:1 22:1 to 3:1 mepanipyrim 18:1 to 1:3 6:1 to 1:1 6:1 to 1:1 mepronil 7:1 to 1:36 2:1 to 1:12 1:1 to 1:6 meptyldinocap 7:1 to 1:9 2:1 to 1:3 2:1 to 1:3 metalaxyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 metalaxyl-M 7:1 to 1:90 2:1 to 1:30 1:1 to 1:12 metconazole 3:1 to 1:18 1:1 to 1:6 1:1 to 1:6 methasulfocarb 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 metiram 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 metominostrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 metrafenone 6:1 to 1:12 2:1 to 1:4 2:1 to 1:4 myclobutanil 5:1 to 1:26 1:1 to 1:9 1:1 to 1:8 naftifine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 neo-asozin (ferric methanearsonate) 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 nuarimol 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 octhilinone 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 ofurace 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 orysastrobin 9:1 to 1:12 3:1 to 1:4 3:1 to 1:3 oxadixyl 15:1 to 1:45 5:1 to 1:15 1:1 to 1:6 oxolinic acid 30:1 to 1:9 10:1 to 1:3 7:1 to 1:2 oxpoconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 oxycarboxin 18:1 to 1:6 6:1 to 1:2 4:1 to 1:2 oxytetracycline 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pefurazoate 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 penconazole 1:1 to 1:45 1:2 to 1:15 1:2 to 1:15 pencycuron 150:1 to 1:2 50:1 to 2:1 11:1 to 2:1 penflufen 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 penthiopyrad 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 phosphorous acid and salts thereof 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 phthalide 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 picoxystrobin 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 piperalin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 polyoxin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 probenazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 prochloraz 22:1 to 1:4 7:1 to 1:1 7:1 to 1:2 procymidone 45:1 to 1:3 15:1 to 1:1 11:1 to 2:1 propamocarb or propamocarb- 30:1 to 1:2 10:1 to 2:1 10:1 to 2:1 hydrochloride propiconazole 4:1 to 1:18 1:1 to 1:6 1:1 to 1:5 propineb 45:1 to 1:2 15:1 to 2:1 11:1 to 2:1 proquinazid 3:1 to 1:36 1:1 to 1:12 1:1 to 1:12 prothiocarb 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 prothioconazole 6:1 to 1:18 2:1 to 1:6 1:1 to 1:5 pyraclostrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 pyrametostrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 pyraoxystrobin 9:1 to 1:18 3:1 to 1:6 2:1 to 1:4 pyrazophos 150:1 to 1:36 50:1 to 1:12 15:1 to 1:1 pyribencarb 15:1 to 1:6 5:1 to 1:2 4:1 to 1:2 pyrifenox 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyrimethanil 30:1 to 1:6 10:1 to 1:2 3:1 to 1:2 pyriofenone 6:1 to 1:12 2:1 to 1:4 2:1 to 1:4 pyrisoxazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyroquilon 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 pyrrolnitrin 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 quinconazole 4:1 to 1:12 1:1 to 1:4 1:1 to 1:4 quinmethionate 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 quinoxyfen 4:1 to 1:18 1:1 to 1:6 1:1 to 1:6 quintozene 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 silthiofam 7:1 to 1:18 2:1 to 1:6 2:1 to 1:4 simeconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 spiroxamine 22:1 to 1:4 7:1 to 1:2 5:1 to 1:2 streptomycin 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 sulfur 300:1 to 3:1 100:1 to 9:1 75:1 to 9:1 tebuconazole 7:1 to 1:18 2:1 to 1:6 1:1 to 1:5 tebufloquin 100:1 to 1:100 10:1 to 1:10 3:1 to 1:3 tecloftalam 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 tecnazene 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 terbinafine 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 tetraconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 thiabendazole 45:1 to 1:4 15:1 to 1:2 11:1 to 2:1 thifluzamide 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 thiophanate 45:1 to 1:3 15:1 to 2:1 11:1 to 2:1 thiophanate-methyl 45:1 to 1:3 15:1 to 2:1 11:1 to 2:1 thiram 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 tiadinil 12:1 to 1:9 4:1 to 1:3 2:1 to 1:3 tolclofos-methyl 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 tolnifanide 15:1 to 1:18 5:1 to 1:6 3:1 to 1:3 tolylfluanid 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 triadimefon 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 triadimenol 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 triarimol 3:1 to 1:90 1:1 to 1:30 1:2 to 1:24 triazoxide 150:1 to 1:36 50:1 to 1:12 15:1 to 2:1 tricyclazole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 tridemorph 30:1 to 1:3 10:1 to 1:1 7:1 to 1:1 trifloxystrobin 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 triflumizole 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 triforine 15:1 to 1:9 5:1 to 1:3 3:1 to 1:3 trimorphamide 45:1 to 1:9 15:1 to 1:3 7:1 to 1:2 triticonazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 uniconazole 15:1 to 1:36 5:1 to 1:12 1:1 to 1:5 validamycin 150:1 to 1:36 50:1 to 1:12 3:1 to 1:3 valifenalate 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 vinclozolin 120:1 to 1:2 40:1 to 2:1 15:1 to 2:1 zineb 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 ziram 150:1 to 1:2 50:1 to 2:1 37:1 to 5:1 zoxamide 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 5-chloro-6-(2,4,6-trifluorophenyl)- 15:1 to 1:36 5:1 to 1:12 1:1 to 1:6 7-(4-methylpiperidin-1-yl)[1,2,4]triazolo- [1,5-a]pyrimidine (DPX-BAS600F) N-[2-[4-[[3-(4-chlorophenyl)-2-propyn- 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 1-yl]oxy]-3-methoxyphenyl]ethyl]- 3-methyl-2-[(methylsulfonyl)amino]- butanamide N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1- 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl- 2-[(ethylsulfonyl)amino]butanamide 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)- 6:1 to 1:18 2:1 to 1:6 2:1 to 1:4 ethyl]sulfonyl]methyl]propyl]carbamate N-[[(cyclopropylmethoxy)amino][6- 1:1 to 1:90 1:2 to 1:30 1:2 to 1:24 (difluoromethoxy)-2,3-difluorophenyl]- methylene]benzeneacetamide -[methoxyimino]-N-methyl-2-[[[1-[3- 9:1 to 1:18 3:1 to 1:6 3:1 to 1:3 (trifluoromethyl)phenyl]ethoxy]imino]- methyl]benzeneacetamide N-[4-[4-chloro-3-(trifluoromethyl)- 15:1 to 1:18 5:1 to 1:6 3:1 to 1:3 phenoxy]-2,5-dimethylphenyl]-N-ethyl- N-methylmethanimidamide

[1215] As already noted, the present invention includes embodiments wherein in the composition comprising components (a) and (b), component (b) comprises at least one fungicidal compound from each of two groups selected from (b1) through (b54). Tables C1 through C28 list specific mixtures (compound numbers refer to compounds in Index Tables A through E) to illustrate embodiments wherein component (b) includes at least one fungicidal compound from each of two groups selected from (b1) through (b54). In Table C1, each line below the column headings Component (a) and Component (b) specifically discloses a mixture of Component (a), which is Compound 7, with at least two Component (b) fungicidal compounds. The entries under the heading Illustrative Ratios disclose three specific weight ratios of Component (a) to each Component (b) fungicidal compound in sequence for the disclosed mixture. For example, the first line discloses a mixture of Compound 7 with cyproconazole and azoxystrobin and lists weight ratios of Compound 7 to cyproconazole to azoxystrobin of 1:1:1, 2:1:1 or 3:1:1.

TABLE-US-00018 TABLE C1 Component (a) Component (b) Illustrative Ratios(*) Compound 7 cyproconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole pyrametrostrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 cyproconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 cyproconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 cyproconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 cyproconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 difenconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenoconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 difenconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 difenconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 difenconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 difenconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 epoxiconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 epoxiconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 epoxiconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 epoxiconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 epoxiconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 metconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 metconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 metconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 metconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 metconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 metconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 metconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 metconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 metconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 metconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 metconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 metconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 metconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 metconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 metconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 myclobutanil azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil bixafen 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil boscalid 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 myclobutanil fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 myclobutanil sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 myclobutanil picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 myclobutanil trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 prothioconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 prothioconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 prothioconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 prothioconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 prothioconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 tebuconazole azoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole kresoxim-methyl 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole picoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole pyraclostrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole pyrametostrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole pyraoxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole trifloxystrobin 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole bixafen 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole boscalid 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole cyflufenamid 1:2:1 2:2:1 3:2:1 Compound 7 tebuconazole fluopyram 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole isopyrazam 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole metrafenone 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole penthiopyrad 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole proquinazid 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole pyriofenone 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole quinoxyfen 1:1:1 2:1:1 3:1:1 Compound 7 tebuconazole sedaxane 1:1:2 2:1:2 3:1:2 Compound 7 tebuconazole picoxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 Compound 7 tebuconazole trifloxystrobin proquinazid 1:1:1:1 2:1:1:1 3:1:1:1 (*)Ratios of Component (a) relative to Component (b) in sequence, by weight.

[1216] Tables C2 through C29 are each constructed the same as Table C1 above except that entries below the Component (a) column heading are replaced with the respective Component (a) Column Entry shown below. Thus, for example, in Table C2 the entries below the Component (a) column heading all recite Compound 18, and the first line in below the column headings in Table C2 specifically discloses a mixture of Compound 18 with cyproconazole and azoxystrobin, and the illustrative weight ratios of 1:1:1, 2:1:1 and 3:1:1 of Compound 18:cyproconazole:azoxystrobin. Tables C3 through C28 are constructed similarly.

TABLE-US-00019 Table Number Component (a) Column Entry C2 Compound 18 C3 Compound 21 C4 Compound 22 C5 Compound 23 C6 Compound 27 C7 Compound 30 C8 Compound 31 C9 Compound 35 C10 Compound 45 C11 Compound 46 C12 Compound 47 C13 Compound 48 C14 Compound 50 C15 Compound 52 C16 Compound 105 C17 Compound 108 C18 Compound 109 C19 Compound 119 C20 Compound 120 C21 Compound 121 C22 Compound 123 C23 Compound 124 C24 Compound 125 C25 Compound 127 C26 Compound 131 C27 Compound 132 C28 Compound 133 C29 Compound 135

[1217] Of note is a composition of the present invention comprising a compound of Formula 1 (or an N-oxide or salt thereof) with at least one other fungicidal compound that has a different site of action from the compound of Formula 1. In certain instances, a combination with at least one other fungicidal compound having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can advantageously comprise at least one fungicidal active compound selected from the group consisting of (b1) through (b54) as described above, having a similar spectrum of control but a different site of action.

[1218] Compositions of component (a), or component (a) with component (b), can be further mixed with one or more other biologically active compounds or agents including insecticides, nematocides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Thus the present invention also pertains to a composition comprising a fungicidally effective amount of component (a), or a mixture of component (a) with component (b), and a biologically effective amount of at least one additional biologically active compound or agent and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can also be separately formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For compositions of the present invention, one or more other biologically active compounds or agents can be formulated together with one or both of components (a) and (b) to form a premix, or one or more other biologically active compounds or agents can be formulated separately from components (a) and (b) and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.

[1219] Examples of such biologically active compounds or agents with which compositions of component (a), or component (a) with component (b), can be formulated are: insecticides such as abamectin, acephate, acequinocyl, acetamiprid, acrinathrin, acynonapyr, afidopyropen ([(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-4-yl]methyl cyclopropanecarboxylate), amidoflumet, amitraz, avermectin, azadirachtin, azinphos-methyl, benfuracarb, bensultap, benzpyrimoxan, bifenthrin, kappa-bifenthrin, bifenazate, bistrifluron, borate, broflanilide, buprofezin, cadusafos, carbaryl, carbofuran, cartap, carzol, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chloroprallethrin, chlorpyrifos, chlorpyrifos-e, chlorpyrifos-methyl, chromafenozide, clofentezin, chloroprallethrin, clothianidin, cyantraniliprole (3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1H-pyrazole-5-carboxamide), cyclaniliprole (3-bromo-N-[2-bromo-4-chloro-6-[[(1-cyclopropylethyl)amino]carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide), cycloprothrin, cycloxaprid ((5S,8R)-1-[(6-chloro-3-pyridinyl)methyl]-2,3,5,6,7,8-hexahydro-9-nitro-5,8-Epoxy-1H-imidazo[1,2-a]azepine), cyenopyrafen, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalodiamide, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dicloromesotiaz, dieldrin, diflubenzuron, dimefluthrin, dimehypo, dimethoate, dimpropyridaz, dinotefuran, diofenolan, emamectin, emamectin benzoate, endosulfan, esfenvalerate, ethiprole, etofenprox, epsilon-metofluthrin, etoxazole, fenbutatin oxide, fenitrothion, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flometoquin (2-ethyl-3,7-dimethyl-6-[4-(trifluoromethoxy)phenoxy]-4-quinolinyl methyl carbonate), flonicamid, fluazaindolizine, flubendiamide, flucythrinate, flufenerim, flufenoxuron, flufenoxystrobin (methyl (E)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]--(methoxymethylene)benzeneacetate), fluensulfone (5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]thiazole), fluhexafon, fluopyram, flupiprole (1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methyl-2-propen-1-yl)amino]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile), flupyradifurone (4-[[(6-chloro-3-pyridinyl)methyl](2,2-difluoroethyl)amino]-2(5H)-furanone), flupyrimin, fluvalinate, tau-fluvalinate, fluxametamide, fonophos, formetanate, fosthiazate, gamma-cyhalothrin, halofenozide, heptafluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2-dimethyl-3-[(1Z)-3,3,3-trifluoro-1-propen-1-yl]cyclopropanecarboxylate), hexaflumuron, hexythiazox, hydramethylnon, imidacloprid, indoxacarb, insecticidal soaps, isofenphos, isocycloseram, kappa-tefluthrin, lambda-cyhalothrin, lufenuron, malathion, meperfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl (1R,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate), metaflumizone, metaldehyde, methamidophos, methidathion, methiocarb, methomyl, methoprene, methoxychlor, metofluthrin, methoxyfenozide, epsilon-metofluthrin, epsilon-momfluorothrin, monocrotophos, monofluorothrin ([2,3,5,6-tetrafluoro-4-(methoxy-methyl)phenyl]methyl 3-(2-cyano-1-propen-1-yl)-2,2-dimethylcyclopropanecarboxylate), nicotine, nitenpyram, nithiazine, novaluron, noviflumuron, oxamyl, oxazosulfyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, propargite, protrifenbute, pyflubumide (1,3,5-trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]-phenyl]-1H-pyrazole-4-carboxamide), pymetrozine, pyrafluprole, pyrethrin, pyridaben, pyridalyl, pyrifluquinazon, pyriminostrobin (methyl (E)-2-[[[2-[(2,4-dichlorophenyl)amino]-6-(trifluoromethyl)-4-pyrimidinyl]oxy]methyl]--(methoxymethylene)benzeneacetate), pyriprole, pyriproxyfen, rotenone, ryanodine, silafluofen, spinetoram, spinosad, spirodiclofen, spiromesifen, spiropidion, spirotetramat, sulprofos, sulfoxaflor (N-[methyloxido[1-[6-(trifluoromethyl)-3-pyridinyl]ethyl]-.sup.4-sulfanylidene]cyanamide), tebufenozide, tebufenpyrad, teflubenzuron, tefluthrin, kappa-tefluthrin, terbufos, tetrachlorantraniliprole, tetrachlorvinphos, tetramethrin, tetramethylfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2,3,3-tetramethyl-cyclopropanecarboxylate), tetraniliprole, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tioxazafen (3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole), tolfenpyrad, tralomethrin, triazamate, trichlorfon, triflumezopyrim (2,4-dioxo-1-(5-pyrimidinylmethyl)-3-[3-(trifluoromethyl)phenyl]-2H-pyrido[1,2-a]pyrimidinium inner salt), triflumuron, tyclopyrazoflor, zeta-cypermethrin, Bacillus thuringiensis delta-endotoxins, entomopathogenic bacteria, entomopathogenic viruses or entomopathogenic fungi.

[1220] One embodiment of biological agents for mixing with compounds of this disclosure include entomopathogenic bacteria such as Bacillus thuringiensis, and the encapsulated delta-endotoxins of Bacillus thuringiensis such as MVP and MVPII bioinsecticides prepared by the CellCap process (CellCap, MVP and MVPII are trademarks of Mycogen Corporation, Indianapolis, Indiana, USA); entomopathogenic fungi such as green muscardine fungus; and entomopathogenic (both naturally occurring and genetically modified) viruses including baculovirus, nucleopolyhedro virus (NPV) such as Helicoverpa zea nucleopolyhedrovirus (HzNPV), Anagrapha falcifera nucleopolyhedrovirus (AfNPV); and granulosis virus (GV) such as Cydia pomonella granulosis virus (CpGV).

[1221] General references for these agricultural protectants (i.e. insecticides, fungicides, nematocides, acaricides, herbicides and biological agents) include The Pesticide Manual, 13th Edition, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U. K., 2003 and The BioPesticide Manual, 2nd Edition, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U. K., 2001.

[1222] For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to component (a), or a mixture of component (a) with component (b), is generally between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:100 and about 3000:1, or between about 1:30 and about 300:1 (for example ratios between about 1:1 and about 30:1). It will be evident that including these additional components may expand the spectrum of diseases controlled beyond the spectrum controlled by component (a), or a mixture of component (a) with component (b).

[1223] Component (a) compounds and/or combinations thereof with component (b) compounds and/or one or more other biologically active compounds or agents can be applied to plants genetically transformed to express proteins toxic to invertebrate pests (such as Bacillus thuringiensis delta-endotoxins). The effect of the exogenously applied present component (a) alone or in combination with component (b) may be synergistic with the expressed toxin proteins.

[1224] Of note is the combination or the composition comprising component (a), or components (a) and (b), as described in the Summary of the Invention further comprising at least one invertebrate pest control compound or agent (e.g., insecticide, acaricide). Of particular note is a composition comprising component (a) and at least one (i.e. one or more) invertebrate pest control compound or agent, which then can be subsequently combined with component (b) to provide a composition comprising components (a) and (b) and the one or more invertebrate pest control compounds or agents. Alternatively without first mixing with component (b), a biologically effective amount of the composition comprising component (a) with at least one invertebrate pest control agent can be applied to a plant or plant seed (directly or through the environment of the plant or plant seed) to protect the plant or plant seed from diseases caused by fungal pathogens and injury caused by invertebrate pests.

[1225] For embodiments where one or more of invertebrate pest control compounds are used, the weight ratio of these compounds (in total) to the component (a) compounds is typically between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:300 and about 300:1 (for example ratios between about 1:30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity.

[1226] Of note is a composition of the present invention which comprises in addition to a component (a) compound, alone or in combination with component (b), at least one invertebrate pest control compound or agent selected from the group consisting abamectin, acetamiprid, acrinathrin, acynonapyr, afidopyropen, amitraz, avermectin, azadirachtin, benfuracarb, bensultap, bifenthrin, buprofezin, broflanilide, cadusafos, carbaryl, cartap, chlorantraniliprole, chloroprallethrin, chlorfenapyr, chlorpyrifos, clothianidin, cyantraniliprole, cyclaniliprole, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, epsilon-metofluthrin, esfenvalerate, ethiprole, etofenprox, etoxazole, fenitrothion, fenothiocarb, fenoxycarb, fenvalerate, fipronil, flometoquin, fluxametamide, flonicamid, flubendiamide, fluensulfone, flufenoxuron, flufenoxystrobin, flufensulfone, flupiprole, flupyrimin, flupyradifurone, fluvalinate, formetanate, fosthiazate, gamma-cyhalothrin, heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isocycloseram, kappa-tefluthrin, lambda-cyhalothrin, lufenuron, meperfluthrin, metaflumizone, methiodicarb, methomyl, methoprene, methoxyfenozide, metofluthrin, monofluorothrin, nitenpyram, nithiazine, novaluron, oxamyl, pyflubumide, pymetrozine, pyrethrin, pyridaben, pyridalyl, pyriminostrobin, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor, tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumezopyrim, triflumuron, tyclopyrazoflor, zeta-cypermethrin, Bacillus thuringiensis delta-endotoxins, all strains of Bacillus thuringiensis and all strains of nucleo polyhedrosis viruses.

[1227] In certain instances, combinations of a a component (a) compound of this invention, alone or in mixture with component (b), with other biologically active (particularly fungicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. When an enhanced effect of fungicidal active ingredients occurs at application rates giving agronomically satisfactory levels of fungal control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load.

[1228] Table D1 lists specific combinations of invertebrate pest control agents with Compound 7 (compound numbers refer to compounds in Index Tables A through E) as a component (a) compound illustrative of mixtures and compositions comprising these active ingredients and methods using them according to the present invention. The second column of Table D1 lists the specific invertebrate pest control agents (e.g., Abamectin in the first line). The third column of Table D1 lists the mode of action (if known) or chemical class of the invertebrate pest control agents. The fourth column of Table D1 lists embodiment(s) of ranges of weight ratios for rates at which the invertebrate pest control agent is typically applied relative to Compound 7 alone or in combination with component (b) (e.g., 50:1 to 1:50 of abamectin relative to a Compound 7 by weight). Thus, for example, the first line of Table D1 specifically discloses the combination of Compound 7 with abamectin is typically applied in a weight ratio between 50:1 to 1:50. The remaining lines of Table D1 are to be construed similarly.

TABLE-US-00020 TABLE D1 Invertebrate Pest Mode of Action or Typical Component (a) Control Agent Chemical Class Weight Ratio Compound 7 Abamectin macrocyclic lactones 50:1 to 1:50 Compound 7 Acetamiprid neonicotinoids 150:1 to 1:200 Compound 7 Amitraz octopamine receptor ligands 200:1 to 1:100 Compound 7 Avermectin macrocyclic lactones 50:1 to 1:50 Compound 7 Azadirachtin ecdysone agonists 100:1 to 1:120 Compound 7 Beta-cyfluthrin sodium channel modulators 150:1 to 1:200 Compound 7 Bifenthrin sodium channel modulators 100:1 to 1:10 Compound 7 Buprofezin chitin synthesis inhibitors 500:1 to 1:50 Compound 7 Cartap nereistoxin analogs 100:1 to 1:200 Compound 7 Chlorantraniliprole ryanodine receptor ligands 100:1 to 1:120 Compound 7 Chlorfenapyr mitochondrial electron transport 300:1 to 1:200 inhibitors Compound 7 Chlorpyrifos cholinesterase inhibitors 500:1 to 1:200 Compound 7 Clothianidin neonicotinoids 100:1 to 1:400 Compound 7 Cyantraniliprole ryanodine receptor ligands 100:1 to 1:120 Compound 7 Cyfluthrin sodium channel modulators 150:1 to 1:200 Compound 7 Cyhalothrin sodium channel modulators 150:1 to 1:200 Compound 7 Cypermethrin sodium channel modulators 150:1 to 1:200 Compound 7 Cyromazine chitin synthesis inhibitors 400:1 to 1:50 Compound 7 Deltamethrin sodium channel modulators 50:1 to 1:400 Compound 7 Dieldrin cyclodiene insecticides 200:1 to 1:100 Compound 7 Dinotefuran neonicotinoids 150:1 to 1:200 Compound 7 Diofenolan molting inhibitor 150:1 to 1:200 Compound 7 Emamectin macrocyclic lactones 50:1 to 1:10 Compound 7 Endosulfan cyclodiene insecticides 200:1 to 1:100 Compound 7 Esfenvalerate sodium channel modulators 100:1 to 1:400 Compound 7 Ethiprole GABA-regulated chloride channel 200:1 to 1:100 blockers Compound 7 Fenothiocarb 150:1 to 1:200 Compound 7 Fenoxycarb juvenile hormone mimics 500:1 to 1:100 Compound 7 Fenvalerate sodium channel modulators 150:1 to 1:200 Compound 7 Fipronil GABA-regulated chloride channel 150:1 to 1:100 blockers Compound 7 Flonicamid 200:1 to 1:100 Compound 7 Flubendiamide ryanodine receptor ligands 100:1 to 1:120 Compound 7 Flufenoxuron chitin synthesis inhibitors 200:1 to 1:100 Compound 7 Hexaflumuron chitin synthesis inhibitors 300:1 to 1:50 Compound 7 Hydramethylnon mitochondrial electron transport 150:1 to 1:250 inhibitors Compound 7 Imidacloprid neonicotinoids 1000:1 to 1:1000 Compound 7 Indoxacarb sodium channel modulators 200:1 to 1:50 Compound 7 Lambda-cyhalothrin sodium channel modulators 50:1 to 1:250 Compound 7 Lufenuron chitin synthesis inhibitors 500:1 to 1:250 Compound 7 Meperfluthrin sodium channel modulators 100:1 to 1:400 Compound 7 Metaflumizone 200:1 to 1:200 Compound 7 Methomyl cholinesterase inhibitors 500:1 to 1:100 Compound 7 Methoprene juvenile hormone mimics 500:1 to 1:100 Compound 7 Methoxyfenozide ecdysone agonists 50:1 to 1:50 Compound 7 Nitenpyram neonicotinoids 150:1 to 1:200 Compound 7 Nithiazine neonicotinoids 150:1 to 1:200 Compound 7 Novaluron chitin synthesis inhibitors 500:1 to 1:150 Compound 7 Oxamyl cholinesterase inhibitors 200:1 to 1:200 Compound 7 Pymetrozine 200:1 to 1:100 Compound 7 Pyrethrin sodium channel modulators 100:1 to 1:10 Compound 7 Pyridaben mitochondrial electron transport 200:1 to 1:100 inhibitors Compound 7 Pyridalyl 200:1 to 1:100 Compound 7 Pyriproxyfen juvenile hormone mimics 500:1 to 1:100 Compound 7 Ryanodine ryanodine receptor ligands 100:1 to 1:120 Compound 7 Spinetoram macrocyclic lactones 150:1 to 1:100 Compound 7 Spinosad macrocyclic lactones 500:1 to 1:10 Compound 7 Spirodiclofen lipid biosynthesis inhibitors 200:1 to 1:200 Compound 7 Spiromesifen lipid biosynthesis inhibitors 200:1 to 1:200 Compound 7 Sulfoxaflor 200:1 to 1:200 Compound 7 Tebufenozide ecdysone agonists 500:1 to 1:250 Compound 7 Tetramethylfluthrin sodium channel modulators 100:1 to 1:40 Compound 7 Thiacloprid neonicotinoids 100:1 to 1:200 Compound 7 Thiamethoxam neonicotinoids 1250:1 to 1:1000 Compound 7 Thiodicarb cholinesterase inhibitors 500:1 to 1:400 Compound 7 Thiosultap-sodium 150:1 to 1:100 Compound 7 Tralomethrin sodium channel modulators 150:1 to 1:200 Compound 7 Triazamate cholinesterase inhibitors 250:1 to 1:100 Compound 7 Triflumuron chitin synthesis inhibitors 200:1 to 1:100 Compound 7 Bacillus thuringiensis biological agents 50:1 to 1:10 Compound 7 Bacillus thuringiensis delta- biological agents 50:1 to 1:10 endotoxin Compound 7 NPV (e.g., Gemstar) biological agents 50:1 to 1:10

[1229] Tables D2 through D29 are each constructed the same as Table D1 above except that entries below the Component (a) column heading are replaced with the respective Component (a) Column Entry shown below. Thus, for example, in Table D2 the entries below the Component (a) column heading all recite Compound 18, and the first line in below the column headings in Table D2 specifically discloses a mixture of Compound 18 with abamectin. Tables D3 through D28 are constructed similarly.

TABLE-US-00021 Table Number Component (a) Column Entry D2 Compound 18 D3 Compound 21 D4 Compound 22 D5 Compound 23 D6 Compound 27 D7 Compound 30 D8 Compound 31 D9 Compound 35 D10 Compound 45 D11 Compound 46 D12 Compound 47 D13 Compound 48 D14 Compound 50 D15 Compound 52 D16 Compound 105 D17 Compound 108 D18 Compound 109 D19 Compound 119 D20 Compound 120 D21 Compound 121 D22 Compound 123 D23 Compound 124 D24 Compound 125 D25 Compound 127 D26 Compound 131 D27 Compound 132 D28 Compound 133 D29 Compound 135

[1230] Compositions comprising compounds of Formula 1 useful for seed treatment can further comprise bacteria and fungi that have the ability to provide protection from the harmful effects of plant pathogenic fungi or bacteria and/or soil born animals such as nematodes. Bacteria exhibiting nematicidal properties may include but are not limited to Bacillus firmus, Bacillus cereus, Bacillius subtiliis and Pasteuria penetrans. A suitable Bacillus firmus strain is strain CNCM I-1582 (GB-126) which is commercially available as BioNem. A suitable Bacillus cereus strain is strain NCMM I-1592. Both Bacillus strains are disclosed in U.S. Pat. No. 6,406,690. Other suitable bacteria exhibiting nematicidal activity are B. amyloliquefaciens IN937a and B. subtilis strain GB03. Bacteria exhibiting fungicidal properties may include but are not limited to B. pumilus strain GB34. Fungal species exhibiting nematicidal properties may include but are not limited to Myrothecium verrucaria, Paecilomyces lilacinus and Purpureocillium lilacinum.

[1231] Seed treatments can also include one or more nematicidal agents of natural origin such as the elicitor protein called harpin which is isolated from certain bacterial plant pathogens such as Erwinia amylovora. An example is the Harpin-N-Tek seed treatment technology available as N-Hibit Gold CST.

[1232] Seed treatments can also include one or more species of legume-root nodulating bacteria such as the microsymbiotic nitrogen-fixing bacteria Bradyrhizobium japonicum. These inocculants can optionally include one or more lipo-chitooligosaccharides (LCOs), which are nodulation (Nod) factors produced by rhizobia bacteria during the initiation of nodule formation on the roots of legumes. For example, the Optimize brand seed treatment technology incorporates LCO Promoter Technology in combination with an inocculant.

[1233] Seed treatments can also include one or more isoflavones which can increase the level of root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by enhancing the root uptake of nutrients such as water, sulfates, nitrates, phosphates and metals. Examples of isoflavones include, but are not limited to, genistein, biochanin A, formononetin, daidzein, glycitein, hesperetin, naringenin and pratensein. Formononetin is available as an active ingredient in mycorrhizal inocculant products such as PHC Colonize AG.

[1234] Seed treatments can also include one or more plant activators that induce systemic acquired resistance in plants following contact by a pathogen. An example of a plant activator which induces such protective mechanisms is acibenzolar-S-methyl.

[1235] In the present fungicidal compositions, the Formula 1 compounds of component (a) can work synergically with the additional fungicidal compounds of component (b) to provide such beneficial results as broadening the spectrum of plant diseases controlled, extending duration of preventative and curative protection, and suppressing proliferation of resistant fungal pathogens. In particular embodiments, compositions are provided in accordance with this invention that comprise proportions of component (a) and component (b) that are especially useful for controlling particular fungal diseases (such as Alternaria solani, Blumeria graminis f. sp. tritici, Botrytis cinerea, Puccinia recondita f. sp. tritici, Rhizoctonia solani, Septoria nodorum, Septoria tritici).

[1236] Mixtures of fungicides may also provide significantly better disease control than could be predicted based on the activity of the individual components. This synergism has been described as the cooperative action of two components of a mixture, such that the total effect is greater or more prolonged than the sum of the effects of the two (or more) taken independently (see P. M. L. Tames, Neth. J. Plant Pathology 1964, 70, 73-80). In methods providing plant disease control in which synergy is exhibited from a combination of active ingredients (e.g., fungicidal compounds) applied to the plant or seed, the active ingredients are applied in a synergistic weight ratio and synergistic (i.e. synergistically effective) amounts. Measures of disease control, inhibition and prevention cannot exceed 100%. Therefore expression of substantial synergism typically requires use of application rates of active ingredients wherein the active ingredients separately provide much less than 100% effect, so that their additive effect is substantially less than 100% to allow the possibility of increase in effect as result of synergism. On the other hand, application rates of active ingredients that are too low may show not show much activity in mixtures even with the benefit of synergism. One skilled in the art can easily identify and optimize through simple experimentation the weight ratios and application rates (i.e. amounts) of fungicidal compounds providing synergy.

[1237] The presence of a synergistic effect between two active ingredients was established with the aid of the Colby equation (see Colby, S. R. Calculating Synergistic and Antagonistic Responses of Herbicide Combinations, Weeds, (1967), 15, 20-22):

[00001]$p=A+B-\left[\frac{AB}{100}\right].$

[1238] Using the method of Colby, the presence of a synergistic interaction between two active ingredients is established by first calculating the predicted activity, p, of the mixture based on activities of the two components applied alone. If p is lower than the experimentally established effect, synergism has occurred. In the equation above, A is the fungicidal activity in percentage control of one component applied alone at rate x. The B term is the fungicidal activity in percentage control of the second component applied at rate y. The equation estimates p, the expected fungicidal activity of the mixture of A at rate x with B at rate y if their effects are strictly additive and no interaction has occurred.

[1239] The following TESTS demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Tables A through E below for compound descriptions. The following abbreviations are used in the Index Tables: Me means methyl, Et means ethyl, n-Pr means n-propyl, i-Pr means iso-propyl, c-Pr means cyclopropyl, n-Bu means n-butyl, i-Bu means iso-butyl, c-Bu means cyclobutyl, c-hexyl means cyclohexyl, Ph means phenyl, MeO means methoxy and EtO means ethoxy. The abbreviation Cmpd. No. stands for Compound Number, and the abbreviation Ex. stands for Example and is followed by a number indicating in which example the compound is prepared. The abbreviation m.p. stands for melting point. The numerical value reported in the column MS is the molecular weight of the highest isotopic abundance positively charged parent ion (M+1) formed by addition of H.sup.+ (molecular weight of 1) to the molecule having the highest isotopic abundance, or the highest isotopic abundance negatively charged ion (M-1) formed by loss of H.sup.+ (molecular weight of 1). The presence of molecular ions containing one or more higher atomic weight isotopes of lower abundance (e.g., .sup.37Cl, .sup.81Br) is not reported. The reported MS peaks were observed by mass spectrometry using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI).

TABLE-US-00022 INDEX TABLE A [00072] Unless otherwise indicated, the configuration of substituents about the double bond in the above structure is as shown in the structure. Cmpd. MS m.p. No. R.sup.9 L A R.sup.2c .sup.19FNMR (M + 1) ( C.) 1 t-BuONC(OEt) CH.sub.2 O CH.sub.2CH.sub.3 456 2 NH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.09 (s) 358 3 i-BuONC(OEt) CH.sub.2 O CH.sub.2CH.sub.3 456 5 (Ex. 2) MeON(Me)C(O)CH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 414 7 (Ex. 3) CH.sub.3CH.sub.2OC(S) CH.sub.2 O CH.sub.2CH.sub.3 401 8 (CH.sub.3).sub.2NC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 13 c-PrCH.sub.2OC(O)CH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 425 14 CH.sub.2CHCH.sub.2OC(O)CH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 411 15 MeNHC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 16 Cl.sub.2CHC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 17 CF.sub.3C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s), 430 75.10 (s) 18 CH.sub.3ON(Me)C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 430 19 ClF.sub.2CC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 63.95 (s), 70.11 (s) 20 (CH.sub.3C(O)).sub.2NOCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 442 21 (Ex. 4) CH.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 399 22 CH.sub.3C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 23 CH.sub.3OCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 24 NCCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 25 c-PrCH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 426 26 MeOC(O)CH.sub.2CH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 457 27 i-BuC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 427 28 CH.sub.3CH.sub.2OC(O)C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 443 29 c-pentyl-C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 439 30 CH.sub.3(CH.sub.2).sub.2CH(Me)C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 441 31 PhCH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 462 32 ClCHCHCH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 446 33 CH.sub.2CHCH.sub.2ON(Me)C(O)CH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 426 34 c-PrCH.sub.2ONC(OMe) CH.sub.2 O CH.sub.2CH.sub.3 440 35 CF.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 63.45 (s), 453 70.11 (s) 36 (CH.sub.3CH.sub.2).sub.2CHC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 441 39 c-PrCH.sub.2ON(Me)C(O) CH.sub.2 O CH.sub.2CH.sub.3 440 40 (Ex. 7) CH.sub.2CHCH.sub.2ONC(OEt) CH.sub.2 O CH.sub.2CH.sub.3 440 41 CH.sub.2CHCH.sub.2ON(Et)C(O) CH.sub.2 O CH.sub.2CH.sub.3 440 42 CH.sub.2CHCH.sub.2ONC(OBu) CH.sub.2 O CH.sub.2CH.sub.3 468 43 CH.sub.2CHCH.sub.2ON(Bu)C(O) CH.sub.2 O CH.sub.2CH.sub.3 468 44 CHCCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 45 CF.sub.3CH.sub.2ONHC(O)CH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 454 46 i-PrC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 47 t-BuC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 48 CH.sub.3OC(O)C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 49 t-BuCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 50 CH.sub.3SCH.sub.2CH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 51 c-PrC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.10 (s) 52 CH.sub.3OC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 401 53 CH.sub.3CH.sub.2OC(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 70.11 (s) 54 (Ex. 5) EtOC(O)CH(OC(O)Me) CH.sub.2 O CH.sub.2CH.sub.3 457 55 (Ex. 6) CH.sub.2CHCH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 412 79-82 56 NH.sub.2C(NOH) CH.sub.2 O CH.sub.2CH.sub.3 371 81-84 57 [00073] CH.sub.2 O CH.sub.2CH.sub.3 411 58 c-PrOCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 383 59 c-BuOCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 397 60 CH.sub.2CHCH.sub.2ONHC(O) (CH.sub.2).sub.3 O CH.sub.2CH.sub.3 440 61 CH.sub.2CHCH.sub.2ONC(OEt) (CH.sub.2).sub.2 O CH.sub.2CH.sub.3 454 62 CH.sub.2CHCH.sub.2ONHC(O) (CH.sub.2).sub.2 O CH.sub.2CH.sub.3 426 63 c-pentyl-CH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 425 64 c-PrCH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 397 65 CHCCH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 381 66 CH.sub.2CHCH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 383 67 OHCH.sub.2CH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 416

TABLE-US-00023 INDEX TABLE A1 [00074] Unless otherwise indicated, the configuration of substituents about the double bond in the above structure is as shown in the structure. Cmpd. MS m.p. No. R.sup.9 L A (R.sup.7).sub.q (M + 1) ( C.) 68 c-PrCH.sub.2OCH.sub.2 CH.sub.2 O 2-F 415 69 CH.sub.3OC(O)OCH.sub.2 CH.sub.2 O 2,3-di-F 437 70 CH.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 O 2,3-di-F 435 71 c-PrC(O)OCH.sub.2 CH.sub.2 O 2,3-di-F 447 72 t-BuC(O)OCH.sub.2 CH.sub.2 O 2,3-di-F 463 73 t-BuC(O)OCH.sub.2 CH.sub.2 O 2-F 445 74 CH.sub.3OCH.sub.2C(O)OCH.sub.2 CH.sub.2 O 2,3-di-F 451 75 CH.sub.3OCH.sub.2C(O)OCH.sub.2 CH.sub.2 O 2-F 433 76 c-PrC(O)OCH.sub.2 CH.sub.2 O 2-F 429 77 CH.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 O 2-F 417 78 NCCH.sub.2ONHC(O) CH.sub.2 O 2,3-di-F 447 125-128 79 CF.sub.3CH.sub.2ONHC(O) CH.sub.2 O 2,3-di-F 490 104-107 80 c-PrCH.sub.2ONHC(O) CH.sub.2 O 2,3-di-F 462 116-119 81 NCCH.sub.2ONHC(O) CH.sub.2 O 2-F 429 82 c-PrCH.sub.2ONHC(O) CH.sub.2 O 2-F 444

TABLE-US-00024 INDEX TABLE B [00075] Unless otherwise indicated, the configuration of substituents about the double bond in the above structure is as shown in the structure. Cmpd. MS No. R.sup.9 L A R.sup.2c (M + 1) 9 NCCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 411 10 MeOCH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 416 11 CF.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 454 12 c-pentyl-C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 440 37 CH.sub.3C(O)OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 386 38 CHCCH.sub.2OCH.sub.2 CH.sub.2 O CH.sub.2CH.sub.3 382 83 CH.sub.2CHCH.sub.2ONHC(O) CH.sub.2 O CH.sub.2CH.sub.3 413

TABLE-US-00025 INDEX TABLE C [00076] Cmpd. MS m.p. No. R.sup.9 L A (M + 1) ( C.) 4 (Ex. 1) c-pentyl-C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 455 84 CH.sub.2CCHC(O)NHCH.sub.2 CH.sub.2 OCH.sub.2 424 123-126 85 CH.sub.3CH.sub.2OC(O)OCH.sub.2 CH.sub.2 OCH.sub.2 431 86 CH.sub.3OCH.sub.2C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 431 87 CH.sub.3OCH.sub.2CH.sub.2C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 445 88 c-PrCH.sub.2C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 441 89 CH.sub.2CHCH.sub.2C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 427 90 CH.sub.3C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 401 91 CH.sub.3CH.sub.2OC(O)C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 459 92 i-BuC(O)OCH.sub.2 CH.sub.2 OCH.sub.2 443 93 CF.sub.3CH.sub.2C(O)OCH.sub.2 CH.sub.2 OCH.sub.2 469 94 CHCCH.sub.2OCH.sub.2 CH.sub.2 OCH.sub.2 397

TABLE-US-00026 INDEX TABLE D [00077] Cmpd. MS No. R.sup.9 B L A (M + 1) 95 CH.sub.2CHCH.sub.2ONC(OEt) N CH.sub.2 O 468 96 c-PrCH.sub.2ONHC(O) N CH.sub.2 O 454 97 CH.sub.2CHCH.sub.2ONHC(O) N CH.sub.2 O 440 98 NCCH.sub.2ONHC(O) CH.sub.2 CH.sub.2 O 438 99 CHCCH.sub.2ON(Me)C(O) CH.sub.2 CH.sub.2 O 451 100 CHCCH.sub.2ONHC(O) CH.sub.2 CH.sub.2 O 437 101 CH.sub.3OCH.sub.2CH.sub.2ON(Me)C(O) CH.sub.2 CH.sub.2 O 471 102 c-PrCH.sub.2ON(Me)C(O) CH.sub.2 CH.sub.2 O 467 103 CH.sub.3OCH.sub.2CH.sub.2ONHC(O) CH.sub.2 CH.sub.2 O 457 104 c-PrCH.sub.2ONHC(O) CH.sub.2 CH.sub.2 O 453

TABLE-US-00027 INDEX TABLE E Cmpd. MS MS m.p. No. Structure (M + 1) (M 1) ( C.) 6 [00078] 386 105 [00079] 423 153-156 106 [00080] 462 107 [00081] 434 115-118 108 [00082] 437 109 [00083] 423 110 [00084] 440 111 [00085] 412 112 [00086] 447 113 [00087] 440 114 [00088] 412 115 [00089] 411 140-143 116 [00090] 443 117 [00091] 429 118 [00092] 450 119 [00093] 452 120 [00094] 479 121 [00095] 435 122 [00096] 487 123 [00097] 451 124 [00098] 437 125 [00099] 421 126 [00100] 473 127 [00101] 465 128 [00102] 450 129 [00103] 439 130 [00104] 453 131 [00105] 421 132 [00106] 437 79-81 133 [00107] 465 134 [00108] 435 135 [00109] 437

Biological Examples of the Invention

[1240] General protocol for preparing test suspensions for Test A: the test compounds were first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant PEG400 (polyhydric alcohol esters). The resulting test suspensions were then used in Test A.

Test A

[1241] The test solution was sprayed to the point of run-off on soybean seedlings. The following day the seedlings were inoculated with a spore suspension of Phakopsora pachyrhizi (the causal agent of Asian soybean rust) and incubated in a saturated atmosphere at 22 C. for 24 h and then moved to a growth chamber at 22 C. for 8 days, after which time visual disease ratings were made.

[1242] In addition to Test A, some compounds of this invention were also sprayed on wheat seedlings inoculated with a spore suspension of Puccinia recondita f. sp. tritici (the causal agent of wheat leaf rust) 24 h after treatment. The wheat seedlings were incubated in a saturated atmosphere at 20 C. for 24 h, and then moved to a growth chamber at 20 C. for 7 days, after which time disease ratings were made. The compounds tested did not show noticeable activity against this pathogen under the test conditions at the application rates tested.

[1243] Results for Test A are given in Table A below. A rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls).

TABLE-US-00028 TABLE A Cmpd No. Rate in ppm Test A 1 10 97 2 10 44 3 10 100 4 10 90 5 50 94 6 10 0 7 10 100 8 50 60 9 10 0 10 10 0 11 10 0 12 10 79 13 10 96 14 10 96 15 50 100 16 10 100 17 10 100 18 10 100 19 10 100 20 10 79 21 10 100 22 10 100 23 10 100 24 10 100 25 10 100 26 10 100 27 10 100 29 10 100 30 10 100 31 10 100 32 10 100 33 10 100 34 10 97 35 10 100 36 10 100 37 10 100 38 10 78 38 10 88 39 10 100 40 10 100 41 10 94 42 10 96 43 10 87 44 10 100 45 10 100 46 10 100 47 10 100 48 10 100 49 10 99 50 10 100 51 10 100 52 10 100 53 10 100 54 10 100 55 10 100 56 10 84 57 10 100 59 10 100 60 10 96 61 10 100 62 10 100 63 10 100 64 10 100 65 10 100 66 10 100 67 10 100 68 10 100 69 10 100 70 10 100 71 10 100 72 10 100 73 10 100 74 10 100 75 10 100 76 10 100 77 10 100 78 10 100 79 10 100 80 10 100 81 10 100 82 10 100 83 10 99 84 10 99 85 10 86 86 50 100 87 50 100 88 50 100 89 50 100 90 50 100 91 50 100 92 50 100 93 50 100 94 50 100 98 10 99 99 10 92 100 10 98 101 10 94 102 10 99 103 10 97 104 10 100 108 10 100 109 10 100 110 10 99 111 10 100 112 10 100 113 10 87 114 10 100 115 10 96 116 10 100 117 10 100 118 10 100 119 10 100 120 10 100 121 10 100 122 10 100 123 10 100 124 10 100 125 10 100 126 10 99 127 10 99 128 250 100 129 10 98 130 10 99 131 10 100 132 10 100 133 10 100 134 10 99 135 10 100

[1244] The test results presented above in Table A for compounds of Formula 1 illustrate the fungicidal activity of component (a) contributing to the plant disease control utility of compositions comprising component (a) in combination with component (b) and optionally at least one additional fungicidal compound according to the present invention.